Compositions for reducing hot flashes and symptoms associated with anxiety and formulations thereof

Abstract

Described herein are compositions for relief of menopausal symptoms including hot flashes, mood changes and difficulty sleeping, and anxiety and its associated symptoms, the compositions comprising a fenugreek seed extract, a Cordyceps species, a tea extract, a nitric oxide source preferably beetroot, Bacopa monnieri, D-aspartic acid, panax ginseng and a vitamin preferably vitamin B6, and additional or alternative components can comprise Ashwagandha extract, Astragalus membranaceus extract, Panax notoginseng extract, a chelating agent preferably EDTA, oat straw, ginger, sage, diindolylmethane, magnesium, zinc citrate, lecithin and melatonin.

Description

WSGR Docket No.59851-708.601 COMPOSITIONS FOR REDUCING HOT FLASHES AND SYMPTOMS ASSOCIATED WITH ANXIETY AND FORMULATIONS THEREOF CROSS REFERENCE

[0001] This application claims the benefit of US Provisional Application No. 63 / 612,208, filed December 19, 2023, US Provisional Application No.63 / 614,234, filed December 22, 2023, and US Provisional Application No.63 / 662,725, filed June 21, 2024, all of which are incorporated by reference in their entirety herein. BACKGROUND

[0002] There is high incidence of hot flashes (e.g., in woman undergoing menopause and perimenopause) and anxiety symptoms in persons. SUMMARY

[0003] Hormone therapies are common for the treatment of hot flashes. However, there are risks associated with hormone therapies and such therapies need to be tailored to a persons needs to avoid severe outcomes (such as endometrial cancer). There are very few non-hormone treatments for hot flashes.

[0004] Symptoms associated with anxiety that interfere with everyday life is common.

[0005] In one aspect, provided herein are compositions and formulations for use by an individual to reduce hot flashes that reduce and / or eliminate use of hormone therapies.

[0006] In one aspect, provided herein are compositions and formulations for use by an individual to reduce the symptoms of anxiety.

[0007] The above features and methods are of representative embodiments only and are not intended to limit the scope and breadth of the claims.

[0008] In one aspect, provided is a composition comprising: about 60 mg to about 420 mg of a maca, about 60 mg to about 300 mg of a fenugreek seed extract, about 1 mg to about 25 mg of a cordyceps species, about 1 mg to about 25 mg of a tea extract, about 1 mg to about 25 mg of a nitric oxide source, about 1 mg to about 25 mg of bacopa monnieri, about 0.5 mg to about 15 mg of an amino acid comprising D-aspartic acid, about 0.5 mg to about 15 mg of panax ginseng, and about 0.1 mg to about 10 mg of a vitamin. In some embodiments, the composition comprises about 120 mg to about 320 mg of maca about 120 mg to about 220 mg of fenugreek seed extract, about 5 mg to about 15 mg of cordyceps species, about 5 mg to about 15 mg of the tea extract, about 5 mg to about 15 mg of the nitric oxide source, about 5 mg to about 15 mg of the bacopa monnieri, about 1 mg to about 10 mg of the amino acid, about 1 mg to about 10 mg of the panax ginseng, and about 0.5 to about 5 mg of the vitamin. In some embodiments, the composition comprisesWSGR Docket No.59851-708.601 about 60 mg to about 160 mg of maca about 60 mg to about 110 mg of fenugreek seed extract, about 2.5 mg to about 7.5 mg of cordyceps species, about 2.5 mg to about 7.5 mg of the tea extract, about 2.5 mg to about 7.5 mg of the nitric oxide source, about 2.5 mg to about 7.5 mg of the bacopa monnieri, about 0.5 mg to about 5 mg of the amino acid, about 0.5 mg to about 5 mg of the panax ginseng, and about 0.25 to about 2.5 mg of the vitamin. In some embodiments, the composition comprises about 220 mg of maca, about 170 mg of fenugreek seed extract, about 10 mg of cordyceps species, about 10 mg of the tea extract, about 10 mg of the nitric oxide source, about 10 mg of the bacopa monnieri, about 5 mg of the amino acid, about 5 mg of the panax ginseng, and about 1.7 mg of the vitamin. In some embodiments, the cordyceps species is a cordyceps mushroom. In some embodiments, the tea extract is a green tea extract. In some embodiments, the composition comprises about 110 mg of maca, about 85 mg of fenugreek seed extract, about 5 mg of cordyceps species, about 5 mg of the tea extract, about 5 mg of the nitric oxide source, about 5 mg of the bacopa monnieri, about 2.5 mg of the amino acid, about 2.5 mg of the panax ginseng, and about 0.85 mg of the vitamin. In some embodiments, the nitric oxide source is a beet root powder. In some embodiments, the vitamin is vitamin B6. In some embodiments, the composition further comprises about 75 mg to about 450 mg of an ashwagandha extract, about 1 mg to about 175 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 175 mg of a second excipient comprising a chelating agent. In some embodiments, the composition further comprises about 37.5 mg to about 225 mg of an ashwagandha extract, about 0.5 mg to about 87.5 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 0.5 mg to about 87.5 mg of a second excipient comprising a chelating agent. In some embodiments, the composition comprises about 150 mg to about 350 mg of the ashwagandha extract, about 5 mg to about 100 mg of the first excipient, and about 5 mg to about 100 mg of the second excipient. In some embodiments, the composition comprises about 75 mg to about 175 mg of the ashwagandha extract, about 2.5 mg to about 50 mg of the first excipient, and about 2.5 mg to about 50 mg of the second excipient. In some embodiments, the composition comprises about 230 mg of the ashwagandha extract; about 250 mg of the ashwagandha extract; about 241 mg of the ashwagandha extract; about 285 mg of the ashwagandha extract; or about 281 mg of the ashwagandha extract. In some embodiments, the composition comprises about 115 mg of the ashwagandha extract; about 125 mg of the ashwagandha extract; about 120.5 mg of the ashwagandha extract; about 142.5 mg of the ashwagandha extract; or about 140.5 mg of the ashwagandha extract. In some embodiments, the composition comprises about 55 mg of the first excipient; about 65 mg of the first excipient; about 59 mg of the first excipient; about 50 mg of the first excipient; or about 79 mg of the first excipient. In some embodiments, the compositionWSGR Docket No.59851-708.601 comprises about 27.5 mg of the first excipient; about 32.5 mg of the first excipient; about 24.5 mg of the first excipient; about 25 mg of the first excipient; or about 39.5 mg of the first excipient. In some embodiments, the composition comprises about 56 mg of the second excipient; about 81 mg of the second excipient; about 59 mg of the second excipient; about 50 mg of the second excipient; or about 51 mg of the second excipient. In some embodiments, about 28 mg of the second excipient; about 40.5 mg of the second excipient; about 24.5 mg of the second excipient; about 25 mg of the second excipient; or about 25.5 mg of the second excipient. In some embodiments, the chelating agent is disodium EDTA.

[0009] In one aspect, provided is a composition comprising: about 50 mg to about 400 mg of a cordyceps mushroom, about 25 mg to about 250 mg of a component of a magnolia tree, about 1 mg to about 75 mg of oat straw, about 1 mg to about 25 mg of ginger, about 1 mg to about 25 mg of sage, about 1 mg to about 25 mg of diindolylmethane (DIM), about 25 mg to about 250 mg of a compound comprising magnesium, and about 1 mg to about 25 mg of zinc citrate. In some embodiments, the composition comprises about 100 mg to about 300 mg of the cordyceps mushroom, about 50 mg to about 150 mg of the component of the magnolia tree, about 5 mg to about 50 mg of the oat straw, about 5 mg to about 15 mg of the ginger, about 5 mg to about 15 mg of the sage, about 5 mg to about 15 mg of the DIM, about 50 mg to about 150 mg of the compound comprising magnesium, and about 5 mg to about 15 mg of the zinc citrate. In some embodiments, the composition comprises about 50 mg to about 150 mg of the cordyceps mushroom, about 25 mg to about 75 mg of the component of the magnolia tree, about 2.5 mg to about 25 mg of the oat straw, about 2.5 mg to about 7.5 mg of the ginger, about 2.5 mg to about 7.5 mg of the sage, about 2.5 mg to about 7.5 mg of the DIM, about 25 mg to about 75 mg of the compound comprising magnesium, and about 2.5 mg to about 7.5 mg of the zinc citrate. In some embodiments, the composition comprises about 185 mg of the cordyceps mushroom, about 100 mg of the component of the magnolia tree, about 25 mg of the oat straw, about 12.5 mg of the ginger, about 10 mg of the sage, about 10 mg of the DIM, about 100 mg of the compound comprising magnesium, and about 8 mg of the zinc citrate. In some embodiments, the composition comprises about 92.5 mg of the cordyceps mushroom, about 50 mg of the component of the magnolia tree, about 12.5 mg of the oat straw, about 6.25 mg of the ginger, about 5 mg of the sage, about 5 mg of the DIM, about 50 mg of the compound comprising magnesium, and about 4 mg of the zinc citrate. In some embodiments, the component of the magnolia tree is magnolia officinalis. In some embodiments, the sage comprises a sage leaf powder. In some embodiments, the compound comprising magnesium is magnesium glycinate. In some embodiments, the composition further comprises about 75 mg to about 450 mg of an ashwagandha extract, about 1 mg to about 175 mg of a first excipient comprising an extract of astragalus membranaceus and anWSGR Docket No.59851-708.601 extract of panax notoginseng, and about 1 mg to about 175 mg of a second excipient comprising a chelating agent. In some embodiments, the composition further comprises about 37.5 mg to about 225 mg of an ashwagandha extract, about 0.5 mg to about 87.5 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 0.5 mg to about 87.5 mg of a second excipient comprising a chelating agent. In some embodiments, the composition comprises about 150 mg to about 350 mg of the ashwagandha extract, about 5 mg to about 100 mg of the first excipient, and about 5 mg to about 100 mg of the second excipient. In some embodiments, the composition comprises about 75 mg to about 175 mg of the ashwagandha extract, about 2.5 mg to about 50 mg of the first excipient, and about 2.5 mg to about 50 mg of the second excipient. In some embodiments, the composition comprises about 160 mg of the ashwagandha extract; about 218 mg of the ashwagandha extract; about 250 mg of the ashwagandha extract; about 251 mg of the ashwagandha extract; or about 300 mg of the ashwagandha extract. In some embodiments, the composition comprises about 80 mg of the ashwagandha extract; about 109 mg of the ashwagandha extract; about 125 mg of the ashwagandha extract; about 125.5 mg of the ashwagandha extract; or about 150 mg of the ashwagandha extract. In some embodiments, the composition comprises about 51 mg of the first excipient; about 50 mg of the first excipient; about 29 mg of the first excipient; about 90 mg of the first excipient; or about 71 mg of the first excipient. In some embodiments, the composition comprises about 25.5 mg of the first excipient; about 25 mg of the first excipient; about 14.5 mg of the first excipient; about 45 mg of the first excipient; or about 35.5 mg of the first excipient. In some embodiments, about 50 mg of the second excipient; about 61 mg of the second excipient; about 58 mg of the second excipient; about 51 mg of the second excipient; or about 30 mg of the second excipient. In some embodiments, the composition comprises about 25 mg of the second excipient; about 30.5 mg of the second excipient; about 29 mg of the second excipient; about 25.5 mg of the second excipient; or about 15 mg of the second excipient. In some embodiments, the chelating agent is disodium EDTA.

[0010] In one aspect, provided is a composition comprising: about 1 mg to about 25 mg of phosphatidylserine, about 1 mg to about 25 mg of a component of a magnolia tree, about 1 mg to about 25 mg of an amino acid comprising L-theanine, about 1 mg to about 25 mg of an amino acid comprising L-tryptophan, about 0.5 mg to about 15 mg of a reishi mushroom, and about 0.05 mg to about 10 mg of melatonin. In some embodiments, the composition comprises about 5 mg to about 15 mg of the phosphatidylserine, about 5 mg to about 15 mg of the component of the magnolia tree, about 5 mg to about 15 mg of the amino acid comprising L-theanine, about 3 mg to about 15 mg of the amino acid comprising L-tryptophan, about 1 mg to about 10 mg of the reishi mushroom, and about 0.1 mg to about 5 mg of the melatonin. In some embodiments, theWSGR Docket No.59851-708.601 composition comprises about 12.5 mg of the phosphatidylserine, about 12.5 mg of the component of the magnolia tree, about 10 mg of the amino acid comprising L-theanine, about 7.5 mg of the amino acid comprising L-tryptophan, about 5 mg of the reishi mushroom, and about 2.5 mg of the melatonin. In some embodiments, the component of the magnolia tree is magnolia officinalis. In some embodiments, the composition further comprises about 25 mg to about 250 mg of an ashwagandha extract, about 1 mg to about 75 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 75 mg of a second excipient comprising a chelating agent. In some embodiments, the composition comprises about 50 mg to about 150 mg of the ashwagandha extract, about 5 mg to about 50 mg of the first excipient, and about 5 mg to about 50 mg of the second excipient. In some embodiments, the composition comprises about 125 mg of the ashwagandha extract; about 135 mg of the ashwagandha extract; about 100 mg of the ashwagandha extract; about 75 mg of the ashwagandha extract; or about 120 mg of the ashwagandha extract. In some embodiments, the composition comprises about 35 mg of the first excipient; about 25 mg of the first excipient; about 29 mg of the first excipient; about 21 mg of the first excipient; or about 40 mg of the first excipient. In some embodiments, the composition comprises about 25 mg of the second excipient; about 35 mg of the second excipient; about 28 mg of the second excipient; about 26 mg of the second excipient; or about 45 mg of the second excipient. In some embodiments, the chelating agent is disodium EDTA.

[0011] In one aspect, provided is a composition comprising: about 1 mg to about 25 mg of phosphatidylserine, about 1 mg to about 25 mg of a component of a magnolia tree, about 1 mg to about 175 mg of an amino acid comprising L-theanine, about1 mg to about 25 mg of an amino acid comprising L-tryptophan, about 0.5 mg to about 15 mg of a reishi mushroom, about 1 mg to about 75 mg of GABA, about 1 mg to about 75 mg of a combination of magnesium citrate and magnesium glycinate (magnesium citrate glycinate), and about 1 mg to about 175 mg of magnesium L-threonate. In some embodiments, the composition comprises about 5 mg to about 15 mg of the phosphatidylserine, about 5 mg to about 15 mg of the component of the magnolia tree, about 5 mg to about 100 mg of the amino acid comprising L-theanine, about 3 mg to about 15 mg of the amino acid comprising L-tryptophan, about 1 mg to about 10 mg of the reishi mushroom, about 5 mg to about 50 mg of the GABA, about 5 mg to about 50 mg of the magnesium citrate glycinate, and about 5 mg to about 100 mg of the magnesium L-threonate. In some embodiments, the composition comprises about 12.5 mg of the phosphatidylserine, about 12.5 mg of the component of the magnolia tree, about 53 mg of the amino acid comprising L-theanine, about 8 mg of the amino acid comprising L-tryptophan, about 5 mg of the reishi mushroom, about 26 mg of the GABA, about 33 mg of the magnesium citrate glycinate, and about 63 mg of theWSGR Docket No.59851-708.601 magnesium L-threonate. In some embodiments, the component of the magnolia tree is magnolia officinalis. In some embodiments, the composition further comprises about 25 mg to about 250 mg of an ashwagandha extract, about 1 mg to about 75 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 75 mg of a second excipient comprising a chelating agent. In some embodiments, the composition comprises about 50 mg to about 150 mg of the ashwagandha extract, about 5 mg to about 50 mg of the first excipient, and about 5 mg to about 50 mg of the second excipient. In some embodiments, the composition comprises about 134 mg of the ashwagandha extract; about 131 mg of the ashwagandha extract; about 125 mg of the ashwagandha extract; about 120 mg of the ashwagandha extract; or about 140 mg of the ashwagandha extract. In some embodiments, the composition comprises about 26 mg of the first excipient; about 25 mg of the first excipient; about 28 mg of the first excipient; about 35 mg of the first excipient; or about 31 mg of the first excipient. In some embodiments, the composition comprises about 25 mg of the second excipient; about 34 mg of the second excipient; about 26 mg of the second excipient; about 45mg of the second excipient; or about 21 mg of the second excipient. In some embodiments, the chelating agent is disodium EDTA.

[0012] In one aspect, provided is a method of alleviating a symptom associated with perimenopause or menopause in an individual, the method comprising the individual taking a composition provided herein, thereby alleviating the symptom. In some embodiments, the symptom comprises a hot flash, change in hormone levels, mood changes, difficulty sleeping, or a combination of two or more thereof.

[0013] In one aspect, provided is a method of reducing hot flashes in an individual, the method comprising the individual taking a composition provided herein, thereby reducing the hot flashes.

[0014] In one aspect, provided is a method of reducing symptoms associated with anxiety in an individual, the method comprising the individual taking a composition provided herein, thereby reducing the anxiety.

[0015] In one aspect, provided is a composition comprising a maca, fenugreek seed extract, cordyceps species, tea extract, nitric oxide source, bacopa monnieri, amino acid, panax ginseng, or a vitamin, or a combination of two or more thereof. In some embodiments, the composition comprises the maca, wherein the maca is from about 5 mg to about 520 mg of the composition. In some embodiments, the composition comprises the maca, wherein the maca is from about 60 mg to about 420 mg of the composition. In some embodiments, the composition comprises the maca, wherein the maca is from about 120 mg to about 320 mg of the composition. In some embodiments, the composition comprises the maca, wherein the maca is about 220 mg. In some embodiments, the composition comprises the fenugreek seed extract, wherein the fenugreek seedWSGR Docket No.59851-708.601 extract is from about 5 mg to about 400 mg of the composition. In some embodiments, the composition comprises the fenugreek seed extract, wherein the fenugreek seed extract is from about 60 mg to about 300 mg of the composition. In some embodiments, the composition comprises the fenugreek seed extract, wherein the fenugreek seed extract is from about 120 mg to about 220 mg of the composition. In some embodiments, the composition comprises the fenugreek seed extract, wherein the fenugreek seed extract is about 170 mg of the composition. In some embodiments, the composition comprises the cordyceps species, wherein the cordyceps species comprises a cordyceps mushroom, a cordyceps sinensis, or a combination of the two. In some embodiments, the composition comprises the cordyceps species, wherein the cordyceps species is a cordyceps mushroom. In some embodiments, the composition comprises the cordyceps species, wherein the cordyceps species is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the cordyceps species, wherein the cordyceps species is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the cordyceps species, wherein the cordyceps species is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the cordyceps species, wherein the cordyceps species is about 10 mg of the composition. In some embodiments, the composition comprises the tea extract, wherein the tea extract comprises a black tea extract, green tea extract, oolong tea extract, or a combination of two or more thereof. In some embodiments, the composition comprises the tea extract, wherein the tea extract is a green tea extract. In some embodiments, the composition comprises the tea extract, wherein the tea extract is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the tea extract, wherein the tea extract is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the tea extract, wherein the tea extract is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the tea extract, wherein the tea extract is about 10 mg of the composition. In some embodiments, the composition comprises the nitric oxide source, wherein the nitric oxide source is a beet root powder. In some embodiments, the composition comprises the nitric oxide source, wherein the nitric oxide source is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the nitric oxide source, wherein the nitric oxide source is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the nitric oxide source, wherein the nitric oxide source is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the nitric oxide source, wherein the nitric oxide source is about 10 mg of the composition. In some embodiments, the composition comprises the bacopa monnieri, wherein the bacopa monnieri is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the bacopa monnieri,WSGR Docket No.59851-708.601 wherein the bacopa monnieri is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the bacopa monnieri, wherein the bacopa monnieri is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the bacopa monnieri, wherein the bacopa monnieri is about 10 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is D- aspartic acid from about 0.05 mg to about 25 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is D-aspartic acid from about 0.5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is D-aspartic acid from about 1 mg to about 10 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is D-aspartic acid and the D-aspartic acid is about 5 mg of the composition. In some embodiments, the composition comprises the panax ginseng, wherein the panax ginseng is from about 0.05 mg to about 25 mg of the composition. In some embodiments, the composition comprises the panax ginseng, wherein the panax ginseng is from about 0.5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the panax ginseng, wherein the panax ginseng is from about 1 mg to about 10 mg of the composition. In some embodiments, the composition comprises the panax ginseng, wherein the panax ginseng is about 5 mg of the composition. In some embodiments, the composition comprises the vitamin, wherein the vitamin is vitamin B6. In some embodiments, the composition comprises the vitamin, wherein the vitamin is from about 0.01 mg to about 20 mg of the composition. In some embodiments, the composition comprises the vitamin, wherein the vitamin is from about 0.1 mg to about 10 mg of the composition. In some embodiments, the composition comprises the vitamin, wherein the vitamin is from about 0.5 mg to about 5 mg of the composition. In some embodiments, the composition comprises the vitamin, wherein the vitamin is about 1.7 mg of the composition. In some embodiments, the composition further comprises an ashwagandha extract, a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and a second excipient comprising a chelating agent. In some embodiments, the ashwagandha extract is from about 1 mg to about 550 mg of the composition. In some embodiments, the ashwagandha extract is from about 75 mg to about 450 mg of the composition. In some embodiments, the ashwagandha extract is from about 150 mg to about 350 mg of the composition. In some embodiments, the first excipient is from about 0.5 mg to about 250 mg of the composition. In some embodiments, the first excipient is from about 1 mg to about 175 mg of the composition. In some embodiments, the first excipient is from about 5 mg to about 100 mg of the composition. In some embodiments, the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), disodium EDTA, deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol,WSGR Docket No.59851-708.601 ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof. In some embodiments, the chelating agent is disodium EDTA. In some embodiments, the second excipient is from about 0.5 mg to about 250 mg of the composition. In some embodiments, the second excipient is from about 1 mg to about 175 mg of the composition. In some embodiments, the second excipient is from about 5 mg to about 100 mg of the composition.

[0016] In one aspect, provided is a composition comprising a cordyceps mushroom, a component of a magnolia tree, oat straw, ginger, sage, diindolylmethane (DIM), a compound comprising magnesium, or zinc citrate, or a combination of two or more thereof. In some embodiments, the composition comprises the cordyceps mushroom, wherein the cordyceps mushroom is from about 5 mg to about 500 mg of the composition. In some embodiments, the composition comprises the cordyceps mushroom, wherein the cordyceps mushroom is from about 50 mg to about 400 mg of the composition. In some embodiments, the composition comprises the cordyceps mushroom, wherein the cordyceps mushroom is from about 100 mg to about 300 mg of the composition. In some embodiments, the composition comprises the cordyceps mushroom, wherein the cordyceps mushroom is about 185 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is magnolia officinalis. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is from about 1 mg to about 350 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is from about 25 mg to about 250 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is from about 50 mg to about 150 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is about 100 mg of the composition. In some embodiments, the composition comprises the oat straw, wherein the oat straw is from about 0.5 mg to about 100 mg of the composition. In some embodiments, the composition comprises the oat straw, wherein the oat straw is from about 1 mg to about 75 mg of the composition. In some embodiments, the composition comprises the oat straw, wherein the oat straw is from about 5 mg to about 50 mg of the composition. In some embodiments, the composition comprises the oat straw, wherein the oat straw is about 25 mg of the composition. In some embodiments, the composition comprises the ginger, wherein the ginger is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the ginger, wherein the ginger is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the ginger, wherein the ginger is from about 5 mg to about 15 mg of the composition.WSGR Docket No.59851-708.601 In some embodiments, the composition comprises the ginger, the ginger is about 12.5 mg of the composition. In some embodiments, the composition comprises the sage, wherein the sage comprises a sage leaf powder. In some embodiments, the composition comprises the sage, wherein the sage is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the sage, wherein the sage is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the sage, wherein the sage is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the sage, wherein the sage is about 10 mg of the composition. In some embodiments, the composition comprises the DIM, wherein the DIM is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the DIM, wherein the DIM is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the DIM, wherein the DIM is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the DIM, wherein the DIM is about 10 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is magnesium glycinate. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 1 mg to about 350 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 25 mg to about 250 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 50 mg to about 150 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is about 100 mg of the composition. In some embodiments, the composition comprises the zinc citrate, wherein the zinc citrate is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the zinc citrate, wherein the zinc citrate is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the zinc citrate, wherein the zinc citrate is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the zinc citrate, wherein the zinc citrate is about 8 mg of the composition. In some embodiments, the composition further comprises an ashwagandha extract, a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and a second excipient comprising a chelating agent. In some embodiments, the ashwagandha extract is from about 1 mg to about 550 mg of the composition. In some embodiments, the ashwagandha extract is from about 75 mg to about 450 mg of the composition. In some embodiments, the ashwagandha extract is from about 150 mg to about 350 mg of the composition. In some embodiments, the ashwagandha extract isWSGR Docket No.59851-708.601 about 250 mg of the composition. In some embodiments, the first excipient is from about 0.5 mg to about 250 mg of the composition. In some embodiments, the first excipient is from about 1 mg to about 175 mg of the composition. In some embodiments, the first excipient is from about 5 mg to about 100 mg of the composition. In some embodiments, the first excipient is about 50 mg of the composition. In some embodiments, the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), disodium EDTA, deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol, ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof. In some embodiments, the chelating agent is disodium EDTA. In some embodiments, the second excipient is from about 0.5 mg to about 250 mg of the composition. In some embodiments, the second excipient is from about 1 mg to about 175 mg of the composition. In some embodiments, the second excipient is from about 5 mg to about 100 mg of the composition. In some embodiments, the second excipient is about 50 mg of the composition.

[0017] In one aspect, provided is a composition comprising phosphatidylserine, a component of a magnolia tree, amino acid, reishi mushroom, or melatonin, or a combination of two or more thereof. In another aspect, provided is a composition comprising phosphatidylserine, a component of a magnolia tree, amino acid, reishi mushroom, GABA, a compound comprising magnesium or a combination of two or more thereof. In some embodiments, the composition comprises the phosphatidylserine, wherein the phosphatidylserine is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the phosphatidylserine, wherein the phosphatidylserine is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the phosphatidylserine, wherein the phosphatidylserine is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the phosphatidylserine, wherein the phosphatidylserine is about 12.5 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is magnolia officinalis. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the component of the magnolia tree, wherein the component of the magnolia tree is about 12.5 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine from about 0.5 mg to about 250WSGR Docket No.59851-708.601 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine from about 1 mg to about 175 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine from about 5 mg to about 100 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine and the L-theanine is about 53 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine from about 5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-theanine and the L-theanine is about 10 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-tryptophan from about 0.1 mg to about 50 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-tryptophan from about 1 mg to about 25 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-tryptophan from about 3 mg to about 15 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-tryptophan and the L-tryptophan is about 7.5 mg of the composition. In some embodiments, the composition comprises the amino acid, wherein the amino acid is L-tryptophan and the L-tryptophan is about 8 mg of the composition. In some embodiments, the composition comprises the reishi mushroom, wherein the reishi mushroom is from about 0.05 mg to about 25 mg of the composition. In some embodiments, the composition comprises the reishi mushroom, wherein the reishi mushroom is from about 0.5 mg to about 15 mg of the composition. In some embodiments, the composition comprises the reishi mushroom, wherein the reishi mushroom is from about 1 mg to about 10 mg of the composition. In some embodiments, the composition comprises the reishi mushroom, wherein the reishi mushroom is about 5 mg of the composition. In some embodiments, the composition comprises the melatonin, wherein the melatonin is from about 0.01 mg to about 20 mg of the composition. In some embodiments, the composition comprises the melatonin, wherein the melatonin is from about 0.05 mg to about 10 mg of the composition. In some embodiments, the composition comprises the melatonin, wherein the melatonin is from about 0.1 mg to about 5 mg of the composition. In some embodiments, the composition comprises the melatonin, wherein the melatonin is about 2.5 mg of the composition. In some embodiments, the composition comprises the GABA, wherein the GABA is from about 0.5 mg to about 100 mg of the composition. In some embodiments, the composition comprises the GABA, wherein the GABAWSGR Docket No.59851-708.601 is from about 1 mg to about 75 mg of the composition. In some embodiments, the composition comprises the GABA, wherein the GABA is from about 5 mg to about 50 mg of the composition. In some embodiments, the composition comprises the GABA, wherein the GABA is about 26 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is magnesium citrate, magnesium glycinate, magnesium L-threonate, or a combination of two or more thereof. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is a combination of magnesium citrate and magnesium glycinate. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is magnesium L-threonate. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 0.1 mg to about 100 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 1 mg to about 75 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 5 mg to about 50 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is about 33 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 0.5 mg to about 250 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 1 mg to about 175 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is from about 5 mg to about 100 mg of the composition. In some embodiments, the composition comprises the compound comprising magnesium, wherein the compound comprising magnesium is about 63 mg of the composition. In some embodiments, the composition further comprises an ashwagandha extract, a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and a second excipient comprising a chelating agent. In some embodiments, the ashwagandha extract is from about 1 mg to about 350 mg of the composition. In some embodiments, the ashwagandha extract is from about 25 mg to about 250 mg of the composition. In some embodiments, the ashwagandha extract is from about 50 mg to about 150 mg of the composition. In some embodiments, the first excipient is from about 0.5 mg to about 100 mg of the composition. In some embodiments, the first excipient is from about 1 mg to about 75 mg of the composition. In some embodiments, the first excipient is from about 5 mg to about 50 mg of the composition. In some embodiments, the chelating agentWSGR Docket No.59851-708.601 comprises ethylenediaminetetraacetic acid (EDTA), disodium EDTA, deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol, ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof. In some embodiments, the chelating agent is disodium EDTA. In some embodiments, the second excipient is from about 0.5 mg to about 100 mg of the composition. In some embodiments, the second excipient is from about 1 mg to about 75 mg of the composition. In some embodiments, the second excipient is from about 5 mg to about 50 mg of the composition.

[0018] In one aspect, provided is a method of alleviating a symptom associated with perimenopause or menopause in an individual, the method comprising the individual taking a composition herein, thereby alleviating the symptom. In some embodiments, the symptom comprises a hot flash, change in hormone levels, mood changes, difficulty sleeping, or a combination of two or more thereof. In some embodiments, the symptom is a hot flash. In some embodiments, the individual takes the composition within about 0.5 hours of waking up. In some embodiments, the individual takes the composition from about 4 pm to about 7 pm. In some embodiments, the individual takes the composition within about 0.5 hours before going to sleep. In some embodiments, the individual takes: a composition provided herein within about 0.5 hours of waking up, a composition provided herein from about 4 pm to about 7 pm, and a composition provided herein within about 0.5 hours before going to sleep.

[0019] In one aspect, provided is a method of reducing hot flashes in an individual, the method comprising the individual taking a composition provided herein, thereby reducing the hot flashes. In some embodiments, the individual takes the composition within about 0.5 hours of waking up. In some embodiments, the individual takes the composition from about 4 pm to about 7 pm. In some embodiments, the individual takes the composition within about 0.5 hours before going to sleep. In some embodiments, the individual takes: a composition provided herein within about 0.5 hours of waking up, a composition provided herein from about 4 pm to about 7 pm, and a composition provided herein within about 0.5 hours before going to sleep.

[0020] In one aspect, provided is a method of reducing symptoms associated with anxiety in an individual, the method comprising the individual taking a composition provided herein, thereby reducing the anxiety. In some embodiments, the individual takes the composition within about 0.5 hours of waking up. In some embodiments, the individual takes the composition from about 4 pm to about 7 pm. In some embodiments, the individual takes the composition within about 0.5 hours before going to sleep. In some embodiments, the individual takes: a composition provided herein within about 0.5 hours of waking up, a composition provided herein from about 4 pm to about 7 pm, and a composition provided herein within about 0.5 hours before going to sleep.WSGR Docket No.59851-708.601 BRIEF DESCRIPTION OF THE FIGURES

[0021] Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

[0022] FIG.1 schematically illustrates a system for monitoring the health of a person, in accordance with an embodiment.

[0023] FIG.2 illustrates a user interface, in accordance with an embodiment.

[0024] FIG.3 illustrates a method of monitoring the health of a person, in accordance with an embodiment.

[0025] FIG.4 shows a computer system that is programmed or otherwise configured to implement methods provided herein.

[0026] FIG.5 is a flow chart of an example computer implemented method for assessing the health or wellbeing of a person based on information associated with a person.

[0027] FIG.6 is a flow diagram of an example web-based computer system for monitoring and tracking the health and wellbeing of a person or persons and making recommendations based on the person’s health.

[0028] FIGS.7A-7O illustrate an example method of providing a health score and recommendation to a user.

[0029] FIG.8 illustrates an example personalized email with results and recommendations generated in response to a user taking a health score quiz.

[0030] FIG.9 illustrates an example visual score display.

[0031] FIG.10A shows mean change in hot flashes in a person compared to baseline over a 12 week period.

[0032] FIG.10B shows percent reduction in hot flashes in a person compared to baseline over a 12 week period.

[0033] FIG. 11 shows reduction in hot flashes compared to baseline in 4 different groups of persons over a 12 week period.

[0034] FIG. 12 shows reported effects of compositions provided herein by persons using such compositions. DETAILED DESCRIPTION

[0035] In some aspects, provided herein are compositions and oral formulations of a composition that may be used to improve the health of a person.

[0036] In some embodiments, about means within 10% of the stated amount. For instance, an agent present in a composition (e.g., a composition provided herein) at about 30% may comprise 27% to 33% of the agent.WSGR Docket No.59851-708.601 Perimenopause and menopause

[0037] In one aspect, provided are compositions and formulations that may be used to modulate changes in hormone levels, hot flashes (including shivering, sweating, and reddening of the skin), mood changes, and / or difficulty sleeping in perimenopausal and menopausal women. In some aspects, onset of menopause and / or perimenopause in women may be indicated by changes in hormone levels. In some aspects, onset of menopause and / or perimenopause in women may be indicated by age (e.g., between 47 and 54 years of age).

[0038] In one aspect, provide herein are compositions and formulations for application to a person that reduce / and or alleviate symptoms associated with menopause or perimenopause.

[0039] Hot flashes are a common symptom of menopause and perimenopause. Hot flashes are typically experienced as a feeling of intense heat with sweating and rapid heartbeat. Usually, each hot flash lasts about 2 to about 30 minutes and can repeat one or more times a week or every few minutes each day. Usually, the sensation of heat usually begins in the face or chest, but it can also present elsewhere such as the back of the neck and the heat sensation can spread throughout the whole body. In some instances, people feel as if they are about to faint. Moreover, in addition to the internal hot sensation, the surface of the skin (especially on the face) becomes hot to the touch and may be present with reddening of the face. In some instances, hot flashes appear several years before menopause starts and last for years afterward menopause ends. And the experience of the person undergoing menopause or perimenopause varies. In certain instances, persons never have hot flashes where others experience dozens of hot flashes each day. In addition, hot flashes are often more frequent and more intense during hot weather or in an overheated space. In some instances, frequent incidence of hot flashes make it difficult to sleep and otherwise impair the mood, concentration, and cause other physical problems in a person.

[0040] In one aspect, provide herein are compositions and formulations for application to a person that reduce / and or eliminate incidence of hot flashes. Anxiety

[0041] In one aspect, provided are compositions and formulations that may be used to modulate symptoms of anxiety. Symptoms of anxiety include: feeling restless, wound-up or on edge, being easily fatigued; having difficulty concentrating; being irritable; having difficulty controlling feelings of worry; having headaches, muscle aches, stomachaches, or unexplained pains; having sleep problems, such as difficulty falling or staying asleep. Anxiety disorders are one of most common mental disorders and affect nearly 30% of adults at some point in their lives.

[0042] In one aspect, provide herein are compositions and formulations for application to a person that reduce / and or eliminate symptoms associated with anxiety.WSGR Docket No.59851-708.601 Cortisol

[0043] In one aspect, provided are compositions and formulations used to modulate cortisol levels in a person. Cortisol is a steroid hormone synthesized from cholesterol in the adrenal cortex. Specifically, the zona fasciculata layer of the adrenal cortex. Secretion of cortisol is controlled by the hypothalamus, the pituitary gland, and the adrenal gland. These three are commonly known together as the HPA axis. Cortisol is known for being the stress hormone, but it is also responsible for much more. Without being bound by theory, cortisol has been shown to affect many functions in the human body. For example, cortisol has been shown to regulate the metabolism, control blood sugar levels, modulate inflammation in the body, play an important role in memory formation, play an important role in controlling blood pressure, and have controlling effects on salt and water balance. Moreover, in women cortisol levels may be important to the developing fetus during pregnancy. Cortisol levels thus may be instrumental in an individual’s health and well-being. Furthermore, high cortisol levels have been associated with negative indications such as changes in a woman’s libido and menstrual cycle, anxiety, and depression. High levels of cortisol may cause downstream negative effects in the body. High levels of cortisol may suppress the normal function of other hormones in the body. Other indications of high cortisol may include weight gain, high blood pressure, muscle weakness, fatigue, a weak immune system, difficulty healing wounds, thinning skin that is easily bruised, headaches, irritability, low libido, infertility, bone loss, insulin resistance leading to type 2 diabetes, negative effects on the frontal cortex affecting thinking and mood. Negative symptoms of low cortisol may include levels include fatigue, muscle or joint pain, low blood pressure, low blood sugar, nausea, vomiting, diarrhea, hyperpigmentation, irritability, depression, and hair loss. Use of compositions to modulate cortisol levels can mitigate these negative effects. Organic Extracts (e.g., ashwagandha)

[0044] In one aspect, provided herein are compositions and formulations of such compositions comprising an extract or powder from an organic material. In certain embodiments, a composition (e.g., a composition provided herein) comprises ashwagandha (e.g., an ashwagandha extract). In some embodiments, the composition comprises an ashwagandha extract. Ashwagandha, or withania somnifera, is an herb that has been used in the traditional Indian medicine system, Aryuveda, for thousands of years. Ashwagandha is typically available as a fine powder and is commonly mixed into and taken with food. The herb has demonstrated anti-stress, anti-tumor, rejuvenation, anti-arthritic, and anti-neurodegenerative effects in scientific studies. Withania somnifera comprises several biologically active chemical constituents including alkaloids, steroidal lactones, saponins, and anti-stress agents. Alkaloids are cyclic organic compounds containing nitrogen in a negative oxidation state. Thousands of alkaloids are known, most havingWSGR Docket No.59851-708.601 been isolated from plants. Numerous alkaloid compounds have application in the pharmaceutical field, both in their purified forms or in unpurified plant extract form. Many alkaloids derive bioactive properties in man, typically from their heterocyclic tertiary nitrogen. The alkaloid components of ashwagandha include isopelletierine, anaferine, cuseohygrine, and anahygrine. Steroidal lactones include withanolides. Withanolides are a group of naturally occurring 28 carbon steroids. One such withanolide, withanolide A, is isolated from the ashwagandha plant and has antioxidant and neuroprotective properties. Specifically, it has been shown to help promote neurite outgrowth in cultured neurons and in rodents. Another, withanolide B, contains enzymes that promote the production of nitric oxide, important for cellular signaling in humans. Withaferin A was the first withanolide-type constituent isolated from the withania somnifera (ashwagandha) plant. Withaferin A contains many of the bioactive components of the ashwagandha plant. Reports show that Witheraferin A has multiple potential health benefits such as anti-inflammatory, anti- diabetic, anti-cancer, and anti-angiogenesis effects. Withania somnifera has demonstrated anti- stress agents, such as sitoindosides and acylsterylglucosides. Anti-stress agents are compounds that mitigate stress-induced increases in physiological levels of certain compounds, such as urea nitrogen levels in blood. Saponins are a group of naturally occurring plant glycosides, characterized by their strong foam-forming properties in aqueous solution. Saponins include sitoindosides VII and VIII. In a non-limiting embodiment, ashwagandha is KSM-66®, which is a branded, full-spectrum extract, with the highest concentration of all major root only extracts. KSM-66® has at least 5% withanolides percent by weight (w / w). KSM-66® ashwagandha is produced using green chemistry extraction processes, without the use of chemical solvents. The KSM-66 extraction process uses the roots of the ashwagandha plant with no addition of leaves. Most scientific studies explore the therapeutic effects of the roots and not the leaves. The KSM- 66 process produces a full-spectrum extract which maintains the balance of the efficacious compounds of the ashwagandha root in their natural proportions. The KSM-66® extraction process may entail pre-treating the ashwagandha roots with milk. Doing so promotes retention of both the hydrophilic and lipophilic components. Alternatively, the KSM-66® process may use a milk-free vegan process. The remainder of both processes may be done with green chemistry as described above.

[0045] Studies of KSM-66® ashwagandha extract demonstrate its natural properties. Specifically, root extract of ashwagandha has sleep-inducing potential. It is well-tolerated and improves sleep onset and sleep quality in persons with insomnia. Further, it has the potential to be used to improve sleep parameters for individuals with anxiety and insomnia. Furthermore, intake of an ashwagandha extract plays an important role in the modulation of cortisol levels in the human body. Ashwagandha intake has been shown to result in reduction of cortisol levels. Furthermore,WSGR Docket No.59851-708.601 ashwagandha is an adaptogen, meaning it enables the body to adapt to stress (e.g., by mitigating the cortisol or adrenal response). Thus, intake of ashwagandha may diminish the downstream effects cortisol has on the human body.

[0046] In certain embodiments, about 1 mg to about 550 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In some embodiments, about 75 mg to about 450 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In certain embodiments, about 150 mg to about 350 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In specific embodiments, about 200 mg to about 300 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In certain embodiments, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, or about 300 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In specific embodiments, about 250 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In yet more specific embodiments, about 230 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract.

[0047] In certain embodiments, about 1 mg to about 350 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In some embodiments, about 25 mg to about 250 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In certain embodiments, about 50 mg to about 150 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In specific embodiments, about 110 mg to about 140 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In certain embodiments, about 85 mg, about 95 mg, about 105 mg, about 115 mg, about 125 mg, about 135 mg, about 145 mg, about 155 mg, about 165 mg, about 175 mg, or about 185 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In specific embodiments, about 125 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In yet more specific embodiments, about 145 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In some embodiments, about 131 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In some embodiments, about 140 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In some embodiments, about 139 mg of a composition (e.g., a composition provided herein) is an ashwagandha extract. In some embodiments, a composition (e.g., a composition provided herein) comprising ashwagandha is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours afterWSGR Docket No.59851-708.601 waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In certain embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 150 mg to about 350 mg, about 175 mg to about 325 mg, about 200 mg to about 300 mg, about 225 mg to about 275 mg, or about 250 mg. An example product is called RHM.

[0048] In some embodiments, a composition (e.g., a composition provided herein) comprising ashwagandha is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. In certain embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 150 mg to about 350 mg, about 175 mg to about 325 mg, about 200 mg to about 300 mg, about 225 mg to about 275 mg, or about 250 mg. An example product is called RHA.

[0049] In some embodiments, a composition (e.g., a composition provided herein) comprising ashwagandha is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. In certain embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein is about 1 mg to about 350 mg, about 25 mg to about 250 mg, about 50 mg to about 150 mg, about 85 mg to about 145 mg, about 125 mg, about 133 mg, or about 140 mg. In specific embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 125 mg. In some embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 131 mg. In some embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 150 mg. In some embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 129 mg. In some embodiments, the amount of ashwagandha extract present in a composition (e.g., a composition provided herein) is about 134 mg. An example product is called RHN.

[0050] As described above, intake of ashwagandha may lead to various effects relating to a person. For example, intake of ashwagandha may lead to improved ability to fall asleep, improved sleep, reduction of anxiety, modulation of cortisol levels, and regulated stress levels. Intake of ashwagandha may facilitate hormonal balance, which may lead to increased energy, increased relaxation, or both. While KSM-66® is described above as a source of ashwagandha, KSM-66®WSGR Docket No.59851-708.601 is exemplary and other sources of ashwagandha may be used. In some embodiments, intake of ashwagandha alleviates a hot flash. In some embodiments, intake of ashwagandha alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of ashwagandha alleviates one or more symptoms associated with menopause. In some embodiments, intake of ashwagandha alleviates one or more symptoms associated with anxiety. Maca

[0051] In one aspect, provided are compositions and formulations of such compositions comprising maca. In certain embodiments, a composition (e.g., a composition provided herein) comprises maca. Maca (Lepidium meyenii) is a root, belonging to the cabbage family, native to the Andean region of Peru, where it has been cultivated for at least 2000 years. Maca is rich in fiber, essential amino acids, fatty acids, and other nutrients, including vitamins such as vitamin A, vitamin b6, manganese, copper, iron, and calcium. Further, the root contains bioactive compounds that have been shown to be responsible for therapeutic benefits to the human body, e.g., regulation of sexual dysfunction, memory enhancement, anti-depressant effects, antioxidant effects, anti- inflammatory effects, anti-cancer effects, neuroprotective effects, and skin protection. Experimental studies indicate the effects maca has on energy, mood, nutrition, fertility, hormone production, and memory. Furthermore, maca has been shown to improve sperm production, sperm motility and semen volume. Additionally, there are indications that maca may be used to reduce prostate size. The role maca plays in homeostatic balance is related to bone metabolism. Use of maca by menopausal women has been associated with improvements in sexual dysfunction and reduction in instances of anxiety and depression. Maca is used as a supplement to enhance fertility and improve libido as well as the effects listed above. Typically, maca is extracted and available in a powdered form.

[0052] In certain embodiments, about 5 mg to about 520 mg of a composition (e.g., a composition provided herein) is maca (e.g., a powdered maca root). In some embodiments, about 60 mg to about 420 mg of a composition (e.g., a composition provided herein) is maca. In certain embodiments, about 120 mg to about 320 mg of a composition (e.g., a composition provided herein) is maca. In specific embodiments, about 170 mg to about 270 mg of a composition (e.g., a composition provided herein) is maca. In certain embodiments, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, or about 270 mg of a composition (e.g., a composition provided herein) is maca. In specific embodiments, about 220 mg of a composition (e.g., a composition provided herein) is maca. In yet more specific embodiments, about 240 mg of a composition (e.g., a composition provided herein) is maca.

[0053] In certain instances, compositions provided herein comprise maca. In some embodiments,WSGR Docket No.59851-708.601 a composition (e.g., a composition provided herein) comprising maca is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of maca present in the composition is about 5 mg to about 520 mg, about 60 mg to about 420 mg, about 120 mg to about 320 mg, about 170 mg to about 270 mg, or about 220 mg. An example product is called RHM.

[0054] In certain embodiments, intake of maca may lead to various effects relating to a person. For example, maca has nutritional benefits such as containing fiber, essential amino acids, fatty acids, vitamins, manganese, copper, iron, and calcium. Intake of maca may further lead to other benefits such as improving or diminishing effects from sexual dysfunction, depression, inflammation, and cancer. Intake of maca may also lead to effects such as enhanced memory, reducing risk of disease by maca’s antioxidant properties, and increased skin protection. In some embodiments, intake of maca alleviates a hot flash. In some embodiments, intake of maca alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of maca alleviates one or more symptoms associated with menopause. In some embodiments, intake of maca alleviates one or more symptoms associated with anxiety. Fenugreek

[0055] In one aspect, provided herein are compositions and formulations comprising such compositions comprising fenugreek seed extract. In certain embodiments, a composition (e.g., a composition provided herein) comprises fenugreek seed extract. Fenugreek seeds have been used historically as an herbal remedy mitigating nutritive and metabolic dysfunctions. The extract has been shown to inhibit fat accumulation. Fenugreek, or Trigonella foenum-graecum (TFG) seeds belong to the Fabaceae family. TFG extract has been used against diabetes and has been included as an active ingredient in weight loss medications. TFG extract has been shown to possess hypoglycemic, antioxidant, and hypolipidemic effects. One extract of TFG seeds, Testosurge®, has been shown to improve strength, body composition (e.g., fat burning), and hormonal profiles. In specific embodiments, the fenugreek seed extract comprises Testosurge® fenugreek extract (std. min 80% grecunin).

[0056] In certain embodiments, about 5 mg to about 400 mg of a composition (e.g., a composition provided herein) is a fenugreek seed extract (e.g., Testosurge®). In some embodiments, about 60 mg to about 300 mg of a composition (e.g., a composition provided herein) is a fenugreek seed extract. In certain embodiments, about 120 mg to about 220 mg of a composition (e.g., aWSGR Docket No.59851-708.601 composition provided herein) is a fenugreek seed extract. In specific embodiments, about 140 mg to about 200 mg of a composition (e.g., a composition provided herein) is a fenugreek seed extract. In certain embodiments, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, or about 200 mg of a composition (e.g., a composition provided herein) is a fenugreek seed extract. In specific embodiments, about 170 mg of a composition (e.g., a composition provided herein) is a fenugreek seed extract (e.g., Testosurge®). In yet more specific embodiments, about 190 mg of a composition (e.g., a composition provided herein) is a fenugreek seed extract (e.g., Testosurge®).

[0057] In certain instances, compositions provided herein comprise fenugreek seed extract. In some embodiments, a composition (e.g., a composition provided herein) comprising fenugreek seed extract (e.g., Testosurge®) is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of fenugreek seed extract present in the composition is about 5 mg to about 400 mg, about 60 mg to about 300 mg, about 120 mg to about 220 mg, about 140 mg to about 200 mg, or about 170 mg. An example product is called RHM.

[0058] As described above, intake of fenugreek seed extract may lead to various effects for a person. For example, intake of fenugreek seed extract may inhibit fat accumulation and symptoms of diabetes. As another example, intake of fenugreek seed may promote weight loss, body composition, and increased strength of a person. While Testosurge® is described above an example of fenugreek extract, Testosurge® is exemplary and other sources of fenugreek extract may be used. In some embodiments, intake of a fenugreek seed extract alleviates a hot flash. In some embodiments, intake of a fenugreek seed extract alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a fenugreek seed extract alleviates one or more symptoms associated with menopause. In some embodiments, intake of a fenugreek seed extract alleviates one or more symptoms associated with anxiety. Cordyceps mushroom (e.g., CordycepsPrime™)

[0059] In one aspect, provided herein are compositions or formulations comprising such composition comprising a cordyceps species. In certain embodiments, the cordyceps species is a cordyceps mushroom (e.g., CordycepsPrime™), or cordyceps sinensis. Cordyceps species have been known to exhibit a wide range of pharmacological effects including antioxidative, anti- inflammatory, anticancer, anti-obesity, and antidiabetic. The pharmacological potential of theseWSGR Docket No.59851-708.601 plants has been demonstrated. Cordyceps mushrooms from CordycepsPrime™ are grown using unique fermentation technologies in nutrient-dense solution. In specific embodiments, the cordyceps species comprises an extract of cordyceps mycelium (e.g., CordycepsPrime™).

[0060] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom (e.g., CordycepsPrime™). In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, or about 13 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom (e.g., CordycepsPrime™). In yet more specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom (e.g., CordycepsPrime™).

[0061] In certain embodiments, about 5 mg to about 500 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom (e.g., CordycepsPrime™). In some embodiments, about 50 mg to about 500 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In certain embodiments, about 100 mg to about 300 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In specific embodiments, about 150 mg to about 250 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In certain embodiments, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 185 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, or about 250 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom. In specific embodiments, about 185 mg of a composition (e.g., a composition provided herein) Is a cordyceps mushroom (e.g., CordycepsPrime™). In yet more specific embodiments, about 200 mg of a composition (e.g., a composition provided herein) is a cordyceps mushroom (e.g., CordycepsPrime™).

[0062] In certain instances, compositions provided herein comprise cordyceps mushroom. In some such cases, the amount of cordyceps mushroom present in the composition is about 2 mg to about 8 mg, about 3 mg to about 7 mg, about 3 mg to about 6 mg, or about 5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising a cordyceps mushroom (e.g., CordycepsPrime™) is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. InWSGR Docket No.59851-708.601 still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of cordyceps mushroom present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, about 7 mg to about 13 mg, or about 10 mg. An example product is called RHM.

[0063] In some embodiments, a composition (e.g., a composition provided herein) comprising a cordyceps mushroom (e.g., CordycepsPrime™) is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. In some such cases, the amount of cordyceps mushroom present in the composition is about 5 mg to about 500 mg, about 50 mg to about 400 mg, about 100 mg to about 300 mg, about 150 mg to about 250 mg, or about 185 mg. An example product is called RHA.

[0064] As described above, intake of cordyceps mushroom may lead to various effects for a person. For example, intake of cordyceps mushroom may lead to reduction of disease and inflammation as well as reducing the risk of cancer, obesity, and diabetes. While CordycepsPrime™ is described above as a source of cordyceps mushroom, CordycepsPrime™ is exemplary and other cordyceps mushrooms may be used. In some embodiments, intake of a cordyceps mushroom alleviates a hot flash. In some embodiments, intake of a cordyceps mushroom alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a cordyceps mushroom alleviates one or more symptoms associated with menopause. In some embodiments, intake of a cordyceps mushroom alleviates one or more symptoms associated with anxiety. Vitamins (e.g., Vitamin B6)

[0065] In one aspect, provided herein are compositions and formulations of such compositions comprising a vitamin (e.g., vitamin B6). In certain embodiments, a composition (e.g., a composition provided herein) comprises a vitamin. In some embodiments, the vitamin comprises vitamin A, C, D, E, K, B1, B2, B3, B5, B6, B7, B9, B12, or a combination of two or more thereof. In certain embodiment, the vitamin comprises pyridoxine, cyanocobalamin, ascorbic acid, biotin niacin, folate, pantothenic acid, riboflavin, thiamine, choline, carnitine, folic acid, or a combination of two or more thereof. In specific embodiments, a composition (e.g., a composition provided herein) comprises Vitamin B6. In yet more specific embodiments, a composition (e.g., a composition provided herein) comprises Vitamin C. Many vitamins are required for the body to work properly, and serve important functions and work as, as non-limiting examples, antioxidants, coagulants, and means to regulate basic cellular metabolism. In some embodiments, provided are compositions comprising vitamin B6. Vitamin B6 is an important compound for general cellularWSGR Docket No.59851-708.601 metabolism and is a potent antioxidant.

[0066] In certain embodiments, about 0.01 mg to about 20 mg of a composition (e.g., a composition provided herein) is a vitamin. In some embodiments, about 0.1 mg to about 10 mg of a composition (e.g., a composition provided herein) is a vitamin. In certain embodiments, about 0.5 mg to about 5 mg of a composition (e.g., a composition provided herein) is a vitamin. In specific embodiments, about 1 mg to about 2 mg of a composition (e.g., a composition provided herein) is a vitamin. In certain embodiments, about 0.5 mg, about 0.7 mg, about 0.9 mg, about 1.1 mg, about 1.3 mg, about 1.5 mg, about 1.7 mg, about 1.9 mg, about 2.1 mg, about 2.3 mg, about 2.3 mg, about 2.5 mg, about 2.7 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, or about 5 mg of a composition (e.g., a composition provided herein) is a vitamin. In specific embodiments, about 1.7 mg of a composition (e.g., a composition provided herein) is a vitamin. In yet more specific embodiments, about 1.3 mg of a composition (e.g., a composition provided herein) is a vitamin.

[0067] In certain instances, compositions provided comprise a vitamin (e.g., Vitamin B6). In some embodiments, a composition (e.g., a composition provided herein) comprising a vitamin (e.g., Vitamin B6) is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of a vitamin (e.g., vitamin B6) present in the composition is about 0.01 mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to about 5 mg, about 1 mg to about 3 mg, or about 1.7 mg. An example product is called RHM.

[0068] In certain embodiments, intake of vitamins may lead to various effects for a person. In some instances, intake of vitamins may lead to reduction of the risk of certain diseases. In certain instances, intake of vitamins may also improve the ability of a person to regulate his or her metabolism. In some embodiments, intake of a vitamin (e.g., Vitamin B6) alleviates a hot flash. In some embodiments, intake of a vitamin alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a vitamin alleviates one or more symptoms associated with menopause. In some embodiments, intake of a vitamin alleviates one or more symptoms associated with anxiety. Nitric Oxide (beet root powder)

[0069] In one aspect, provided are compositions and formulations of such compositions comprising a nitric oxide source (e.g., beet root powder). In certain embodiments, a composition (e.g., a composition provided herein) comprises a nitric oxide source (e.g., beet root powder). InWSGR Docket No.59851-708.601 specific embodiments, a composition (e.g., a composition provided herein) comprises beet root powder. In certain instances, beet root powder is used as a food supplement due to its health promoting and disease preventing functionalities. In some instances, ingestion of beet root powder can serve as a natural method of increasing in vivo nitric oxide availability. In certain instances, beet root powder is used against pathologies such as hypertension and endothelial dysfunction. Furthermore, nitric oxide in beet root powder has been shown to open up blood vessels, facilitating blood flow to the brain, resulting in improvements to cognition.

[0070] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is a nitric oxide source (e.g., beet root powder). In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is a nitric oxide source. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is a nitric oxide source. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is nitric oxide source. In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, or about 13 mg of a composition (e.g., a composition provided herein) is a nitric oxide source. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is a nitric oxide source. In yet more specific embodiments, about 12 mg of a composition (e.g., a composition provided herein) is a nitric oxide source.

[0071] In certain instances, compositions provided herein comprise a nitric oxide source (e.g., beet root powder). In some embodiments, a composition (e.g., a composition provided herein) comprising a nitric oxide source is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of a nitric oxide source present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, about 7 mg to about 13 mg, or about 10 mg. An example product is called RHM.

[0072] In certain embodiments, intake of nitric oxide may lead to various effects for a person. In some embodiments, intake of nitric oxide may lead to reduction of the risk of certain diseases as well as the reduction of hypertension and endothelial dysfunction. In certain embodiments, intake of nitric oxide may lead to more blood flow to the brain and increased cognition. In some embodiments, intake of a nitric oxide source alleviates a hot flash. In some embodiments, intake of a nitric oxide source alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a nitric oxide source alleviates one or more symptoms associated withWSGR Docket No.59851-708.601 menopause. In some embodiments, intake of a nitric oxide source alleviates one or more symptoms associated with anxiety. Green Tea Extract

[0073] In one aspect, provided herein are compositions and formulations comprising such compositions comprising a tea extract (e.g., a green tea extract). In certain embodiments, a composition (e.g., a composition provided herein) comprises a tea extract (e.g., a green tea extract). In some embodiments, the tea extract comprises black tea, oolong tea, green tea, or a combination of two or more thereof. In specific embodiments, a composition (e.g., a composition provided herein) comprises a green tea extract. In certain instances, green tea extract may be a decaffeinated green tea polyphenol mixture isolated from the plant from which it originates, Camellia sinensis. In some instances, green tea extract has antiviral, antioxidant, and potential chemopreventive activities. Green tea extract contains compounds such as antioxidant compounds, flavonoids, and polyphenols such as catechins. In specific embodiments, the tea extract is green tea extract comprising 50% Epigallocatechin gallate (EGCG) leaf.

[0074] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is a tea extract (e.g., green tea extract). In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is a tea extract. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is a tea extract. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is tea extract. In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, or about 13 mg of a composition (e.g., a composition provided herein) is a tea extract. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is a tea extract. In yet more specific embodiments, about 12 mg of a composition (e.g., a composition provided herein) is a tea extract.

[0075] In certain instances, compositions provided herein comprise a tea extract (e.g., green tea extract). In some embodiments, a composition (e.g., a composition provided herein) comprising a tea extract is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of a tea extract source present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, about 7 mg to about 13 mg, or about 10 mg. An example product is called RHM.

[0076] In certain embodiments, intake of a tea extract may lead to various effects for a person.WSGR Docket No.59851-708.601 For example, intake of tea extract may reduce the risk of contracting certain diseases. In some embodiments, intake of a tea extract alleviates a hot flash. In some embodiments, intake of a tea extract alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a tea extract alleviates one or more symptoms associated with menopause. In some embodiments, intake of a tea extract alleviates one or more symptoms associated with anxiety. Panax Ginseng

[0077] In one aspect, provided herein are compositions and formulations comprising such compositions comprising panax ginseng. In certain embodiments, a composition (e.g., a composition provided herein) comprises panax ginseng. Panax ginseng is a plant native to China, Korea, and Russia. It is a commonly used herbal remedy that is derived from the roots of the plant. The active components of panax ginseng are ginsenosides. Research and clinical studies demonstrate its beneficial effects, such as anti-inflammatory, antioxidant, and anticancer effects. Furthermore, it is primarily used to improve exercise performance, psychologic function, conditions associated with diabetes, and immune function.

[0078] In certain embodiments, about 0.05 mg to about 25 mg of a composition (e.g., a composition provided herein) is panax ginseng. In some embodiments, about 0.5 mg to about 15 mg of a composition (e.g., a composition provided herein) is panax ginseng. In certain embodiments, about 1 mg to about 10 mg of a composition (e.g., a composition provided herein) is panax ginseng. In specific embodiments, about 3 mg to about 7 mg of a composition (e.g., a composition provided herein) is panax ginseng. In certain embodiments, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg or about 7 mg of a composition (e.g., a composition provided herein) is panax ginseng. In specific embodiments, about 5 mg of a composition (e.g., a composition provided herein) is panax ginseng. In yet more specific embodiments, about 3 mg of a composition (e.g., a composition provided herein) is panax ginseng.

[0079] In certain instances, compositions provided comprise panax ginseng. In some embodiments, a composition (e.g., a composition provided herein) comprising panax ginseng is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of panax ginseng present in the composition is about 0.05 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1 mg to about 10 mg, about 3 mg to about 7 mg, or about 5 mg. An example product is called RHM.WSGR Docket No.59851-708.601

[0080] In certain embodiments, intake of panax ginseng may lead to various effects for a person. For example, intake of panax ginseng may lead to a reduction of inflammation as well as reduce the risk of certain diseases and cancer. Intake of panax ginseng may also improve symptoms of diabetes and may improve immune functions. In some embodiments, intake of panax ginseng alleviates a hot flash. In some embodiments, intake of panax ginseng alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of panax ginseng alleviates one or more symptoms associated with menopause. In some embodiments, intake of panax ginseng alleviates one or more symptoms associated with anxiety. Phosphatidylserine (sunflower powder)

[0081] In one aspect, provided herein are compositions and formulations comprising such compositions comprising phosphatidylserine (e.g., sunflower powder). In certain embodiments, a composition (e.g., a composition provided herein) comprises phosphatidylserine. Phosphatidylserine can be derived from sunflower seeds, specifically sunflower lecithin. Research and clinical studies have demonstrated that phosphatidylserine improves memory and has improved symptoms of behavioral disorders such as ADHD in children.

[0082] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In specific embodiments, about 8 mg to about 14 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In certain embodiments, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 13.5 mg, or about 14 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In specific embodiments, about 12.5 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In yet more specific embodiments, about 9 mg of a composition (e.g., a composition provided herein) is phosphatidylserine.

[0083] In certain embodiments, about 5 mg to about 500 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In some embodiments, about 50 mg to about 500 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In certain embodiments, about 100 mg to about 300 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In specific embodiments, about 105 mg to about 200 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In certain embodiments, about 105 mg, about 115 mg, about 125 mg, about 135 mg, about 145 mg, about 155 mg, about 165 mg, about 175 mg, about 185 mg, about 195, or about 200 mg of a composition (e.g., a compositionWSGR Docket No.59851-708.601 provided herein) is phosphatidylserine. In specific embodiments, about 125 mg of a composition (e.g., a composition provided herein) is phosphatidylserine. In yet more specific embodiments, about 175 mg of a composition (e.g., a composition provided herein) is phosphatidylserine.

[0084] In certain instances, compositions provided herein are formulated with components (e.g., phosphatidylserine) for improving memory and cognitive function. In certain embodiments, the amount of phosphatidylserine present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 12.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising phosphatidylserine is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0085] In some embodiments, a composition (e.g., a composition provided herein) comprising phosphatidylserine is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. In some such cases, the amount of phosphatidylserine present in the composition is about 5 mg to about 500 mg, about 50 mg to about 400 mg, about 100 mg to about 300 mg, about 105 mg to about 200 mg, or about 125 mg. An example product is called RHA.

[0086] As described above, intake of phosphatidylserine may lead to various effects for a person. For example, intake of phosphatidylserine may lead to improved memory and improved symptoms of behavioral disorders. In some embodiments, intake of phosphatidylserine alleviates a hot flash. In some embodiments, intake of phosphatidylserine alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of phosphatidylserine alleviates one or more symptoms associated with menopause. In some embodiments, intake of phosphatidylserine alleviates one or more symptoms associated with anxiety. Minerals (e.g., Magnesium Glycinate, Zinc Citrate)

[0087] In one aspect, provided herein are compositions and formulations of such compositions comprising a mineral. In certain embodiments, a composition (e.g., a composition provided herein) comprises a mineral. In some embodiments, supplemental minerals comprise magnesium, calcium, choline, chromium, cesium, copper, fluoride, iodine, iron, manganese, molybdenum, potassium, selenium, zinc, or a combination of two or more thereof. In certain embodiments, supplemental minerals are sourced from any suitable naturally occurring source. In someWSGR Docket No.59851-708.601 embodiments, a composition (e.g., a composition provided herein) comprises a supplemental source of magnesium or a compound comprising magnesium. In certain embodiments, a supplemental source of magnesium or a compound comprising magnesium comprises magnesium sulfate, magnesium glycinate, magnesium L-threonate, magnesium gluconate, magnesium malate, magnesium chloride, magnesium orotate, or any suitable source of magnesium. In specific embodiments, a composition (e.g., a composition provided herein) comprises magnesium citrate. Magnesium citrate is a supplemental form of magnesium. In specific embodiments, a composition (e.g., a composition provided herein) comprises magnesium glycinate. Magnesium glycinate is a supplemental form of magnesium. In yet more specific embodiments, a composition (e.g., a composition provided herein) comprises a combination of magnesium glycinate and magnesium citrate. In still more specific embodiments, a composition (e.g., a composition provided herein) comprises magnesium L-threonate. Magnesium is essential for maintaining normal organ and cellular function. An imbalance of magnesium is associated with disorders such as skeletal deformities, metabolic syndrome, and cardiovascular diseases. Supplemental magnesium glycinate is formed from elemental magnesium and the amino acid, glycine. Magnesium glycinate has been shown to facilitate the production of GABA, and thereby may calm the nervous system.

[0088] In some embodiments, a composition (e.g., a composition provided herein) comprises a supplemental source of zinc. In certain embodiments, a supplemental source of zinc comprises zinc picolinate, zinc citrate, zinc acetate, zinc glycerate, zinc monomethionine, or any suitable source of zinc. In specific embodiments, a composition (e.g., a composition provided herein) comprises zinc citrate. Zinc is a nutrient found throughout the human body and is important for immune system and metabolism function. Growth retardation, loss of appetite, an impaired immune system, hair loss, delayed sexual maturation, impotence, hypogonadism in males, taste abnormalities, diarrhea, mental lethargy, and delayed wound healing have all been associated with deficient zinc levels. Zinc deficiency in humans is prevalent, affecting more than 2 billion people. As a result, studies suggest use of zinc supplementation (e.g., zinc citrate) for such conditions.

[0089] In certain embodiments, about 1 mg to about 350 mg of a composition (e.g., a composition provided herein) is a supplemental source of magnesium or a compound comprising magnesium (e.g., as provided herein).

[0090] In certain embodiments, about 1 mg to about 350 mg of a composition (e.g., a composition provided herein) is magnesium glycinate. In some embodiments, about 25 mg to about 250 mg of a composition (e.g., a composition provided herein) is magnesium glycinate. In certain embodiments, about 50 mg to about 150 mg of a composition (e.g., a composition provided herein) is magnesium glycinate. In specific embodiments, about 75 mg to about 125 mg of a composition (e.g., a composition provided herein) is magnesium glycinate. In certain embodiments, about 75WSGR Docket No.59851-708.601 mg, about 85 mg, about 95 mg, about 100 mg, about 105 mg, about 115 mg, or about 125 mg of a composition (e.g., a composition provided herein) is magnesium glycinate. In specific embodiments, about 100 mg of a composition (e.g., a composition provided herein) is magnesium glycinate. In yet more specific embodiments, about 85 mg of a composition (e.g., a composition provided herein) is magnesium glycinate.

[0091] In certain embodiments, about 0.1 mg to about 100 mg of a composition (e.g., a composition provided herein) is a combination of magnesium glycinate and magnesium citrate (magnesium citrate glycinate). In certain embodiments, a combination of magnesium glycinate and magnesium citrate contains about 15% (w / w) magnesium. In certain embodiments, the total amount of magnesium comprised in a composition provided herein (e.g., RHN) is about 1 mg to about 50 mg (e.g., about 2 mg to about 40 mg, about 3 mg to about 30 mg, about 4 mg to about 20 mg, about 5 mg to about 15 mg, about 8 mg, about 9 mg, about 10 mg). In specific embodiments, the total amount of magnesium in a composition provided (e.g., RHN) herein is about 10 mg. In yet more specific embodiments, the total amount of magnesium in a composition provided (e.g., RHN) herein is about 12 mg. In still more specific embodiments, the total amount of magnesium in a composition provided (e.g., RHN) herein is about 9 mg. In some embodiments, about 1 mg to about 75 mg of a composition (e.g., a composition provided herein) is magnesium citrate glycinate. In certain embodiments, about 5 mg to about 50 mg of a composition (e.g., a composition provided herein) is magnesium citrate glycinate. In specific embodiments, about 18 mg to about 45 mg of a composition (e.g., a composition provided herein) is magnesium citrate glycinate. In certain embodiments, about 20 mg, about 25 mg, about 30 mg, about 32 mg, about 33 mg, about 35 mg, or about 45 mg of a composition (e.g., a composition provided herein) is magnesium citrate glycinate. In specific embodiments, about 33 mg of a composition (e.g., a composition provided herein) is magnesium citrate glycinate. In yet more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is magnesium citrate glycinate.

[0092] In certain embodiments, about 0.5 mg to about 250 mg of a composition (e.g., a composition provided herein) is magnesium L-threonate. In some embodiments, about 1 mg to about 175 mg of a composition (e.g., a composition provided herein) is magnesium L-threonate. In certain embodiments, about 5 mg to about 100 mg of a composition (e.g., a composition provided herein) is magnesium L-threonate. In specific embodiments, about 35 mg to about 85 mg of a composition (e.g., a composition provided herein) is magnesium L-threonate. In certain embodiments, about 35 mg, about 45 mg, about 55 mg, about 60 mg, about 63 mg, about 65 mg, 75 mg, or about 80 mg of a composition (e.g., a composition provided herein) is magnesium L- threonate. In specific embodiments, about 63 mg of a composition (e.g., a composition providedWSGR Docket No.59851-708.601 herein) is magnesium L-threonate. In yet more specific embodiments, about 75 mg of a composition (e.g., a composition provided herein) is magnesium L-threonate.

[0093] In certain instances, compositions provided herein comprise magnesium glycinate. In certain embodiments, the amount of magnesium glycinate present in the composition is about 1 mg to about 350 mg, about 25 mg to about 250 mg, about 50 mg to about 150 mg, or about 100 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising magnesium glycinate is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. An example product is called RHA.

[0094] In certain instances, compositions provided herein comprise a combination of magnesium glycinate and magnesium citrate (magnesium citrate glycinate). In certain embodiments, the amount of magnesium citrate glycinate present in the composition is about 0.1 mg to about 100 mg, about 1 mg to about 75 mg, about 5 mg to about 50 mg, or about 33 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising magnesium citrate glycinate is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0095] In certain instances, compositions provided herein comprise magnesium L-threonate. In certain embodiments, the amount of magnesium L-threonate present in the composition is about 0.5 mg to about 250 mg, about 1 mg to about 175 mg, about 5 mg to about 100 mg, or about 63 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising magnesium L-threonate is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0096] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is zinc citrate. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is zinc citrate. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is zinc citrate. In specificWSGR Docket No.59851-708.601 embodiments, about 6 mg to about 10 mg of a composition (e.g., a composition provided herein) is zinc citrate. In certain embodiments, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg of a composition (e.g., a composition provided herein) is zinc citrate. In specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is zinc citrate. In yet more specific embodiments, about 3 mg of a composition (e.g., a composition provided herein) is zinc citrate.

[0097] In certain instances, compositions provided herein comprise zinc citrate. In certain embodiments, the amount of zinc citrate present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 8 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising zinc citrate is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. An example product is called RHA.

[0098] As described above, intake of certain minerals may lead to various effects for a person. For example, intake of certain minerals may improve the ability to maintain normal organ and cellular function, and may reduce the risk of skeletal deformities, metabolic syndrome, and cardiovascular diseases. Intake of certain minerals may also reduce the risk of growth retardation, hair loss, delayed sexual maturation, impotence, and hypogonadism, and may prevent or reduce the symptoms of loss of appetite, diarrhea, mental lethargy, and delayed wound healing. Intake of certain minerals may also improve immune system and metabolic functions of the person. In some embodiments, intake of a mineral alleviates a hot flash. In some embodiments, intake of a mineral alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a mineral alleviates one or more symptoms associated with menopause. In some embodiments, intake of a mineral alleviates one or more symptoms associated with anxiety. GABA

[0099] In one aspect, provided herein are compositions and formulations of such compositions comprising gamma-aminobutyric acid (GABA). GABA is a non-proteinogenic amino acid and is inhibitory neurotransmitter. Intake of natural and biosynthetic GABA may have beneficial effects on stress and sleep.

[0100] In certain embodiments, about 0.5 mg to about 100 mg of a composition (e.g., a composition provided herein) comprises GABA. In some embodiments, about 1 mg to about 75 mg of a composition (e.g., a composition provided herein) is GABA. In certain embodiments, about 5 mg to about 50 mg of a composition (e.g., a composition provided herein) is GABA. In specific embodiments, about 10 mg to about 40 mg of a composition (e.g., a composition provided herein) is GABA. In certain embodiments, about 10 mg, about 15 mg, about 20 mg, about 25 mg,WSGR Docket No.59851-708.601 about 26 mg, about 27 mg, about 30 mg, about 35 mg, or about 40 mg of a composition (e.g., a composition provided herein) is GABA. In specific embodiments, about 25 mg of a composition (e.g., a composition provided herein) is GABA. In yet more specific embodiments, about 26 mg of a composition (e.g., a composition provided herein) is GABA. In still more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is GABA.

[0101] In some embodiments, a composition (e.g., a composition provided herein) comprising gamma-aminobutyric acid (GABA) is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. In certain embodiments, the amount of the GABA present in a composition (e.g., a composition provided herein is about 0.5 mg to about 100 mg, about 1 mg to about 75 mg, about 5 mg to about 50 mg, about 10 mg to about 40 mg, about 25 mg, or about 26 mg. An example product is called RHN. Magnolia Officinalis

[0102] In one aspect, provided herein are compositions and formulations of such compositions comprising a component of a magnolia tree (e.g., magnolia officinalis). In certain embodiments, a component of a magnolia tree is magnolia officinalis. In some embodiments, a composition (e.g., a composition provided herein) comprises a component of a magnolia tree. In specific embodiments, a composition (e.g., a composition provided herein) comprises magnolia officinalis. Magnolia officinalis is an herb used in traditional medicine. It is derived from bark from the magnolia tree. The bark contains active compounds honokiol and magnolol. These compounds may help to reduce inflammation and stress. Studies have shown that magnolia officinalis can relieve vasomotor symptoms, and help individuals manage weight and maintain oral health.

[0103] In certain embodiments, about 1 mg to about 350 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In some embodiments, about 25 mg to about 250 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In certain embodiments, about 50 mg to about 150 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In specific embodiments, about 75 mg to about 125 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In certain embodiments, about 75 mg, about 85 mg, about 95 mg, about 100 mg, about 105 mg, about 115 mg, or about 125 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In specific embodiments, about 100 mg of a composition (e.g., a composition provided herein) is magnoliaWSGR Docket No.59851-708.601 officinalis. In yet more specific embodiments, about 125 mg of a composition (e.g., a composition provided herein) is magnolia officinalis.

[0104] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In specific embodiments, about 8 mg to about 14 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In certain embodiments, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 13.5 mg, or about 14 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In specific embodiments, about 12.5 mg of a composition (e.g., a composition provided herein) is magnolia officinalis. In yet more specific embodiments, about 9 mg of a composition (e.g., a composition provided herein) is magnolia officinalis.

[0105] In certain instances, compositions provided herein are formulating with components (e.g., magnolia officinalis) for reducing inflammation and stress or improving sleep. In some embodiments, a composition (e.g., a composition provided herein) comprising magnolia officinalis is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. In some such cases, the amount of magnolia officinalis present in the composition is about 1 mg to about 350 mg, about 25 mg to about 250 mg, about 50 mg to about 150 mg, or about 100 mg. An example product is called RHA.

[0106] In certain embodiments, the amount of magnolia officinalis present is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 12.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising magnolia officinalis is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0107] As described above, intake of magnolia officinalis may lead to various effects for a person. For example, intake of magnolia officinalis may reduce inflammation and stress as well as help regulate a person’s weight and maintain a person’s oral health. In some embodiments, intake of magnolia officinalis alleviates a hot flash. In some embodiments, intake of magnoliaWSGR Docket No.59851-708.601 officinalis alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of magnolia officinalis alleviates one or more symptoms associated with menopause. In some embodiments, intake of magnolia officinalis alleviates one or more symptoms associated with menopause. In some embodiments, intake of magnolia officinalis alleviates one or more symptoms associated with anxiety. Ginger

[0108] In one aspect, provided herein are compositions and formulations of such compositions comprising ginger. In certain embodiments, a composition (e.g., a composition provided herein) comprises ginger. Ginger is a well-known plant used commonly as a flavoring agent and for traditional remedies. Classes of ginger compounds having bioactive properties include gingerols, shogaols, zingiberene, zingerone, terpenes and other vitamins and minerals. Gingerols are considered the primary components and have been shown to have associated bioactivities such as antioxidant, antimicrobial, and anti-neuroinflammation, among others. In specific embodiments, the ginger is ginger root.

[0109] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is ginger. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is ginger. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is ginger. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is ginger. In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 10.5 mg, about 11 mg, about 12 mg, about 12.5 mg, or about 13 mg of a composition (e.g., a composition provided herein) is ginger. In specific embodiments, about 12.5 mg of a composition (e.g., a composition provided herein) is ginger. In yet more specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is ginger.

[0110] In certain instances, compositions provided herein comprise ginger. In certain embodiments, the amount of ginger present is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 12.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising ginger is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. An example product is called RHA.

[0111] As described above, intake of ginger may lead to various effects for a person. For example, intake of ginger may reduce the risk of certain diseases or infections as well as reducing neuroinflammation. Additionally, ginger may be used as a flavoring agent. In some embodiments, intake of ginger alleviates a hot flash. In some embodiments, intake of ginger alleviates one orWSGR Docket No.59851-708.601 more symptoms associated with perimenopause. In some embodiments, intake of ginger alleviates one or more symptoms associated with menopause. In some embodiments, intake of ginger alleviates one or more symptoms associated with anxiety. Sage

[0112] In one aspect, provided herein are compositions and formulations comprising such compositions comprising sage (e.g., sage leaf powder). In certain embodiments, a composition (e.g., a composition provided herein) comprises sage. In specific embodiments, a composition (e.g., a composition provided herein) comprises sage leaf powder (e.g., sclareolide). Sage is an herb with various bioactivities and used in traditional remedies. Studies suggest sage, from the Salvia species, has been shown to be useful against minor common illnesses and may also provide novel natural uses against depression, dementia, diabetes, obesity, lupus, cancer, and cardiovascular disease. In specific embodiments, sage comprises a sclareolide.

[0113] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is sage (e.g., sage leaf powder). In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is sage. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is sage. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is sage (e.g., sage leaf powder). In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 10.5 mg, about 11 mg, about 12 mg, about 12.5 mg, or about 13 mg of a composition (e.g., a composition provided herein) is sage. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is sage (e.g., sage leaf powder). In yet more specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is sage (e.g., sage leaf powder).

[0114] In certain instances, compositions provided herein comprise sage. In certain embodiments, the amount of sage present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 12.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising sage is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. An example product is called RHA.

[0115] As described above, intake of sage may lead to various effects for a person. For example, intake of sage may improve the symptoms of common illnesses, depression, dementia, diabetes, obesity, lupus, cancer, and cardiovascular diseases. In some embodiments, intake of sage alleviates a hot flash. In some embodiments, intake of sage alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of sage alleviates one or moreWSGR Docket No.59851-708.601 symptoms associated with menopause. In some embodiments, intake of sage alleviates one or more symptoms associated with anxiety. Diindolylmethane (DIM)

[0116] In one aspect, provided herein are compositions and formulations of such compositions comprising diindolylmethane (DIM). In certain embodiments, a composition (e.g., a composition provided herein) comprises DIM. DIM is a compound found in cruciferous vegetable such as broccoli, cauliflower, and cabbage. Studies suggest DIM may have anti- inflammatory and anti-cancer effects. Some studies show that DIM benefits some persons with cervical cancer and prostate cancer.

[0117] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is DIM. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is DIM. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is DIM. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is DIM. In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 10.5 mg, about 11 mg, about 12 mg, about 12.5 mg, or about 13 mg of a composition (e.g., a composition provided herein) is DIM. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is DIM. In yet more specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is DIM.

[0118] In certain instances, compositions provided herein comprise DIM. In certain embodiments, the amount of DIM present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 12.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising DIM is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. An example product is called RHA.

[0119] As described above, intake of DIM may lead to various effects for a person. For example, intake of DIM may reduce inflammation as well as reduce the risk of or improve the symptoms of various cancers. In some embodiments, intake of DIM alleviates a hot flash. In some embodiments, intake of DIM alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of DIM alleviates one or more symptoms associated with menopause. In some embodiments, intake of DIM alleviates one or more symptoms associated with anxiety. BACOPA (bacopa monnieri)

[0120] In one aspect, provided herein are compositions and formulations of such compositions comprising bacopa monnieri (bacopa). In certain embodiments, a composition (e.g.,WSGR Docket No.59851-708.601 a composition provided herein) comprises bacopa monnieri. Bacopa monnieri is a medicinal herb used in traditional Indian medicine system, Ayurveda. Bacopa is a creeping perennial with purple flowers and small oblong leaves, native to the warm wetlands of India and Australia. Bacopa is an herb traditionally used for many ailments, but it is best known as a memory enhancer and neural tonic. Studies of bacopa demonstrate its antioxidant neuroprotection, acetylcholinesterase inhibition, choline acetyltransferase activation, beta-amyloid reduction, increased cerebral blood flow, and neurotransmitter modulation capabilities.

[0121] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is bacopa monnieri. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is bacopa monnieri. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is bacopa monnieri. In specific embodiments, about 7 mg to about 13 mg of a composition (e.g., a composition provided herein) is bacopa monnieri. In certain embodiments, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 10.5 mg, about 11 mg, about 12 mg, about 12.5 mg, or about 13 mg of a composition (e.g., a composition provided herein) is bacopa monnieri. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is bacopa monnieri. In yet more specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is bacopa monnieri.

[0122] In certain instances, compositions provided herein comprise bacopa monnieri. In some embodiments, a composition (e.g., a composition provided herein) comprising bacopa monnieri is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of bacopa monnieri present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, about 7 mg to about 13 mg, or about 10 mg. An example product is called RHM.

[0123] As described above, intake of bacopa may lead to various effects for a person. For example, intake of bacopa may lead to increased memory. In some embodiments, intake of bacopa monnieri alleviates a hot flash. In some embodiments, intake of bacopa monnieri alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of bacopa monnieri alleviates one or more symptoms associated with menopause. In some embodiments, intake of bacopa monnieri alleviates one or more symptoms associated with anxiety. Oat StrawWSGR Docket No.59851-708.601

[0124] In one aspect, provided herein are compositions and formulations of such compositions comprising oat straw. In certain embodiments, a composition (e.g., a composition provided herein) comprises oat straw. Oat straw, or green oat, is an extract of from the aerial portion of oat plants (Avena sativa). The tinctures and extracts are formulated from the plant while it is still green. Oat straw contains several bioactive compounds such as terpenes, phenolic acids, polyphenols like flavonoids and avenanthramides. Studies have shown oat straw’s ability to improve cognitive function and modulate the physiological response to a stressor, i.e., improve memory and help assuage anxiety.

[0125] In certain embodiments, about 0.5 mg to about 100 mg of a composition (e.g., a composition provided herein) is oat straw. In some embodiments, about 1 mg to about 75 mg of a composition (e.g., a composition provided herein) is oat straw. In certain embodiments, about 5 mg to about 50 mg of a composition (e.g., a composition provided herein) is oat straw. In specific embodiments, about 10 mg to about 40 mg of a composition (e.g., a composition provided herein) is oat straw. In certain embodiments, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg of a composition (e.g., a composition provided herein) is oat straw. In specific embodiments, about 25 mg of a composition (e.g., a composition provided herein) is oat straw. In yet more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is oat straw.

[0126] In certain instances, compositions provided herein comprising oat straw are used to improve cognitive function and modulate the physiological response to stressors. In certain embodiments, the amount of oat straw present in the composition is about 0.5 mg to about 100 mg, about 1 mg to about 75 mg, about 5 mg to about 50 mg, or about 25 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising oat straw is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. An example product is called RHA.

[0127] As described above, intake of oat straw may lead to various effects for a person. For example, intake of oat straw may improve cognitive function and memory as well as reduce symptoms of anxiety. In some embodiments, intake of oat straw alleviates a hot flash. In some embodiments, intake of oat straw alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of oat straw alleviates one or more symptoms associated with menopause. In some embodiments, intake of oat straw alleviates one or more symptoms associated with anxiety. Amino acids (e.g., D-Aspartic Acid, L-Theanine, L-Tryptophan)

[0128] In one aspect, provided herein are compositions and formulations comprising suchWSGR Docket No.59851-708.601 compositions comprising an amino acid. In certain embodiments, a composition (e.g., a composition provided herein) comprises an amino acid. In some embodiments, the amino acid comprises valine, leucine, isoleucine, tryptophan, histidine, isoleucine, lysine, methionine, valin, D-aspartic acid, L-theanine, L-tryptophan, or a combination of two or more thereof. Studies show regular essential amino acid intake is effective in reversing muscle catabolism, restoring immunological function, and promoting muscle anabolism. In specific embodiments, a composition (e.g., a composition provided herein) comprises D-aspartic acid. In yet more specific embodiments, a composition (e.g., a composition provided herein) comprises L-theanine. In still more specific embodiments, a composition (e.g., a composition provided herein) comprises L- tryptophan. In yet more specific embodiments, a composition (e.g., a composition provided herein) comprises L-theanine and L-tryptophan.

[0129] In certain embodiments, about 0.05 mg to about 50 mg of a composition (e.g., a composition provided herein) is an amino acid (e.g., an amino acid provided herein). In some embodiments, about 0.1 mg to about 35 mg of a composition (e.g., a composition provided herein) is an amino acid. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is an amino acid. In certain embodiments, about 3 mg to about 16 mg of a composition (e.g., a composition provided herein) is an amino acid. In specific embodiments, about 4 mg to about 12 mg of a composition (e.g., a composition provided herein) is an amino acid. In certain embodiments, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, or about 12 mg of a composition (e.g., a composition provided herein) is an amino acid. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is an amino acid. In yet more specific embodiments, about 5 mg of a composition (e.g., a composition provided herein) is an amino acid. In still more specific embodiments, about 7.5 mg of a composition (e.g., a composition provided herein) is an amino acid. In yet more specific embodiments, about 4.5 mg of a composition (e.g., a composition provided herein) is an amino acid. In still more specific embodiments, about 9 mg of a composition (e.g., a composition provided herein) is an amino acid.

[0130] D-aspartic acid is an amino acid that functions, according to research, in the development of the nervous system and in hormonal regulation. In some cases, D-aspartic acid has been shown to increase testosterone, making it useful for supplementation during resistance training in certain cases. Further, studies show that D-aspartic acid plays a crucial role in reproduction either due to its role as a neuromodulator or its involvement in biosynthesis and release of sexual hormones.

[0131] In certain embodiments, about 0.05 mg to about 25 mg of a composition (e.g., aWSGR Docket No.59851-708.601 composition provided herein) is D-aspartic acid. In some embodiments, about 0.5 mg to about 15 mg of a composition (e.g., a composition provided herein) is D-aspartic acid. In certain embodiments, about 1 mg to about 10 mg of a composition (e.g., a composition provided herein) is D-aspartic acid. In specific embodiments, about 3 mg to about 7 mg of a composition (e.g., a composition provided herein) is D-aspartic acid. In certain embodiments, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg or about 7 mg of a composition (e.g., a composition provided herein) is D-aspartic acid. In specific embodiments, about 5 mg of a composition (e.g., a composition provided herein) is D-aspartic acid. In yet more specific embodiments, about 3 mg of a composition (e.g., a composition provided herein) is D-aspartic acid.

[0132] In certain instances, compositions provided herein comprise D-aspartic acid. In some embodiments, a composition (e.g., a composition provided herein) comprising D-aspartic acid is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In some such cases, the amount of D-aspartic acid present in the composition is about 0.05 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1 mg to about 10 mg, about 3 mg to about 7 mg, or about 5 mg. An example product is called RHM.

[0133] As described above, intake of D-aspartic acid may lead to various effects for a person. For example, intake of D-aspartic acid may reverse muscle catabolism, restore immunological functions, and promote muscle anabolism. As another example, intake of D- aspartic acid may promote development of the nervous system and hormone regulation. Intake of D-aspartic acid may also increase testosterone in a person. In some embodiments, intake of D- aspartic acid alleviates a hot flash. In some embodiments, intake of D-aspartic acid alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of D-aspartic acid alleviates one or more symptoms associated with menopause. In some embodiments, intake of D-aspartic acid alleviates one or more symptoms associated with anxiety.

[0134] L-theanine is a unique amino acid found in green tea. L-theanine may modulate aspects of brain function in humans. Studies show that L-theanine has a direct effect on the brain and, at higher amounts, can relax the brain without inducing drowsiness. Further, it is used for potential antioxidant and relaxant effects. In vitro animal studies suggest the following properties: lipid-lowering, neuroprotective, anti-obesity, and anti-tumor.

[0135] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., aWSGR Docket No.59851-708.601 composition provided herein) is L-theanine. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is L-theanine. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is L-theanine. In specific embodiments, about 8 mg to about 14 mg of a composition (e.g., a composition provided herein) is L-theanine. In certain embodiments, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 13.5 mg, or about 14 mg of a composition (e.g., a composition provided herein) is L-theanine. In specific embodiments, about 10 mg of a composition (e.g., a composition provided herein) is L-theanine. In yet more specific embodiments, about 9 mg of a composition (e.g., a composition provided herein) is L-theanine.

[0136] In certain embodiments, about 0.5 mg to about 250 mg of a composition (e.g., a composition provided herein) is L-theanine. In some embodiments, about 1 mg to about 175 mg of a composition (e.g., a composition provided herein) is L-theanine. In certain embodiments, about 5 mg to about 100 mg of a composition (e.g., a composition provided herein) is L-theanine. In specific embodiments, about 25 mg to about 75 mg of a composition (e.g., a composition provided herein) is L-theanine. In certain embodiments, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 53 mg, about 55 mg, about 65 mg, or about 75 mg of a composition (e.g., a composition provided herein) is L-theanine. In specific embodiments, about 53 mg of a composition (e.g., a composition provided herein) is L-theanine. In yet more specific embodiments, about 50 mg of a composition (e.g., a composition provided herein) is L-theanine.

[0137] In certain instances, compositions provided herein comprise L-theanine. In certain embodiments, the amount of L-theanine present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, or about 10 mg. In certain embodiments, the amount of L-theanine present in the composition is about 0.5 mg to about 250 mg, about 1 mg to about 175 mg, about 5 mg to about 100 mg, or about 53 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising L-theanine is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0138] As described above, intake of L-theanine may lead to various effects for a person. For example, intake of L-theanine may lead to increased brain relaxation without drowsiness. Intake of L-theanine may also reduce the risk of certain diseases. In some embodiments, intake ofWSGR Docket No.59851-708.601 L-theanine alleviates a hot flash. In some embodiments, intake of L-theanine alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of L-theanine alleviates one or more symptoms associated with menopause. In some embodiments, intake of L- theanine alleviates one or more symptoms associated with anxiety.

[0139] L-tryptophan is an essential amino acid in humans. It is a precursor of serotonin, and therefore its intake is linked to the suppression of anxiety and depression. L-tryptophan cannot be synthesized by the body so it must be obtained from the diet. Healthy intake of L-tryptophan assures increased brain L-tryptophan levels and leads to enhanced serotonin synthesis. Studies show that L-tryptophan intake has been found to improve the mood of persons vulnerable to stress such as those that have experienced depression. It has also been reported that L-tryptophan improves the sleep of adults with sleep disorders.

[0140] In certain embodiments, about 0.1 mg to about 50 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In some embodiments, about 1 mg to about 25 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In certain embodiments, about 5 mg to about 15 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In specific embodiments, about 6 mg to about 12 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In certain embodiments, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, or about 12 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In specific embodiments, about 7.5 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In yet more specific embodiments, about 9.5 mg of a composition (e.g., a composition provided herein) is L-tryptophan. In still more specific embodiments, about 8 mg of a composition (e.g., a composition provided herein) is L-tryptophan.

[0141] In certain instances, compositions (e.g., a composition provided herein) comprise L-tryptophan. In certain embodiments, the amount of L-tryptophan present in the composition is about 0.1 mg to about 50 mg, about 1 mg to about 25 mg, about 5 mg to about 15 mg, about 8 mg, or about 7.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising L-tryptophan is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0142] As described above, intake of L-tryptophan may lead to various effects for a person. For example, intake of L-tryptophan may reduce the symptoms of anxiety and depressionWSGR Docket No.59851-708.601 as well as increased serotonin in a person. Intake of L-tryptophan may also lead to improved sleep for persons with sleep disorders. In some embodiments, intake of L-tryptophan alleviates a hot flash. In some embodiments, intake of L-tryptophan alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of L-tryptophan alleviates one or more symptoms associated with menopause. In some embodiments, intake of L-tryptophan alleviates one or more symptoms associated with anxiety. Reishi Mushroom

[0143] In one aspect, provided herein are compositions and formulations of such compositions comprising a reishi mushroom. In certain embodiments, a composition (e.g., a composition provided herein) comprises a reishi mushroom. Reishi mushroom, or Ganoderma lucidum, is a mushroom used in traditional Chinese medicine where it is believed to extend life and promote health. Studies show that reishi mushroom may have anticancer properties. Reishi mushrooms contain bioactive components such as terpenoids, steroids, phenols, nucleotides and their derivatives, glycoproteins, and polysaccharides. Mushroom proteins contain essential amino acids and are rich in lysine and leucine. Terpenoids, from the class of terpenes, are naturally occurring compounds that have been found to have anti-inflammatory, anti-tumorigenic and hypolipidemic activity. In specific embodiments, the reishi mushroom comprises the fruiting body of the reishi mushroom.

[0144] In certain embodiments, about 0.05 mg to about 25 mg of a composition (e.g., a composition provided herein) is a reishi mushroom. In some embodiments, about 0.5 mg to about 15 mg of a composition (e.g., a composition provided herein) is a reishi mushroom. In certain embodiments, about 1 mg to about 10 mg of a composition (e.g., a composition provided herein) is a reishi mushroom. In specific embodiments, about 3 mg to about 7 mg of a composition (e.g., a composition provided herein) is a reishi mushroom. In certain embodiments, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg or about 7 mg of a composition (e.g., a composition provided herein) is a reishi mushroom. In specific embodiments, about 5 mg of a composition (e.g., a composition provided herein) is a reishi mushroom. In yet more specific embodiments, about 3 mg of a composition (e.g., a composition provided herein) is a reishi mushroom.

[0145] In certain instances, compositions (e.g., a composition provided herein) comprises a reishi mushroom. In certain embodiments, the amount of a reishi mushroom present in the composition is about 0.05 mg to about 25 mg, about 0.5 mg to about 15 mg, about 1 mg to about 10 mg, or about 5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising a reishi mushroom is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specificWSGR Docket No.59851-708.601 embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0146] As described above, intake of reishi mushroom may lead to various effects for a person. For example, intake of a reishi mushroom may reduce the risk of and / or reduce the symptoms of cancer. Intake of a reishi mushroom may also reduce inflammation. In some embodiments, intake of a reishi mushroom alleviates a hot flash. In some embodiments, intake of a reishi mushroom alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a reishi mushroom alleviates one or more symptoms associated with menopause. In some embodiments, intake of a reishi mushroom alleviates one or more symptoms associated with anxiety. Melatonin

[0147] In one aspect, provided herein are compositions and formulations comprising such compositions comprising melatonin. Melatonin is a hormone secreted by the pineal gland. It regulates circadian rhythms such as neuroendocrine rhythms, sleep-wake rhythm, and body temperature cycles. This is done through its action on MT1 and MT2 receptors. Melatonin is commonly ingested to induce fatigue and decrease the time needed to fall asleep. It is commonly taken to realize these effects and improve sleep. Furthermore, studies show that use of melatonin by healthy adults shows promise against phase shifts from jet lag and improve insomnia.

[0148] In certain embodiments, about 0.01 mg to about 20 mg of a composition (e.g., a composition provided herein) is melatonin. In some embodiments, about 0.05 mg to about 10 mg of a composition (e.g., a composition provided herein) is melatonin. In certain embodiments, about 0.1 mg to about 5 mg of a composition (e.g., a composition provided herein) is melatonin. In specific embodiments, about 1.5 mg to about 4 mg of a composition (e.g., a composition provided herein) is melatonin. In certain embodiments, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about, or about 4 mg of a composition (e.g., a composition provided herein) is melatonin. In specific embodiments, about 2.5 mg of a composition (e.g., a composition provided herein) is melatonin. In yet more specific embodiments, about 3 mg of a composition (e.g., a composition provided herein) is melatonin.

[0149] In certain instances, compositions (e.g., a composition provided herein) comprise melatonin. In certain embodiments, the amount of melatonin present in the composition is about 0.01 mg to about 20 mg, about 0.05 mg to about 10 mg, about 0.1 mg to about 5 mg, or about 2.5 mg. In some embodiments, a composition (e.g., a composition provided herein) comprising melatonin is taken in the evening. In specific embodiments, the composition is taken about 0.1WSGR Docket No.59851-708.601 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. An example product is called RHN.

[0150] As described above, intake of melatonin may lead to various effects for a person. For example, intake of melatonin may induce desired fatigue and improve the ability of a person to fall asleep. In some embodiments, intake of melatonin alleviates a hot flash. In some embodiments, intake of melatonin alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of melatonin alleviates one or more symptoms associated with menopause. In some embodiments, intake of melatonin alleviates one or more symptoms associated with anxiety. Excipients

[0151] In one aspect, provided herein are compositions and formulations of such compositions comprising one or more excipients. Excipients, include enhancing agents, and may be included in compositions herein and serve as vehicles for their delivery. An excipient may be stable and reproducible, have no unwished interactions with compositions, and non-toxic. An acceptable excipient may be an excipient that is useful in preparing a composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human use. The role of excipients may be to aid in the processing of composition delivery systems during composition manufacture. Excipients may protect, support, and / or enhance stability and bioavailability and composition delivery. The excipient may be an anti- caking agent. The excipient may be an adsorbent. The excipient may be a disintegrant. The excipient may be a glidant. The excipient may be a binder. The excipient may be a penetration enhancer. The excipient may include a chelating agent that assists in drug delivery by depleting Ca2+. Non-limiting examples of excipients used in formulations include magnesium stearate, microcrystalline cellulose, starch (corn), silicone / titanium dioxide, stearic acid, sodium starch glycolate, gelatin, talc, sucrose, calcium stearate, povidone, pregelatinized starch, HPMC, croscarmellose, hydroxypropyl cellulose, ethylcellulose, calcium phosphate, and crospovidone, glucose, lactose, sucrose, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, water, saline, dextrose, propylene glycol, glycerol, ethanol, mannitol, polysorbate, or the like, and combinations thereof. In addition, if desired, the composition can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance or maintain the effectiveness of other ingredients. In some embodiments, acceptable excipients, including enhancing agents, can be used forWSGR Docket No.59851-708.601 effective delivery of the composition. Excipients may act as stabilizing agents in compositions and formulations of the present disclosure. Ingredients of compositions herein can be mixed with excipients which are acceptable and compatible with the ingredient and in amounts suitable for use in methods described herein. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous. Compositions as described herein can include acceptable salts. Acceptable salts include the acid addition salts formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, organic acids, for example, acetic, tartaric or mandelic, salts formed from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and salts formed from organic bases such as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like. Liquid compositions can contain liquid phases in addition to and in the exclusion of water, for example, glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions. Physiologically tolerable carriers are well known in the art.

[0152] In some embodiments, about 0.1 mg to about 5000 mg of one or more excipients is present in a composition herein, e.g., about 0.1 mg to about 4000 mg, about 0.1 mg to about 3000 mg, about 0.1 mg to about 2000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 750 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 450 mg, about 0.1 mg to about 400 mg, about 0.1 mg to about 350 mg, about 0.1 mg to about 300 mg, about 0.1 mg to about 250 mg, about 0.1 mg to about 225 mg, about 0.l mg to about 200 mg, about 0.1 mg to about 175 mg, about 0.1 mg to about 150 mg, about 0.1 mg to about 125 mg, about 0.1 mg to about 100 mg, about 0.1 mg to about 75 mg, about 0.1 mg to about 50 mg, about 0.1 mg to about 25 mg, about 0.1 mg to about 20 mg, about 0.1 mg to about 15 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 4 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1.5 mg, about 0.1 mg to about 1.25 mg, about 0.1 mg to about 1 mg, about 0.1 mg to about 0.75 mg, about 0.1 mg to about 0.5 mg, about 0.1 mg to about 0.25 mg, about 0.25 mg to about 5000 mg, about 0.25 mg to about 4000 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 750 mg, about 0.25 mg to about 500 mg, about 0.25 mg to about 450 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 350 mg, about 0.25 mg to about 300 mg, about 0.25 mg to about 250 mg, about 0.25 mg to about 225 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 175 mg, about 0.25 mg to about 150 mg, about 0.25 mg to about 125 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 75 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 25 mg, about 0.25 mg to about 20 mg, about 0.25 mg to about 15 mg, about 0.25 mg to about 10 mg, about 0.25 mg to about 5 mg, about 0.25 mg to about 4 mg, about 0.25 mg to about 3 mg, about 0.25 mg to about 2 mg, about 0.25 mg to about 1.5 mg, about 0.25 mg to about 1.25 mg, aboutWSGR Docket No.59851-708.601 0.25 mg to about 1 mg, about 0.25 mg to about 0.75 mg, about 0.25 mg to about 0.5 mg, about 0.5 mg to about 5000 mg, about 0.5 mg to about 4000 mg, about 0.5 mg to about 3000 mg, about 0.5 mg to about 2000 mg, about 0.5 mg to about 1000 mg, about 0.5 mg to about 750 mg, about 0.5 mg to about 500 mg, about 0.5 mg to about 450 mg, about 0.5 mg to about 400 mg, about 0.5 mg to about 350 mg, about 0.5 mg to about 300 mg, about 0.5 mg to about 250 mg, about 0.5 mg to about 225 mg, about 0.5 mg to about 200 mg, about 0.5 mg to about 175 mg, about 0.5 mg to about 150 mg, about 0.5 mg to about 125 mg, about 0.5 mg to about 100 mg, about 0.5 mg to about 75 mg, about 0.5 mg to about 50 mg, about 0.5 mg to about 25 mg, about 0.5 mg to about 20 mg, about 0.5 mg to about 15 mg, about 0.5 mg to about 10 mg, about 0.5 mg to about 5 mg, about 0.5 mg to about 4 mg, about 0.5 mg to about 3 mg, about 0.5 mg to about 2 mg, about 0.5 mg to about 1.5 mg, about 0.5 mg to about 1.25 mg, about 0.5 mg to about 1 mg, about 0.5 mg to about 0.75 mg, about 0.75 mg to about 5000 mg, about 0.75 mg to about 4000 mg, about 0.75 mg to about 3000 mg, about 0.75 mg to about 2000 mg, about 0.75 mg to about 1000 mg, about 0.75 mg to about 750 mg, about 0.75 mg to about 500 mg, about 0.75 mg to about 450 mg, about 0.75 mg to about 400 mg, about 0.75 mg to about 350 mg, about 0.75 mg to about 300 mg, about 0.75 mg to about 250 mg, about 0.75 mg to about 225 mg, about 0.75 mg to about 200 mg, about 0.75 mg to about 175 mg, about 0.75 mg to about 150 mg, about 0.75 mg to about 125 mg, about 0.75 mg to about 100 mg, about 0.75 mg to about 75 mg, about 0.75 mg to about 50 mg, about 0.75 mg to about 25 mg, about 0.75 mg to about 20 mg, about 0.75 mg to about 15 mg, about 0.75 mg to about 10 mg, about 0.75 mg to about 5 mg, about 0.75 mg to about 4 mg, about 0.75 mg to about 3 mg, about 0.75 mg to about 2 mg, about 0.75 mg to about 1.5 mg, about 0.75 mg to about 1.25 mg, about 0.75 mg to about 1 mg, about 1 mg to about 5000 mg, about 1 mg to about 4000 mg, about 1 mg to about 3000 mg, about 1 mg to about 2000 mg, about 1 mg to about 1000 mg, about 1 mg to about 750 mg, about 1 mg to about 500 mg, about 1 mg to about 450 mg, about 1 mg to about 400 mg, about 1 mg to about 350 mg, about 1 mg to about 300 mg, about 1 mg to about 250 mg, about 1 mg to about 225 mg, about 1 mg to about 200 mg, about 1 mg to about 175 mg, about 1 mg to about 150 mg, about 1 mg to about 125 mg, about 1 mg to about 100 mg, about 1 mg to about 75 mg, about 1 mg to about 50 mg, about 1 mg to about 25 mg, about 1 mg to about 20 mg, about 1 mg to about 15 mg, about 1 mg to about 10 mg, about 1 mg to about 5 mg, about 1 mg to about 4 mg, about 1 mg to about 3 mg, about 1 mg to about 2 mg, about 1 mg to about 1.5 mg, about 1 mg to about 1.25 mg, about 1.25 mg to about 5000 mg, about 1.25 mg to about 4000 mg, about 1.25 mg to about 3000 mg, about 1.25 mg to about 2000 mg, about 1.25 mg to about 1000 mg, about 1.25 mg to about 750 mg, about 1.25 mg to about 500 mg, about 1.25 mg to about 450 mg, about 1.25 mg to about 400 mg, about 1.25 mg to about 350 mg, about 1.25 mg to about 300 mg, about 1.25 mg to about 250 mg, about 1.25 mg to about 225 mg, about 1.25 mgWSGR Docket No.59851-708.601 to about 200 mg, about 1.25 mg to about 175 mg, about 1.25 mg to about 150 mg, about 1.25 mg to about 125 mg, about 1.25 mg to about 100 mg, about 1.25 mg to about 75 mg, about 1.25 mg to about 50 mg, about 1.25 mg to about 25 mg, about 1.25 mg to about 20 mg, about 1.25 mg to about 15 mg, about 1.25 mg to about 10 mg, about 1.25 mg to about 5 mg, about 1.25 mg to about 4 mg, about 1.25 mg to about 3 mg, about 1.25 mg to about 2 mg, about 1.25 mg to about 1.5 mg, about 1.5 mg to about 5000 mg, about 1.5 mg to about 4000 mg, about 1.5 mg to about 3000 mg, about 1.5 mg to about 2000 mg, about 1.5 mg to about 1000 mg, about 1.5 mg to about 750 mg, about 1.5 mg to about 500 mg, about 1.5 mg to about 450 mg, about 1.5 mg to about 400 mg, about 1.5 mg to about 350 mg, about 1.5 mg to about 300 mg, about 1.5 mg to about 250 mg, about 1.5 mg to about 225 mg, about 1.5 mg to about 200 mg, about 1.5 mg to about 175 mg, about 1.5 mg to about 150 mg, about 1.5 mg to about 125 mg, about 1.5 mg to about 100 mg, about 1.5 mg to about 75 mg, about 1.5 mg to about 50 mg, about 1.5 mg to about 25 mg, about 1.5 mg to about 20 mg, about 1.5 mg to about 15 mg, about 1.5 mg to about 10 mg, about 1.5 mg to about 5 mg, about 1.5 mg to about 4 mg, about 1.5 mg to about 3 mg, about 1.5 mg to about 2 mg, about 2 mg to about 5000 mg, about 2 mg to about 4000 mg, about 2 mg to about 3000 mg, about 2 mg to about 2000 mg, about 2 mg to about 1000 mg, about 2 mg to about 750 mg, about 2 mg to about 500 mg, about 2 mg to about 450 mg, about 2 mg to about 400 mg, about 2 mg to about 350 mg, about 2 mg to about 300 mg, about 2 mg to about 250 mg, about 2 mg to about 225 mg, about 2 mg to about 200 mg, about 2 mg to about 175 mg, about 2 mg to about 150 mg, about 2 mg to about 125 mg, about 2 mg to about 100 mg, about 2 mg to about 75 mg, about 2 mg to about 50 mg, about 2 mg to about 25 mg, about 2 mg to about 20 mg, about 2 mg to about 15 mg, about 2 mg to about 10 mg, about 2 mg to about 5 mg, about 2 mg to about 4 mg, about 2 mg to about 3 mg, about 3 mg to about 5000 mg, about 3 mg to about 4000 mg, about 3 mg to about 3000 mg, about 3 mg to about 2000 mg, about 3 mg to about 1000 mg, about 3 mg to about 750 mg, about 3 mg to about 500 mg, about 3 mg to about 450 mg, about 3 mg to about 400 mg, about 3 mg to about 350 mg, about 3 mg to about 300 mg, about 3 mg to about 250 mg, about 3 mg to about 225 mg, about 3 mg to about 200 mg, about 3 mg to about 175 mg, about 3 mg to about 150 mg, about 3 mg to about 125 mg, about 3 mg to about 100 mg, about 3 mg to about 75 mg, about 3 mg to about 50 mg, about 3 mg to about 25 mg, about 3 mg to about 20 mg, about 3 mg to about 15 mg, about 3 mg to about 10 mg, about 3 mg to about 5 mg, about 3 mg to about 4 mg, about 4 mg to about 5000 mg, about 4 mg to about 4000 mg, about 4 mg to about 3000 mg, about 4 mg to about 2000 mg, about 4 mg to about 1000 mg, about 4 mg to about 750 mg, about 4 mg to about 500 mg, about 4 mg to about 450 mg, about 4 mg to about 400 mg, about 4 mg to about 350 mg, about 4 mg to about 300 mg, about 4 mg to about 250 mg, about 4 mg to about 225 mg, about 4 mg to about 200 mg, about 4 mg to about 175 mg, about 4 mg to about 150 mg, about 4 mg toWSGR Docket No.59851-708.601 about 125 mg, about 4 mg to about 100 mg, about 4 mg to about 75 mg, about 4 mg to about 50 mg, about 4 mg to about 25 mg, about 4 mg to about 20 mg, about 4 mg to about 15 mg, about 4 mg to about 10 mg, about 4 mg to about 5 mg, about 5 mg to about 5000 mg, about 5 mg to about 4000 mg, about 5 mg to about 3000 mg, about 5 mg to about 2000 mg, about 5 mg to about 1000 mg, about 5 mg to about 750 mg, about 5 mg to about 500 mg, about 5 mg to about 450 mg, about 5 mg to about 400 mg, about 5 mg to about 350 mg, about 5 mg to about 300 mg, about 5 mg to about 250 mg, about 5 mg to about 225 mg, about 5 mg to about 200 mg, about 5 mg to about 175 mg, about 5 mg to about 150 mg, about 5 mg to about 125 mg, about 5 mg to about 100 mg, about 5 mg to about 75 mg, about 5 mg to about 50 mg, about 5 mg to about 25 mg, about 5 mg to about 20 mg, about 5 mg to about 15 mg, about 5 mg to about 10 mg, about 10 mg to about 5000 mg, about 10 mg to about 4000 mg, about 10 mg to about 3000 mg, about 10 mg to about 2000 mg, about 10 mg to about 1000 mg, about 10 mg to about 750 mg, about 10 mg to about 500 mg, about 10 mg to about 450 mg, about 10 mg to about 400 mg, about 10 mg to about 350 mg, about 10 mg to about 300 mg, about 10 mg to about 250 mg, about 10 mg to about 225 mg, about 10 mg to about 200 mg, about 10 mg to about 175 mg, about 10 mg to about 150 mg, about 10 mg to about 125 mg, about 10 mg to about 100 mg, about 10 mg to about 75 mg, about 10 mg to about 50 mg, about 10 mg to about 25 mg, about 10 mg to about 20 mg, about 10 mg to about 15 mg, about 15 mg to about 5000 mg, about 15 mg to about 4000 mg, about 15 mg to about 3000 mg, about 15 mg to about 2000 mg, about 15 mg to about 1000 mg, about 15 mg to about 750 mg, about 15 mg to about 500 mg, about 15 mg to about 450 mg, about 15 mg to about 400 mg, about 15 mg to about 350 mg, about 15 mg to about 300 mg, about 15 mg to about 250 mg, about 15 mg to about 225 mg, about 15 mg to about 200 mg, about 15 mg to about 175 mg, about 15 mg to about 150 mg, about 15 mg to about 125 mg, about 15 mg to about 100 mg, about 15 mg to about 75 mg, about 15 mg to about 50 mg, about 15 mg to about 25 mg, about 15 mg to about 20 mg, about 20 mg to about 5000 mg, about 20 mg to about 4000 mg, about 20 mg to about 3000 mg, about 20 mg to about 2000 mg, about 20 mg to about 1000 mg, about 20 mg to about 750 mg, about 20 mg to about 500 mg, about 20 mg to about 450 mg, about 20 mg to about 400 mg, about 20 mg to about 350 mg, about 20 mg to about 300 mg, about 20 mg to about 250 mg, about 20 mg to about 225 mg, about 20 mg to about 200 mg, about 20 mg to about 175 mg, about 20 mg to about 150 mg, about 20 mg to about 125 mg, about 20 mg to about 100 mg, about 20 mg to about 75 mg, about 20 mg to about 50 mg, about 20 mg to about 25 mg, about 25 mg to about 5000 mg, about 25 mg to about 4000 mg, about 25 mg to about 3000 mg, about 25 mg to about 2000 mg, about 25 mg to about 1000 mg, about 25 mg to about 750 mg, about 25 mg to about 500 mg, about 25 mg to about 450 mg, about 25 mg to about 400 mg, about 25 mg to about 350 mg, about 25 mg to about 300 mg, about 25 mg to about 250 mg, about 25 mg to about 225 mg, about 25 mg to aboutWSGR Docket No.59851-708.601 200 mg, about 25 mg to about 175 mg, about 25 mg to about 150 mg, about 25 mg to about 125 mg, about 25 mg to about 100 mg, about 25 mg to about 75 mg, about 25 mg to about 50 mg, about 50 mg to about 5000 mg, about 50 mg to about 4000 mg, about 50 mg to about 3000 mg, about 50 mg to about 2000 mg, about 50 mg to about 1000 mg, about 50 mg to about 750 mg, about 50 mg to about 500 mg, about 50 mg to about 450 mg, about 50 mg to about 400 mg, about 50 mg to about 350 mg, about 50 mg to about 300 mg, about 50 mg to about 250 mg, about 50 mg to about 225 mg, about 50 mg to about 200 mg, about 50 mg to about 175 mg, about 50 mg to about 150 mg, about 50 mg to about 125 mg, about 50 mg to about 100 mg, about 50 mg to about 75 mg, about 75 mg to about 5000 mg, about 75 mg to about 4000 mg, about 75 mg to about 3000 mg, about 75 mg to about 2000 mg, about 75 mg to about 1000 mg, about 75 mg to about 750 mg, about 75 mg to about 500 mg, about 75 mg to about 450 mg, about 75 mg to about 400 mg, about 75 mg to about 350 mg, about 75 mg to about 300 mg, about 75 mg to about 250 mg, about 75 mg to about 225 mg, about 75 mg to about 200 mg, about 75 mg to about 175 mg, about 75 mg to about 150 mg, about 75 mg to about 125 mg, about 75 mg to about 100 mg, about 100 mg to about 5000 mg, about 100 mg to about 4000 mg, about 100 mg to about 3000 mg, about 100 mg to about 2000 mg, about 100 mg to about 1000 mg, about 100 mg to about 750 mg, about 100 mg to about 500 mg, about 100 mg to about 450 mg, about 100 mg to about 400 mg, about 100 mg to about 350 mg, about 100 mg to about 300 mg, about 100 mg to about 250 mg, about 100 mg to about 225 mg, about 100 mg to about 200 mg, about 100 mg to about 175 mg, about 100 mg to about 150 mg, about 100 mg to about 125 mg, about 125 mg to about 5000 mg, about 125 mg to about 4000 mg, about 125 mg to about 3000 mg, about 125 mg to about 2000 mg, about 125 mg to about 1000 mg, about 125 mg to about 750 mg, about 125 mg to about 500 mg, about 125 mg to about 450 mg, about 125 mg to about 400 mg, about 125 mg to about 350 mg, about 125 mg to about 300 mg, about 125 mg to about 250 mg, about 125 mg to about 225 mg, about 125 mg to about 200 mg, about 125 mg to about 175 mg, about 125 mg to about 150 mg, about 150 mg to about 5000 mg, about 150 mg to about 4000 mg, about 150 mg to about 3000 mg, about 150 mg to about 2000 mg, about 150 mg to about 1000 mg, about 150 mg to about 750 mg, about 150 mg to about 500 mg, about 150 mg to about 450 mg, about 150 mg to about 400 mg, about 150 mg to about 350 mg, about 150 mg to about 300 mg, about 150 mg to about 250 mg, about 150 mg to about 225 mg, about 150 mg to about 200 mg, about 150 mg to about 175 mg, about 175 mg to about 5000 mg, about 175 mg to about 4000 mg, about 175 mg to about 3000 mg, about 175 mg to about 2000 mg, about 175 mg to about 1000 mg, about 175 mg to about 750 mg, about 175 mg to about 500 mg, about 175 mg to about 450 mg, about 175 mg to about 400 mg, about 175 mg to about 350 mg, about 175 mg to about 300 mg, about 175 mg to about 250 mg, about 175 mg to about 225 mg, about 175 mg to about 200 mg, about 200 mg to about 5000 mg, about 200 mg to aboutWSGR Docket No.59851-708.601 4000 mg, about 200 mg to about 3000 mg, about 200 mg to about 2000 mg, about 200 mg to about 1000 mg, about 200 mg to about 750 mg, about 200 mg to about 500 mg, about 200 mg to about 450 mg, about 200 mg to about 400 mg, about 200 mg to about 350 mg, about 200 mg to about 300 mg, about 200 mg to about 250 mg, about 200 mg to about 225 mg, about 225 mg to about 5000 mg, about 225 mg to about 4000 mg, about 225 mg to about 3000 mg, about 225 mg to about 2000 mg, about 225 mg to about 1000 mg, about 225 mg to about 750 mg, about 225 mg to about 500 mg, about 225 mg to about 450 mg, about 225 mg to about 400 mg, about 225 mg to about 350 mg, about 225 mg to about 300 mg, about 225 mg to about 250 mg, about 250 mg to about 5000 mg, about 250 mg to about 4000 mg, about 250 mg to about 3000 mg, about 250 mg to about 2000 mg, about 250 mg to about 1000 mg, about 250 mg to about 750 mg, about 250 mg to about 500 mg, about 250 mg to about 450 mg, about 250 mg to about 400 mg, about 250 mg to about 350 mg, about 250 mg to about 300 mg, about 5000 mg, about 300 mg to about 4000 mg, about 300 mg to about 3000 mg, about 300 mg to about 2000 mg, about 300 mg to about 1000 mg, about 300 mg to about 750 mg, about 300 mg to about 500 mg, about 300 mg to about 450 mg, about 300 mg to about 400 mg, about 300 mg to about 350 mg, about 5000 mg, about 350 mg to about 4000 mg, about 350 mg to about 3000 mg, about 350 mg to about 2000 mg, about 350 mg to about 1000 mg, about 350 mg to about 750 mg, about 350 mg to about 500 mg, about 350 mg to about 450 mg, about 350 mg to about 400 mg, about 400 mg to about 5000 mg, about 400 mg to about 4000 mg, about 400 mg to about 3000 mg, about 400 mg to about 2000 mg, about 400 mg to about 1000 mg, about 400 mg to about 750 mg, about 400 mg to about 500 mg, about 400 mg to about 450 mg, about 450 mg to about 5000 mg, about 450 mg to about 4000 mg, about 450 mg to about 3000 mg, about 450 mg to about 2000 mg, about 450 mg to about 1000 mg, about 450 mg to about 750 mg, about 450 mg to about 500 mg, about 500 mg to about 5000 mg, about 500 mg to about 4000 mg, about 500 mg to about 3000 mg, about 500 mg to about 2000 mg, about 500 mg to about 1000 mg, about 500 mg to about 750 mg, about 750 mg to about 5000 mg, about 750 mg to about 4000 mg, about 750 mg to about 3000 mg, about 750 mg to about 2000 mg, about 750 mg to about 1000 mg, about 1000 mg to about 5000 mg, about 1000 mg to about 4000 mg, about 1000 mg to about 3000 mg, about 1000 mg to about 2000 mg, about 2000 mg to about 5000 mg, about 2000 mg to about 4000 mg, about 2000 mg to about 3000 mg, about 3000 mg to about 5000 mg, about 3000 mg to about 4000 mg, about 4000 mg to about 5000 mg, about 0.1 mg, about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 300 mg, about 350 mg,WSGR Docket No.59851-708.601 about 400 mg, about 450 mg, about 500 mg, about 750 mg, about 1000 mg, about 2000 mg, about 3000 mg, about 4000 mg, or about 5000 mg. Delivery Enhancing Agents

[0153] In one aspect, provided herein are compositions and formulations of such compositions comprising agents that improve delivery of such compositions in a person. In certain embodiments, a composition (e.g., a composition provided herein) comprises a delivery enhancing agent (e.g., AstraGin®). In specific embodiments, the delivery enhancing agent comprises an isolated astragaloside compound (e.g., from Astragalus membranaceus var. mongholicus). For instance, AstraGin®. AstraGin® is composed of highly purified extracts of panax notoginseng and astragalus membranaceus. In specific embodiments, the delivery enhancing agent is an excipient. In yet more specific embodiments, the excipient comprises an extract of astragalus membranaceus and an extract of panax notoginseng. Delivery enhancing agents such as AstraGin® may enhance the delivery of an ingredient (e.g., an ingredient provided herein), such as, without limitation, organic extracts (e.g., from herbs, roots, plants), vitamins, minerals, amino acids, adaptogens, ashwagandha (including extracts and powders thereof), EDTA or disodium EDTA, maca, , fenugreek, cordyceps mushroom, vitamin B6, nitric oxide, green tea extract, panax ginseng, phosphatidylserine, magnesium glycinate, zinc citrate, magnolia officinalis, ginger, sage (e.g., sage leaf powder), diindolylmethane, bacopa monnieri, oat straw, D-aspartic acid, L- theanine, L-tryptophan, reishi mushroom, melatonin.

[0154] In certain embodiments, the delivery enhancing agent comprises an alkyl saccharide, cyclopentadecalactone; sodium N-[8-(2-hydroxylbenzoyl)amino] caprylate (SNAC); medium chain fatty acids, salts, and derivatives; sodium caprate, modified release formulation; sodium caprylate suspension in hydrophobic medium with matrix forming polymer; protease inhibitor and omega 3 fatty acid; AstraGin®, liquid mixed-micelle spray; combo of protease inhibitor, permeation enhancer, pH modifier, enteric coating; lipid polymer micelle; chitosan; dodecyl-2-N,N-dimethylamino propionate (DDAIP), any other suitable agent, or a combination of two or more thereof. In some embodiments, the delivery-enhancing agent comprises an aggregation inhibitory agent; charge-modifying agent; pH control agent; degradative enzyme inhibitory agent; mucolytic or mucus clearing agent; ciliostatic agent; membrane penetration- enhancing agent; modulatory agent of epithelial junction physiology; vasodilator agent; selective transport-enhancing agent; stabilizing delivery vehicle, carrier, adhesive, support or complex- forming species, or a combination of two or more thereof. In certain embodiments, the delivery enhancing agent comprises citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid (e.g., L-ascorbic acid), sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, or a combination of two or more thereof. In someWSGR Docket No.59851-708.601 cases, a delivery enhancing agent may comprise a membrane penetration enhancing agents, such as: a surfactant; a bile salt; a phospholipid additive, mixed micelle, liposome, or carrier; an alcohol; an enamine; an NO donor compound; a long-chain amphipathic molecule; a small hydrophobic penetration enhancer; sodium or a salicylic acid derivative; a glycerol ester of acetoacetic acid; a cyclodextrin or beta-cyclodextrin derivative; a medium-chain fatty acid; a chelating agent; an amino acid or salt thereof; an N-acetylamino acid or salt thereof; an enzyme degradative to a selected membrane component; an inhibitor of fatty acid synthesis; an inhibitor of cholesterol synthesis; and any combination of the membrane penetration enhancing agents recited above.

[0155] Delivery-enhancing agents may include agents which enhance the release or solubility (e.g., from a formulation delivery vehicle), diffusion rate, penetration capacity and timing, uptake, residence time, stability, effective half-life, peak or sustained concentration levels, clearance, and other desired delivery characteristics (e.g., as measured at the site of delivery, or at a selected target site of activity such as the bloodstream or central nervous system) of a compound. Enhancement of delivery may occur through one or more of a variety of mechanisms, including, for example, by increasing the diffusion, transport, persistence or stability of the compound, increasing membrane fluidity, modulating the availability or action of calcium and other ions that regulate intracellular or paracellular permeation, solubilizing membrane components (e.g., lipids), changing non-protein and protein sulfhydryl levels in tissues, increasing water flux across a surface, modulating epithelial junction physiology, reducing clearance rates, and other mechanisms.

[0156] In certain embodiments, about 0.5 mg to about 100 mg of a composition (e.g., a composition provided herein) comprises an excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng. In some embodiments, about 1 mg to about 75 mg of a composition (e.g., a composition provided herein) is the excipient. In certain embodiments, about 5 mg to about 50 mg of a composition (e.g., a composition provided herein) is the excipient. In specific embodiments, about 10 mg to about 40 mg of a composition (e.g., a composition provided herein) is the excipient. In certain embodiments, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg of a composition (e.g., a composition provided herein) is the excipient. In specific embodiments, about 25 mg of a composition (e.g., a composition provided herein) is the excipient comprising the extract of astragalus membranaceus and an extract of panax notoginseng. In yet more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is the excipient comprising the extract of astragalus membranaceus and an extract of panax notoginseng. In still more specific embodiments, about 26 mg of a composition (e.g., a composition provided herein) is the excipientWSGR Docket No.59851-708.601 comprising the extract of astragalus membranaceus and an extract of panax notoginseng.

[0157] In certain embodiments, about 0.5 mg to about 250 mg of a composition (e.g., a composition provided herein) comprises an excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng. In some embodiments, about 1 mg to about 175 mg of a composition (e.g., a composition provided herein) is the excipient. In certain embodiments, about 5 mg to about 100 mg of a composition (e.g., a composition provided herein) is the excipient. In specific embodiments, about 25 mg to about 75 mg of a composition (e.g., a composition provided herein) is the excipient. In certain embodiments, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 55 mg, about 65 mg, or about 75 mg of a composition (e.g., a composition provided herein) is the excipient. In specific embodiments, about 50 mg of a composition (e.g., a composition provided herein) is the excipient comprising the extract of astragalus membranaceus and an extract of panax notoginseng. In yet more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is the excipient comprising the extract of astragalus membranaceus and an extract of panax notoginseng.

[0158] In some embodiments, a composition (e.g., a composition provided herein) comprising a delivery enhancing agent (e.g., an extract of astragalus membranaceus and an extract of panax notoginseng) is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In certain embodiments, the amount of the delivery enhancing agent present in a composition (e.g., a composition provided herein) is about 0.5 mg to about 250 mg, about 1 mg to about 175 mg, about 5 mg to about 100 mg, about 25 mg to about 75 mg, or about 50 mg. An example product is called RHM.

[0159] In some embodiments, a composition (e.g., a composition provided herein) comprising a delivery enhancing agent (e.g., an extract of astragalus membranaceus and an extract of panax notoginseng) is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. In certain embodiments, the amount of the delivery enhancing agent present in a composition (e.g., a composition provided herein) is about 0.5 mg to about 250 mg, about 1 mg to about 175 mg, about 5 mg to about 100 mg, about 25 mg to about 75 mg, or about 50 mg. An example product is called RHA.

[0160] In some embodiments, a composition (e.g., a composition provided herein) comprising a delivery enhancing agent (e.g., an extract of astragalus membranaceus and an extractWSGR Docket No.59851-708.601 of panax notoginseng) is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. In certain embodiments, the amount of the delivery enhancing agent present in a composition (e.g., a composition provided herein is about 0.5 mg to about 100 mg, about 1 mg to about 75 mg, about 5 mg to about 50 mg, about 10 mg to about 40 mg, about 26 mg, or about 25 mg. An example product is called RHN.

[0161] As described above, intake of AstraGin® may have various effects. For example, intake of AstraGin® may improve a person’s ability to receive nutrients into their body. While AstraGin® is described above as an example of a delivery enhancing agent, AstraGin® is exemplary and other delivery enhancing agents may be used. In some embodiments, intake of a delivery enhancing agent (e.g., an extract of astragalus membranaceus and an extract of panax notoginseng, AstraGin®) alleviates a hot flash. In some embodiments, intake of a delivery enhancing agent alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of a delivery enhancing agent alleviates one or more symptoms associated with menopause. In some embodiments, intake of a delivery enhancing agent alleviates one or more symptoms associated with anxiety. Chelating agent

[0162] In one aspect, provided herein are compositions and formulations of such compositions comprising agents comprising a chelating agent. In certain embodiments, a composition (e.g., a composition provided herein) comprises a chelating agent. Chelating agents are used to reduce levels of injurious heavy metals in blood and tissue. Chelating agents are classified depending upon the heavy metal they bind. In some instances, there are agents that have high specificity and bind to narrow classes of metals. In other cases, there are chelating agents that bind to multiple metals. Because of their affinity to bind to metals, chelating agents are used in medicine, the chemical industry, and in pharmaceutical technologies. A chelating agent is present in some embodiments for its detoxification properties. Specifically, the ability of chelating agents to bind heavy and toxic metals. Furthermore, chelating agents may be added to composition formulations because of their stability, compatibility, and low toxicity. Additionally, chelating agents may be used as disruptors to allow large molecules to enter the bloodstream. These properties may permit the chelating agents to enhance the action of preservative and antibacterial components and stabilize the action of antioxidants. In certain embodiments, the chelating agent comprises deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol,WSGR Docket No.59851-708.601 ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, ethylenediaminetetraacetic acid (EDTA), disodium EDTA, or a combination of two or more thereof. In specific embodiments, the chelating agent is EDTA. In yet more specific embodiments, the chelating agent is disodium EDTA. In still more specific embodiments, a composition (e.g., a composition provided herein) comprises ethylenediaminetetraacetic acid (EDTA). In yet more specific embodiments, a composition (e.g., a composition provided herein) comprises disodium EDTA.

[0163] In certain embodiments, about 0.5 mg to about 100 mg of a composition (e.g., a composition provided herein) comprises a chelating agent. In some embodiments, about 1 mg to about 75 mg of a composition (e.g., a composition provided herein) is the chelating agent. In certain embodiments, about 5 mg to about 50 mg of a composition (e.g., a composition provided herein) is the chelating agent. In specific embodiments, about 10 mg to about 40 mg of a composition (e.g., a composition provided herein) is the chelating agent. In certain embodiments, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg of a composition (e.g., a composition provided herein) is the chelating agent. In specific embodiments, about 25 mg of a composition (e.g., a composition provided herein) is chelating agent (e.g., EDTA or disodium EDTA). In yet more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is chelating agent (e.g., EDTA or disodium EDTA).

[0164] In certain embodiments, about 0.5 mg to about 250 mg of a composition (e.g., a composition provided herein) comprises a chelating agent. In some embodiments, about 1 mg to about 175 mg of a composition (e.g., a composition provided herein) is the excipient. In certain embodiments, about 5 mg to about 100 mg of a composition (e.g., a composition provided herein) is the chelating agent. In specific embodiments, about 25 mg to about 75 mg of a composition (e.g., a composition provided herein) is the chelating agent. In certain embodiments, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 55 mg, about 65 mg, or about 75 mg of a composition (e.g., a composition provided herein) is the chelating agent. In specific embodiments, about 50 mg of a composition (e.g., a composition provided herein) is the chelating agent (e.g., EDTA or disodium EDTA). In yet more specific embodiments, about 35 mg of a composition (e.g., a composition provided herein) is the chelating agent (e.g., EDTA or disodium EDTA).

[0165] In some embodiments, a composition (e.g., a composition provided herein) comprising a chelating agent (e.g., EDTA or disodium EDTA) is taken in the morning. In specific embodiments, the composition is taken from about 0.1 hours to about 3 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.2 hours to about 2 hours after waking up. In still more specific embodiments, the composition is taken from about 0.25WSGR Docket No.59851-708.601 hours to about 0.75 hours after waking up. In yet more specific embodiments, the composition is taken from about 0.5 hours after waking up. In certain embodiments, the amount of the chelating agent present in a composition (e.g., a composition provided herein) is about 0.5 mg to about 250 mg, about 1 mg to about 175 mg, about 5 mg to about 100 mg, about 25 mg to about 75 mg, or about 50 mg. An example product is called RHM.

[0166] In some embodiments, a composition (e.g., a composition provided herein) comprising a chelating agent (e.g., EDTA or disodium EDTA) is taken in the afternoon. In specific embodiments, the composition is taken from about 3 pm to about 7 pm in the afternoon. In yet more specific embodiments, the composition is taken at the same time in the afternoon each day. In certain embodiments, the amount of the chelating agent present in a composition (e.g., a composition provided herein) is about 0.5 mg to about 250 mg, about 1 mg to about 175 mg, about 5 mg to about 100 mg, about 25 mg to about 75 mg, or about 50 mg. An example product is called RHA.

[0167] In some embodiments, a composition (e.g., a composition provided herein) comprising a chelating agent (e.g., EDTA or disodium EDTA) is taken in the evening. In specific embodiments, the composition is taken about 0.1 hours to about 2 hours before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.2 hours to about 1 hours before an individual goes to sleep. In still more specific embodiments, the composition is taken about 0.25 hours to about 0.75 before an individual goes to sleep. In yet more specific embodiments, the composition is taken about 0.5 hours before an individual goes to sleep. In certain embodiments, the amount of the chelating agent present in a composition (e.g., a composition provided herein is about 0.5 mg to about 100 mg, about 1 mg to about 75 mg, about 5 mg to about 50 mg, about 10 mg to about 40 mg, or about 25 mg. An example product is called RHN.

[0168] As described above, intake of a chelating agent (e.g., EDTA or disodium EDTA) may lead to various effects for a person. For example, intake of a chelating agent may reduce levels of heavy metals within a person as well as act as a disruptor to allow large molecules to enter the bloodstream. In some embodiments, intake of a chelating agent (e.g., EDTA or disodium EDTA) alleviates a hot flash. In some embodiments, intake of the chelating agent alleviates one or more symptoms associated with perimenopause. In some embodiments, intake of the chelating agent alleviates one or more symptoms associated with menopause. In some embodiments, intake of the chelating agent alleviates one or more symptoms associated with anxiety. Sodium Starch Glycolate and Disintegrants

[0169] In one aspect, provided are compositions and formulations comprising a disintegrant. In some cases, the disintegrant comprises silicon dioxide (e.g., anhydrous siliconWSGR Docket No.59851-708.601 dioxide) and / or sodium starch glycolate. In one aspect, provided are compositions and formulations comprising sodium starch glycolate (e.g., EXPLOTAB®). In some embodiments, sodium starch glycolate is an excipient and / or enhancing agent, that is added to compositions to improve composition delivery. Sodium starch glycolate may be used for its super-disintegrant properties to promote rapid dissolution of solid compositions. For instance, it may be used as a dissolution excipient for compositions formulated into tablets and capsules. Its ability to rapidly absorb water results in swelling which leads to rapid disintegration of compositions containing sodium starch glycolate. Importantly, in some cases the hydrophilic properties of sodium starch glycolate are uninhibited in the presence of other hydrophobic excipients. In some embodiments, compositions provided herein comprise an agglomerated spherical isomalt in any suitable amount.

[0170] Certain compositions herein are formulated to increase absorption and / or improve composition delivery with a disintegrant and / or sodium starch glycolate.

[0171] As described above, intake of disintegrants and / or sodium starch glycolate may lead to various effects for a person. For example, intake of disintegrants and / or sodium starch glycolate may lead to rapid disintegration of taken compositions, and therefore, may increase the speed of delivery of the taken compositions. While EXPLOTAB® is described above as a source of sodium starch glycolate, EXPLOTAB® is exemplary and other sources of sodium starch glycolate may be used. Silicon Dioxide, Adsorbents, and Glidants

[0172] In one aspect, provided are compositions and formulations comprising silicon dioxide, e.g., colloidal silicon dioxide. In some embodiments, the silicon dioxide is present as an anti-caking agent, adsorbent, disintegrant, and / or glidant to allow powder to flow freely when tablets are processed. In some embodiments, the silicon dioxide is a lubricant.

[0173] As described above, silicon dioxide may be present as an anti-caking agent to aid in the processing of tablets. In some cases, silicon dioxide may act as a lubricant to improve the manufacturing of tablets. Cellulose and Binders / Diluents

[0174] In one aspect, provided are compositions and formulations comprising a binder and / or diluent. In one aspect, provided are compositions and formulations comprising cellulose, such as microcrystalline cellulose. In some cases, cellulose is a binder / diluent. The binder, diluent, and / or cellulose may be used to enhance stability of compositions and extend composition release.

[0175] As described above, intake of cellulose or other binders / diluents may lead to various effects, such as enhancing the stability of a composition or extending the release of a composition that a person has taken.WSGR Docket No.59851-708.601 Sweetening agent

[0176] In one aspect, provided are compositions and formulations comprising a sweetening agent. Non-limiting examples of sweetening agents include acesulfame, aspartame, dextrates, dextrose, erythritol, fructose, galactose, maltitol, maltose, mannitol, saccharin, sorbitol, sucralose, sugar, syrup, and tagatose. In some embodiments, the sweetening agent comprises sucralose.

[0177] As described above, sweetening agents may be added to compositions in order to make the composition sweeter, and, thus, may improve the taste of the composition to various persons. Flavoring agents

[0178] In one aspect, provided are compositions are formulations comprising a flavoring agent (e.g., peppermint flavor dried P-183, another mint flavoring agent, methanol crystals, natural flavoring (e.g., flavor of a fruit such as grapefruit and / or apple), a peppermint oil, a spearmint oil blend, a peppermint / spearmint oil blend, a fruit extract (e.g., monkfruit), a sugar substitute (e.g., STEVIA), or a flavoring agent with another flavor). In some embodiments, the flavoring agent may provide a specific flavor for a tablet.

[0179] As described above, flavoring agents such as peppermint flavor dried P-183 may be added to compositions in order to increase the presence of a certain flavor in the composition, and, thus, may improve the taste of the composition to various persons. Menthol crystals may also be used as a flavoring agent. Some compositions comprise peppermint flavor dried P-183 and menthol crystals. Starch Excipient

[0180] In one aspect, provided are compositions and formulations comprising a starch excipient (e.g., starcap 1500.) In some embodiments, the starch excipient is present as a filling agent to make sure tablets are full. In some embodiments, the starch excipient may be a pregelatinized starch that has been cooked and dried. A starch excipient may be used for a variety of roles. For example, a starch excipient may act as a diluent, disintegrant, glidant, and / or binder.

[0181] As described above, starch excipients may act as filling agents, and thus, may be added to compositions in order fill a tablet or add weight to the tablet. While starcap 1500 is described above as a starch excipient, starcap 1500 is exemplary and other starch excipients, such as blends of corn starch and pregelatinized starch, may be used. Magnesium Stearate

[0182] In one aspect, provided are compositions and formulations comprising magnesium stearate. In some embodiments, the magnesium stearate is present as a flow agent that keeps the ingredients of a tablet separated.WSGR Docket No.59851-708.601

[0183] As described above, magnesium stearate may be added to compositions as a flow agent, and thus, may keep the ingredients of the composition separated. Compositions

[0184] In one aspect, provided is a composition comprising a maca, fenugreek seed extract, cordyceps mushroom, tea extract, nitric oxide source, bacopa monnieri, amino acid, panax ginseng, or a vitamin, or a combination of two or more thereof. In some embodiments, the composition comprises the maca, wherein the maca is from about 5 mg to about 520 mg of the composition.

[0185] In one aspect, provided is a composition comprising a cordyceps mushroom, a component of a magnolia tree, oat straw, ginger, sage (e.g., sage leaf powder), diindolylmethane (DIM), a compound comprising magnesium, or zinc citrate, or a combination of two or more thereof.

[0186] In one aspect, provided is a composition comprising phosphatidylserine, a component of a magnolia tree, amino acid, reishi mushroom, or melatonin, or a combination of two or more thereof.

[0187] In one aspect, provided herein are compositions comprising one or more ingredients herein, e.g., an organic extract or powder (e.g., from herbs, roots, plants), vitamins, minerals, amino acids, adaptogens, ashwagandha (including extracts and powders thereof), EDTA (and derivatives thereof, such as disodium EDTA), extracts of panax notoginseng and astragalus membranaceus (e.g., Astragin®), maca (Lepidium meyenii), fenugreek seed extract, cordyceps mushroom, vitamin B6, beet root powder, green tea extract, panax ginseng, phosphatidylserine, magnesium glycinate, zinc citrate, magnolia officinalis, ginger, sage (e.g., sage leaf powder), diindolylmethane (DIM), bacopa monnieri, oat straw, D-aspartic acid, L-theanine, L-tryptophan, reishi mushroom, and melatonin. In some embodiments, the composition comprises ashwagandha extract (e.g., as described herein) that is useful in a variety of applications including, but not limited to, for use to modulate cortisol levels in a human person in order to address energy levels, relaxation levels, and sleep health. In certain instances, compositions provided herein are useful for alleviating symptoms associated with menopause and perimenopause. In some instances, compositions provided herein are useful for alleviating hot flashes in persons. In some instances, compositions provided herein are useful for alleviating symptoms of anxiety in persons.

[0188] In various embodiments, the compositions are formulated for delivery via any route known in the art.

[0189] In various aspects, the composition is formulated for oral delivery. Oral delivery may provide a means for introduction to the mouth and / or ingestion of compositions in the presence of one or more delivery-enhancing agents. Delivery-enhancing agents may includeWSGR Docket No.59851-708.601 delivery-enhancing agents as described herein (e.g., AstraGin®, EDTA or disodium EDTA). A composition with delivery-enhancing properties may include a combination of ashwagandha, disodium EDTA, and extracts of panax notoginseng and astragalus membranaceus (e.g., Astragin®).

[0190] In some embodiments, the means for introduction to the mouth and / or ingestion by a human person includes a lozenge containing one or more ingredients herein, e.g., ashwagandha extract. The lozenge may dissolve in a human person’s mouth. In other embodiments, the means for introduction to the mouth and / or ingestion includes a pill or tablet containing the ashwagandha extract. The pill or tablet may be swallowed by the person. In some embodiments, the lozenge, pill or tablet comprises a combination of ashwagandha, disodium EDTA, and extracts of panax notoginseng and astragalus membranaceus (e.g., Astragin®). Non-limiting example compositions

[0191] In certain embodiments, a composition (e.g., a composition provided herein) comprises maca, a fenugreek seed extract, cordyceps mushroom, tea extract, nitric oxide source, bacopa monnieri, D-aspartic acid, panax ginseng, and vitamin B-6. In specific embodiments, the composition further comprises one or more of: an ashwagandha extract, a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and a second excipient comprising disodium EDTA. In certain instances, example composition RHM comprises such compositions.

[0192] In certain embodiments, a composition (e.g., a composition provided herein) comprises a cordyceps mushroom, magnolia officinalis, oat straw, ginger, sage (e.g., sage leaf powder), diindolylmethane (DIM), magnesium glycinate, and zinc citrate. In specific embodiments, the composition further comprises one or more of: an ashwagandha extract, a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and a second excipient comprising disodium EDTA. In certain instances, example composition RHA comprises such compositions.

[0193] In certain embodiments, a composition (e.g., a composition provided herein) comprises phosphatidylserine, magnolia officinalis, l-theanine, l-tryptophan, a reishi mushroom, and melatonin. In specific embodiments, the composition further comprises one or more of: an ashwagandha extract, a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and a second excipient comprising disodium EDTA. In certain instances, example composition RHN comprises such compositions.

[0194] In certain embodiments, compositions provided herein are provided to a person in one or more servings, e.g., a serving in the morning, afternoon, and / or evening. In some embodiments, a serving (e.g., a composition provided herein) may be divided into one or moreWSGR Docket No.59851-708.601 units, e.g., 1, 2, 3, 4, or 5 units. Units include, e.g., an oral dissolving tablet or other oral formulation. In specific embodiments, a composition (e.g., a composition provided herein) is taken by a person in 1 unit. In specific embodiments, a composition (e.g., a composition provided herein) is taken by a person in 2 units. In some such cases, the person uses RHN. In some such cases, the person uses RHM. In some such cases, the person uses RHA. In some such cases, the person uses RHM, RHA, and RHN.

[0195] Exemplary compositions are provided in Tables 1-12. Exemplary compositions are prepared, e.g., by mixing together maca, fenugreek seed extract, and / or other solids by any conventional methods. Additional ingredients are added, and the resulting composition is formulated using any suitable method. Amounts stated below reflect the weight of each ingredient, unless otherwise specified. Table 1: RHM Exemplary Composition I e F e C m T N B A D P V A e E a m enotoginsengWSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example DTable 2: RHM Exemplary Composition Ingredient Ingredient Example Example Example Example Example F e C m T N B A D P V A e E a m e nDisodium EDTA 0.5-250 mg 170 98 25 100 70WSGR Docket No.59851-708.601 Table 3: RHM Exemplary Composition Ingredient Ingredient Example Example Example Example Example F e C m T N B A D P V A e E a m e n D. Table 4: RHA Exemplary Composition I e C mWSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example O G S p D ( g P Z A e E m e n DTable 5: RHA Exemplary Composition I e C m O G Spowder)WSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example D ( g P Z A e E m e n DWSGR Docket No.59851-708.601 Table 6: RHA Exemplary Composition Ingredient Ingredient Example Example Example Example Example C m O G S p D ( g P Z A e E m e n D. Table 7: RHN Exemplary Composition I e P A tWSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example A tr R A e E m e n DTable 8: RHN Exemplary Composition I e P A t A tr R A e E m e nDisodium EDTA 0.5-100 mg 92 78 25 31 75WSGR Docket No.59851-708.601 Table 9: RHN Exemplary Composition Ingredient Ingredient Example Example Example Example Example P A t A tr R A e E m e n DTable 10: RHN Exemplary Composition I e P A t A tr R G a(GABA)WSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example C c m m g C c m m t A e E m e n DTable 11: RHN Exemplary Composition I e P A t A tr R G a ( C c m mglycinate)WSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example C c m m t A e E m e n DTable 12: RHN Exemplary Composition I e P A t A tr R G a ( C c m m g C c m m t AextractWSGR Docket No.59851-708.601 Ingredient Ingredient Example Example Example Example Example E m e n DTablet Formulation

[0196] In some aspects, compositions herein may be formulated into one or more solid formations or units, such as a tablet, that may be received orally. In some embodiments, the tablet may be a lozenge or pill. In other embodiments, compositions herein may be formulated in a liquid formation that may be received orally. In some embodiments the formulation may comprise one or more ingredients (e.g., ashwagandha extract, cordyceps species, supplemental mineral, component of a magnolia tree, ginger, sage (e.g., sage leaf powder), DIM, zinc citrate, oat straw, fenugreek seed extract, tea extract, vitamin, nitric oxide source, amino acid, panax ginseng, maca, bacopa monnieri, L-theanine, L-tryptophan, reishi mushroom, melatonin, or a combination of one or more thereof), one or more excipients (e.g., sodium starch glycolate, one or more flavoring agents, one or more sweetening agents, one or more adsorbents, glidants, and / or silicon dioxide, one or more of binders, diluents, and / or cellulose, one or more starch excipients, magnesium stearate, and / or menthol crystals), a chelating agent (e.g., disodium EDTA or EDTA), and a delivery enhancing agent (e.g., AstraGin®). Systems

[0197] In certain aspects, a system is provided herein that in some embodiments is used with a composition herein. In some cases, the system is used prior to taking the composition. In some cases, the system is used after taking the composition. In some cases, the system is used while taking the composition. In some cases, the system is used multiple times, for instance, more than once a week, more than once a day, e.g., 2, 3, 4, 5, or 6 times a day. In some embodiments, the system measures or receives one or more physiological features of a person, e.g., cortisol, biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, magnesium, water, vitamin B12, calcium, sodium, and combinations of two or more thereof. In some embodiments, the system receives one or more factors regarding the person’s lifestyle, e.g., sleep, libido, exercise, and the like. In some cases, the system provides feedback, e.g., makes one or more lifestyle recommendations. In some cases, the system provides feedback, e.g., provides a score or other indication of the person’s cortisol levels. A non-limiting example recommendation is whether toWSGR Docket No.59851-708.601 take the composition. Other non-limiting recommendations include increasing water intake, sleep, dietary recommendations, and the like. Feedback / recommendations for a person may be determined based on one or more factors regarding the person. In some embodiments, the one or more factors regarding the person may be determined based on received information regarding the person. The received information may include data regarding the health, lifestyle, activities, or personal information of the person. The data may be input or provided by the person. The one or more factors regarding the person may also be determined based on a comparison of the received information and data. In some cases, the received information may contain one or more of the one or more factors. Recommendations for a person may also be determined based on information received regarding one or more physiological features of the person, e.g., cortisol levels, pH, metabolite concentration in urine, and the like. Received information is described further herein.

[0198] In one embodiment, a human may analyze the received information and provide feedback such as determine a recommendation. The recommendation may include a lifestyle adjustment, dietary adjustment, and / or whether or not take a certain composition, e.g., a composition herein. The feedback and / or recommendation may be based on the received information and data.

[0199] In some embodiments, the system may determine feedback (e.g., a recommendation) based on the received information using a server (e.g., a physical processing device or a virtual server) or a computing device (e.g., a laptop, smartphone, or another processing device) of the system. In those embodiments, the received information may be compared to the data and the feedback (e.g., recommendation) may be determined based on the comparison. The data may be received by the server or computing device or may be stored in a database on the server or computing device. In some cases, the server or computing device may receive the information from a processing device associated with the information.

[0200] In some embodiments, the received information may be received from the person or from a processing device (e.g., a computing device) associated with the person. The information may be input by the person to the processing device, which then may provide the information to a human or processing device. In embodiments with the processing device associated with the person, the processing device associated with the person may further receive feedback, such as a recommendation, e.g., lifestyle, diet, supplement, from the processing device. The recommendation may indicate that the person should take a first product (e.g., RHM), a second product (e.g., RHA), and a third product (RHN), or any combination thereof.

[0201] In some embodiments, the feedback (e.g., recommendation) is made using the received information and the data. As described above, in some embodiments, recommendationsWSGR Docket No.59851-708.601 are determined based on one or more factors. The one or more factors may include cortisol levels of the person. The cortisol levels may be an average of two or more measurements of the person’s cortisol, e.g., measured the same day. In an example, the cortisol levels or one or more other factors are measured 2, 3, 4, 5, or 6 times a day. The cortisol levels or other factors may be averaged from the 2, 3, 4, 5, or 6 measurements. The cortisol levels of the person may include current cortisol levels of the person as well as desired cortisol levels of the person. The cortisol levels of the person may be determined based on the received information.

[0202] In some embodiments, a second feedback (e.g., recommendation) may be provided based on additional information, edited information, or re-input information. In those embodiments, the person may have the option to input additional information, edit information, or re-input information in order to receive the second recommendation.

[0203] As described above, the feedback (e.g., recommendation) may be determined based on one or more factors (e.g., one or more cortisol levels of a person). The one or more factors may be determined based on the received information, which may be input by a person. Additionally, the one or more factors may include one or more relevant pieces of the received information. For example, as described below, if the received information includes the person’s date of birth, one of the one or more factors may be the date of birth itself, and one of the one or more factors may be the age range determined based on the date of birth.

[0204] As described above, in some embodiments, information about the person is received as input. The information may be received from the person or from a processing device associated with the person. Non-limiting examples of information received by the system include the age and / or date of birth of the person, sleep data of the person, diet of the person, libido level of the person, mental clarity of the person, fatigue levels of the person, mood of the person, daily exercise of the person, level of energy of the person during exercise, daily stress levels of the person, measured cortisol levels of the person in the morning, measured cortisol levels of the person at midday, measured cortisol levels of the person in the evening, measured cortisol levels of the person at night, and averaged cortisol levels of the person from two or more measurements in a day.

[0205] Determining the feedback (e.g., recommendation) may be based on one or more factors associated with the age of the person, such as an age range that the person belongs to. For example, information specifying the date of birth or the age of the person may be received. Relevant age ranges may be determined, and the recommendation may be based on those age ranges, such as age ranges of between 18 and 29 years, between 30 and 39 years, between 40 and 49 years, between 50 and 59 years, or between 60 and 70 years. While certain age ranges are described, these ranges are exemplary, and different ranges may be used.WSGR Docket No.59851-708.601

[0206] The feedback (e.g., recommendation) may be further determined based on one or more factors associated with the daily sleep of the person. For example, information specifying that the person sleeps for a specified average amount of time each night, and that specified average amount of time each night may fall within a specified range may be received. Specified ranges may include less than about 4 hours, from about 4 hours to about 5 hours, from about 5 hours to about 6 hours, from about 6 hours to about 7 hours, from about 7 hours to about 8 hours, from about 8 hours to about 9 hours, from about 9 hours to about 10 hours, or more than about 10 hours. While certain ranges of sleep are described, these ranges are exemplary, and different ranges may be used.

[0207] The feedback (e.g., recommendation) may be further determined based on one or more factors associated with the daily exercise of the person. For example, information specifying that the person exercises for a specified average amount of time each day or night, and that specified average amount of time exercised may fall within a specified range may be received. Specified ranges may include no daily exercise, about 30 minutes of daily exercise, about 1 hour of daily exercise, about 1.5 hours of daily exercise, or about 2 hours or more of daily exercise. While certain ranges of daily, these ranges are exemplary, and different ranges may be used. Additionally, the person may input information specifying that the person did a specific exercise, such as running, lifting weights, swimming, boxing, soccer, or other various exercises, on each day. While certain exercises are described, these exercises are exemplary, and different exercises may be performed and input.

[0208] The feedback (e.g., recommendation) may be further determined based on one or more factors associated with the diet of the person. For example, the person may input information specifying the number of meals per day the person eats, such as two or three meals a day. As another example, the person may input an amount of calories that the person intakes per day, such as 2000 calories per day or 3000 calories per day. As yet another example, the person may input the type of food eaten each day, such as eggs or spinach. While certain amounts of meals, amounts of calories, and types of food are described, these are exemplary, and other amounts or types may be used. In some embodiments, the received information may indicate that the person considers his or her diet to be considerably unhealthy, unhealthy, average, healthy, or considerably healthy. While only certain health levels attributed to a person’s diet are described, these levels are exemplary, and other levels or methods of describing a person’s diet may be used.

[0209] The feedback (e.g., recommendation) may also be determined based on one or more factors associated with subjective information (e.g., information based on the person’s feeling or belief) received, such as libido level of the person, mental clarity of the person, fatigueWSGR Docket No.59851-708.601 levels of the person, mood of the person, level of energy of the person during exercise, and daily stress levels of the person.

[0210] For example, the feedback (e.g., recommendation) may be determined based on one or more factors indicating the overall libido of the person. For example, the received information may indicate that the person feels or believes his or her libido is no libido, libido less than the average man or woman, libido of the average man or woman, more libido than the average man or woman, or substantially more libido than the average man or woman. While certain levels of libido are described, these are exemplary, and other information about libido may be used.

[0211] As another example, the feedback (e.g., recommendation) may be determined based on one or more factors indicating the daily mental clarity of the person. For example, the received information may indicate that the person feels or believes his or her mental clarity is no mental clarity, mental clarity less than the average man or woman, mental clarity of the average man or woman, more mental clarity than the average man or woman, or substantially more mental clarity than the average man or woman. While certain levels of mental clarity are described, these are exemplary, and other information about mental clarity may be used.

[0212] As yet another example, the feedback (e.g., recommendations) may be determined based on one or more factors indicating the daily fatigue level of the person. For example, the received information may indicate that the person feels or believes his or her fatigue level is no fatigue, about a fatigue level less than the average man or woman, about a fatigue level equal to the average man or woman, about a fatigue level greater than the average man or woman, or about a fatigue level substantially greater than the average man or woman. While certain fatigue levels are described, these are exemplary, and other information about a person’s fatigue may be used.

[0213] As even another example, feedback (e.g., recommendations) may be determined based on one or more factors indicating the daily mood of the person. For example, the received information may indicate that the person feels or believes his or her mood is a mood substantially worse than the average man or woman, a mood worse than the average man or woman, a mood the same as the average man or woman, a mood better than the average man or woman, or a mood substantially better than the average man or woman. While certain moods are described, these are exemplary, and other information about a person’s fatigue may be used.

[0214] As yet another example, feedback (e.g., recommendations) may be determined based on one or more factors indicating the daily stress level of the person. For example, the received information may indicate that the person feels or believes his or her daily stress level is no daily stress, about a daily stress level less than the average man or woman, about a dailyWSGR Docket No.59851-708.601 stress level equal to the average man or woman, about a daily stress level greater than the average man or woman, or about a daily stress level substantially greater than the average man or woman. While certain stress levels are described, these are exemplary, and other information about a person’s stress level may be used.

[0215] As one more example, feedback (e.g., recommendations) may be determined based on one or more factors indicating the energy levels of the person during workouts. For example, the received information may indicate that the person feels or believes his or her energy level is substantially less than the average man or woman, about an energy level less than the average man or woman, about an energy level about equal to the average man or woman, about an energy level greater than the average man or woman, or about an energy level substantially greater than the average man or woman. While certain energy levels are described, these are exemplary, and other information about a person’s energy level may be used.

[0216] In some examples, feedback (e.g., recommendations) may include a score. The score may be calculated by the system based on the one or more factors and information about the person regarding those one or more factors. The score may further be determined using weights associated with each of the factors. In some embodiments, higher scores may indicate that the person should not make a lifestyle, dietary, and / or nutrient adjustment, and / or should maintain a lifestyle, diet, and / or nutrient intake, while lower scores may indicate that the person should make the adjustment(s), and vice versa.

[0217] In some embodiments the score is an indication of a person’s cortisol levels. The score may be calculated by the system based on the one or more factors and information about the person regarding those one or more factors. The score may further be determined using weights associated with each of the factors. In some embodiments, higher scores may indicate that the person should not make a lifestyle, dietary, and / or nutrient adjustment, and / or should maintain a lifestyle, diet, and / or nutrient intake, while lower scores may indicate that the person should make the adjustment(s), and vice versa.

[0218] In some embodiments, the algorithm for calculating the user’s cortisol score may be fixed for each user. In some embodiments, the algorithm may take into consideration one or more factors to determine the health score calculations. The one or more user input information or data may be used to determine and / or adjust the weighted values used to calculate the score. In some embodiments, the algorithm may adjust the impact of one or more factors in response to a user input. A non-limiting example is if the users age is 60+, the weight of the user’s libido may be less than the weight of a user libido for a user in the age range of 20-29. In another example, for a 60+ year old user, sleep maybe be weighted higher than for a younger user (e.g., user 20-29 years, old, a user 30-39 years old, a user 40-49 years old, or a user 50-59 years old).WSGR Docket No.59851-708.601

[0219] In some embodiment the algorithm can receive input data from a user in response to approximately 12 sections of health factor questions, each with various levels of weighted scores based on a determined influence the one or more health factors on a user’s overall health and wellbeing. Cortisol can be a strong indicator of a user’s health and wellbeing and therefore the algorithm can be configured to weight the answers and data from the user such that a health score of the user is a direct indication of a user’s cortisol level and outputting a score and feedback to the user corresponding to their cortisol The score and feedback being easier for a user to understand compared to the inconsistent cortisol monitoring methods currently used.

[0220] Below describes a non-limiting example of how the algorithm can weight different sections of user’s answers and input to determine an accurate cortisol level related health score.

[0221] One of the one or more section can be sleep. Sleep is a critical factor to maintaining appropriate hormone levels. The proper circadian rhythm and sleep regimen incorporates light, deep and REM sleep repeated numerous times (three stage sleep state) in a 7-9 hour period for all adults. The majority of our hormones are generated during the deep and REM cycles. Therefore, we weighted sleep heavily in the algorithm. Note that sleep aids knock the user out but do not induce the correct three stage sleep state and hence, most adults do not obtain the ideal 7-9 hours of three stage sleep, with or without sleep aids, causing hormone generation to be sub-optimum. Therefore, the algorithm may be configured to weight a user’s answer regarding their sleep data and information more highly than answers regarding other health factors. A non-limiting example being, if a user identifies that they are getting more than 9 hours of sleep, they will get a lower score, as studies and data suggest that this is indicative of an unhealthy sleep pattern. If a user identifies that they are getting less than 7 hours of sleep, they will get a decreasing score for each hour less than 7-9 hours of sleep. Studies and data suggest that obtaining less than 5 hours of sleep this is indicative of an unhealthy sleep pattern and underling medical issues are of concern, therefore if a user selects less than 5 hours of sleep, they will obtain a negative score that in turn will be weighted in accordance with our proprietary algorithm.

[0222] Another section of the one or more section can be weight. This section can ask the user for weight related information and data to determine a modified BMI index. The algorithm can receive the user data in response to health-related questions presented to the user, such as the examples illustrated in FIGS.7B-7N, to determine a user’s BMI index. The algorithm can be configured to determine a modified BMI index based off the user’s BMI index, to be a more effective indicator of a user’s health compared to a traditional BMI index. The BMI index may be modified in response to a user’s bone and muscle mass weight variation or any other factor that can affect a BMI index. A score may then be determined based off a modified BMI indexWSGR Docket No.59851-708.601 and can be applied to a weighted calculation and incorporated into the overall scoring with “normal” receiving a higher score and “obese” receiving a lower score. It can be determined that weight has a smaller influence on a user’s overall health and wellbeing and / or cortisol level and therefore be weighted less than a score corresponding to the sleep related answers and inputs. In some embodiments, the algorithm can offer a multiple-choice format with an unlimited collection of answers offered up in a randomly generated display order to encourage the user to answer as authentically as possible and without the option to game the system. The algorithm can show multiple-choice answers in a random order for one or more section having a score corresponding to each of the answers of the one or more section. The one or more section and can each be given a corresponding weight to determine of the overall score. The determined weight of each one or more section corresponding directly to the determined influence on the user’ health and wellbeing. An example being a sleep section score may be determined to be a factor that has a large influence on a user’s overall health and wellbeing, because of its relationship to hormone production, as explained above, and receive a weight between 25-70% of the overall score; wherein a weight section score is determined to have less influence, and receive a weight between about 1-15% of the overall score; wherein a stress section score can be determined to have more influence than a weight section score but less influence than a sleep section score and receive a weight between about 5-25% of the overall score, wherein one or more additional section are presented answered, used and weighted to determine the overall score. In a non-limiting example, the score can directly correspond to a user’s cortisol level, wherein the weight of each section is determined based on the sections determined influence on a user’s cortisol level.

[0223] In some embodiments, one or more factors may be determined based on information about the person received by the system (e.g., received by the processing device). In some embodiments, the user may input the information to a user interface. In some embodiments, a person provides a level of physiological feature, such as, without limitation, cortisol, biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, magnesium, water, vitamin B12, calcium, or sodium, or combinations of two or more thereof, to the system. In some embodiments, a computing device inputs a level of a physiological feature, such as, without limitation, cortisol, biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, magnesium, water, vitamin B12, calcium, or sodium, or combinations of two or more thereof, to the system. Non-limiting examples of levels includes levels of a physiological feature of the person measured in the morning, levels of a physiological feature of the person measured at midday, levels of a physiological feature of the person measured in the evening, and levels of a physiological feature of the person measured at night. Non-limiting example a physiologicalWSGR Docket No.59851-708.601 features include cortisol. While levels measured in the morning, at midday, in the evening, and at night are described, these are exemplary times and levels of a physiological feature measured at other times may be used. In some embodiments, levels of a physiological feature are measured 2, 3, 4, 5, or 6 times a day, and two or more of these levels are averaged and provided to the interface.

[0224] In a non-limiting example embodiment, the system is used to determine whether a person should take an example product called RHM. In a non-limiting example embodiment, the system is used to determine an effect of taking an example product called RHM. In a non- limiting example embodiment, the system is used to determine whether a person should take an example product called RHA. In a non-limiting example embodiment, the system is used to determine an effect of taking an example product called RHA. In a non-limiting example embodiment, the system used to determine whether a person should take an example product called RHN. In a non-limiting example embodiment, the system is used to determine an effect of taking an example product called RHN.

[0225] In one aspect, a system for providing recommendations to a person based on information determined about a person’s health data is provided. In some embodiments, the system for providing recommendations to a person based on information determined about a person’s health may be a part of the system previously disclosed herein.

[0226] In some embodiments, the system for providing recommendations may receive information (e.g., indicators of various levels of one or more substances in a person’s blood or urine) about a person and / or one or more samples (e.g., a urine sample or a blood sample) associated with a person. If one or more samples are received, the system for providing recommendations may analyze the one or more samples in order to determine information about the person (e.g., the various levels of one or more substances in the person’s blood or urine or the pH of the person’s blood or urine).

[0227] The system may then analyze the information about the person in order to determine a recommendation. The recommendation may indicate one or more changes that the person should make (e.g., a change in the person’s daily habits, a change in the person’s diet, a change in the person’s sleep habits, and / or a change in the amount of a product the person is taking). The recommendation may also indicate that one or more various levels of one or more substances in a person’s body is not a recommended level (e.g., at a higher level or a lower level than recommended). The one or more substances may include biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, cortisol, magnesium, water, vitamin B12, calcium, and / or sodium.

[0228] The system may then determine the recommendation based on one or more levels ofWSGR Docket No.59851-708.601 the one or more substances. In some embodiments, the recommendation may indicate that one or more levels of the one or more substances is higher or lower than a recommended level, that the person should adjust one or more aspect of the person’s lifestyle for various purposes (e.g., to change the one or more levels of the one or more substances into a recommended range), and / or that the person should take or stop taking one or more products (e.g., RHM, RHA, and / or RHN).

[0229] The recommendation may indicate that the person should take one or more products. For example, the recommendation may indicate that the person should take a first product (e.g., RHM), a second product (e.g., RHA), and a third product (e.g., RHN). In some aspects, the compositions of RHM, RHA, and / or RHN may cause the levels of the one or more substances to rise or fall towards a recommended range.

[0230] Thus, after receiving information about a person and / or samples from a person, the system may determine a recommendation based on the information and / or samples. The system may then provide the recommendation to the person (e.g., to a computing device associated with the person). A non-limiting example of a sample is urine, e.g., information from the urine may related to an amount of a metabolite in the urine sample from the person.

[0231] In some embodiments, the person may provide multiple sets of health data. Further, in those embodiments, the person may provide each set of the multiple sets of health data at different times throughout a day. The different times throughout the day may be immediately after waking up, four to six hours after waking up, four to six hours before going to sleep, or just before going to sleep. While the times of after waking up, four to six hours after waking up, four to six hours before going to sleep, or just before going to sleep are described, these times are exemplary and other times may be used. In those embodiments, the multiple sets of health data may be manipulated (e.g., averaged, grouped, and or transformed) in order to determine an optimized data set that is then used to determine the recommendation. Additional System Embodiments

[0232] In general, assessing an individual’s health and providing a recommendation regarding their health is not a one-size-fits-all process. Many aspects surrounding the individual’s health may constantly change, making it difficult to determine if those aspects are associated with a healthy lifestyle. Additionally, there can be an innumerable number of aspects contribute to the individual’s health quality, and thus, can make it nearly impossible to determine what aspects of the individual’s lifestyle lead to the quality of their health, whether good or bad.

[0233] In particular, a person’s cortisol level is difficult to determine and effectively track. Current methods for determining a person’s cortisol levels include taking a blood sample and testing the person’s blood; however, this is invasive and unreliable as it only provides a snapshot of the patient’s cortisol levels at that specific moment in time and is unable to take into accountWSGR Docket No.59851-708.601 the innumerable factors and variables that effect person’s cortisol levels at any particular moment, e.g., stressful experiences that day or foods eaten prior to the test. Therefore, identifying outlier sample data and interpreting the results can be challenging. Due to the invasive and time- consuming nature of these tests, it is difficult and uncomfortable to preform multiple test over a single day or week, making it hard to track a person’s cortisol over a period of time. Another method involves testing urine samples to determine cortisol levels of a person. While this may allow for more effective tracking of cortisol levels over a time period (e.g., a day or a week), the user is only able to test at times when the person needs to urinate. Further, this method can be uncomfortable and awkward if a person is required to carry around sample bottles throughout the day and collect and store samples while at work or in public. This method can also lead to inaccurate representation of a person’s normal cortisol levels as the person may be pressured to drink more water to collect more samples over a time period, affecting the hydration levels of the person and potentially skewing the cortisol data. Thus, a need exists in the art for assessing an individual’s health, including methods and systems for an accurate and / or broadly representative measurement of an individual’s cortisol level and using aspects associated with the individual’s health to determine what aspects of the individual’s health are beneficial or detrimental, along with providing recommendations on how to change (or not change) one’s lifestyle in relation to those aspects.

[0234] Systems and methods described herein provide for assessing the health or wellbeing of a person based on information associated with or derived from the person. As described above, innumerable aspects may surround an individual’s health; however, the systems and methods described herein provide for determining a score to provide an accurate assessment of the individual’s health as well as recommendations to improve it based on one or more factors surrounding those aspects. The systems and methods provide for combining both subjective and objective information associated with the person in order to account for both physical and nonphysical aspects of the individual’s health. Additionally, the subjective and objective information may indicate one or more deficiencies of the individual’s health, such as high cortisol levels, and thus, the system and methods include feedback, such as recommending that the individual make a lifestyle, diet, and / or nutrient adjustment to combat those deficiencies. As a non-limiting example, the recommendation is to take a nutrient composition comprising a modulator of cortisol. The recommendation may be in response to determining a higher than desired cortisol level. In a non-limiting embodiment, the composition comprises ashwagandha extract.

[0235] In some embodiments, the term “at least,” “greater than,” or “greater than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “atWSGR Docket No.59851-708.601 least,” “greater than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.

[0236] In some embodiments, the term “no more than,” “less than,” or “less than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1. Information

[0237] Systems and methods as described herein may take as input information about a person. The information may comprise data associated with one or more people (e.g., a user). The information may be provided by the user. In some cases, information may be stored in one or more databases. The information stored in the one or more databases may comprise information associated with one or more additional persons other than the user. Alternatively, or additionally, the information stored in the one or more databases may comprise information associated with the user. The stored information may include past scores and / or recommendations.

[0238] The information (e.g., data) may be indicative of one or more factors associated with the person. The one or more factors may be determined based on the information provided by the person. Alternatively, or additionally, the one or more factors may include one or more relevant pieces of the provided information. In an example, if the received information includes the person’s date of birth, one of the one or more factors may be the date of birth itself, and one of the one or more factors may be the age range determined based on the date of birth.

[0239] As described above, in some cases, information about the person may be input. The information may be received from the person or from a computing device associated with the person. Non-limiting examples of provided information includes the age and / or date of birth of the person, sleep data of the person, diet of the person, libido level of the person, mental clarity of the person, fatigue levels of the person, mood of the person, daily exercise of the person, level of energy of the person during exercise, daily stress levels of the person, measured cortisol levels of the person in the morning, measured cortisol levels of the person at midday, measured cortisol levels of the person in the evening, and measured cortisol levels of the person at night.

[0240] In some cases, information about the person or factors thereof may be associated with objective information, such as the age and / or date of birth of the person, sleep data of the person, diet of the person, and measured levels of a substance in a sample associated with the person (e.g., measured cortisol levels of the person in the morning, measured cortisol levels of the person at midday, measured cortisol levels of the person in the evening, and measured cortisol levels of theWSGR Docket No.59851-708.601 person at night). In some cases, measured levels may be averaged from one or more measurements taken throughout the day, e.g., taken 2, 3, 4, 5, or 6 times a day, such as 4 times a day.

[0241] In some cases, information about the person or factors thereof may be associated with the age of the person, such as an age range that the person belongs to. For example, information specifying the date of birth or the age of the person may be received. Relevant age ranges may be determined, and the recommendation may be based on those age ranges, such as age ranges of between 18 and 29 years, between 30 and 39 years, between 40 and 49 years, between 50 and 59 years, or between 60 and 70 years. While certain age ranges are described, these ranges are exemplary, and different ranges may be used.

[0242] In some cases, information about the person or factors thereof may be associated with the daily sleep of the person. For example, information specifying that the person sleeps for a specified average amount of time each night, and that specified average amount of time each night may fall within a specified range may be received. Specified ranges may include less than about 4 hours, from about 4 hours to about 5 hours, from about 5 hours to about 6 hours, from about 6 hours to about 7 hours, from about 7 hours to about 8 hours, from about 8 hours to about 9 hours, from about 9 hours to about 10 hours, or more than about 10 hours. While certain ranges of sleep are described, these ranges are exemplary, and different ranges may be used.

[0243] In some cases, information about the person or factors thereof may be associated with the daily exercise of the person. For example, information specifying that the person exercises for a specified average amount of time each day or night, and that specified average amount of time exercised may fall within a specified range may be received. Specified ranges may include no daily exercise, about 30 minutes of daily exercise, about 1 hour of daily exercise, about 1.5 hours of daily exercise, or about 2 hours or more of daily exercise. While certain ranges of daily exercise are described, these ranges are exemplary, and different ranges may be used. Additionally, the person may input information specifying that the person did a specific exercise, such as running, lifting weights, swimming, boxing, soccer, or other various exercises, on each day. While certain exercises are described, these exercises are exemplary, and different exercises may be performed and input.

[0244] In some cases, information about the person or factors thereof may be associated with the diet of the person. For example, the person may input information specifying the number of meals per day the person eats, such as two or three meals a day. As another example, the person may input a number of calories that the person intakes per day, such as 2000 calories per day or 3000 calories per day. As yet another example, the person may input the type of food eaten each day, such as eggs or spinach. While certain amounts of meals, amounts of calories, and types of food are described, these are exemplary, and other amounts or types may be used. In someWSGR Docket No.59851-708.601 embodiments, the received information may indicate that the person considers his or her diet to be considerably unhealthy, unhealthy, average, healthy, or considerably healthy. While only certain health levels attributed to a person’s diet are described, these levels are exemplary, and other levels or methods of describing a person’s diet may be used.

[0245] In some cases, information about the person or factors thereof may be associated with data indicative of a level of one or more substances in a sample associated with the person. In some cases, the sample is a bodily fluid associated with the person. In some cases, the bodily fluid may be blood, saliva, or urine. The one or more substances may include biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, cortisol, magnesium, water, vitamin B12, calcium, and / or sodium. The data indicating levels of one or more substances in the sample may be from one or more timepoints. In some cases, the data are taken at one time point. Alternatively, the data may be taken at 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more timepoints. The timepoints may be spread over any appropriate length of time. In some cases, the timepoints occur within one day. In some cases, the timepoints occur within one week. In some cases, the timepoints occur within one month. In some cases, the timepoints occur within one year or longer.

[0246] In some cases, the input may comprise the sample itself or a fraction thereof. The sample may be processed (e.g., assayed, analyzed, separated, isolated, stored, or the like) before or after being input into a system as described herein. In such cases, the methods and systems described herein may be configured to determine the level or one or more substances in the (processed) sample or portion thereof.

[0247] In an example, cortisol level data associated with the person is provided. Non-limiting examples of cortisol levels include cortisol levels of the person measured in the morning, cortisol levels of the person measured at midday, cortisol levels of the person measured in the evening, and cortisol levels of the person measured at night. While cortisol levels measured in the morning, at midday, in the evening, and at night are described, these are exemplary times and cortisol levels measured at other times may be used. In some cases, cortisol levels may be averaged from one or more measurements taken throughout the day, e.g., taken 2, 3, 4, 5, or 6 times a day, such as 4 times a day.

[0248] In some cases, information about the person or factors thereof may be associated with subjective information (e.g., information based on the person’s feeling or belief) provided, such as libido level of the person, mental clarity of the person, fatigue levels of the person, mood of the person, level of energy of the person during exercise, and daily stress levels of the person.

[0249] For example, information about the person or factors thereof may indicate the overall libido of the person. For example, the provided information may indicate that the person feels or believes his or her libido is no libido, libido less than the average man or woman, libido of theWSGR Docket No.59851-708.601 average man or woman, more libido than the average man or woman, or substantially more libido than the average man or woman. While certain levels of libido are described, these are exemplary, and other information about libido may be used.

[0250] As another example, the information about the person or factors thereof may indicate the daily mental clarity of the person. For example, the provided information may indicate that the person feels or believes his or her mental clarity is no mental clarity, mental clarity less than the average man or woman, mental clarity of the average man or woman, more mental clarity than the average man or woman, or substantially more mental clarity than the average man or woman. While certain levels of mental clarity are described, these are exemplary, and other information about mental clarity may be used.

[0251] As yet another example information about the person or factors thereof may indicate the daily fatigue level of the person. For example, the provided information may indicate that the person feels or believes his or her fatigue level is no fatigue, about a fatigue level less than the average man or woman, about a fatigue level equal to the average man or woman, about a fatigue level greater than the average man or woman, or about a fatigue level substantially greater than the average man or woman. While certain fatigue levels are described, these are exemplary, and other information about a person’s fatigue may be used.

[0252] As even another example, information about the person or factors thereof may indicate the daily mood of the person. For example, the provided information may indicate that the person feels or believes his or her mood is a mood substantially worse than the average man or woman, a mood worse than the average man or woman, a mood the same as the average man or woman, a mood better than the average man or woman, or a mood substantially better than the average man or woman. While certain moods are described, these are exemplary, and other information about a person’s fatigue may be used.

[0253] As yet another example, information about the person or factors thereof may indicate the daily stress level of the person. For example, the received information may indicate that the person feels or believes his or her daily stress level is no daily stress, about a daily stress level less than the average man or woman, about a daily stress level equal to the average man or woman, about a daily stress level greater than the average man or woman, or about a daily stress level substantially greater than the average man or woman. While certain stress levels are described, these are exemplary, and other information about a person’s stress level may be used.

[0254] As one more example, information about the person or factors thereof may indicate the energy levels of the person during workouts. For example, the received information may indicate that the person feels or believes his or her energy level is substantially less than the average man or woman, about an energy level less than the average man or woman, about an energy level aboutWSGR Docket No.59851-708.601 equal to the average man or woman, about an energy level greater than the average man or woman, or about an energy level substantially greater than the average man or woman. While certain energy levels are described, these are exemplary, and other information about a person’s energy level may be used. Systems for Monitoring and Providing Feedback Based on Person’s Health

[0255] An aspect of the present disclosure provides a system for monitoring the health of a user by receiving and processing information associated with the person. The system may accept input regarding the user, process or analyze the input, and produce output indicative of a health state of the user. Alternatively, or additionally, the system may provide feedback, such as an indication of cortisol level and / or one or more recommendations to the user based on the processed input. In a non-limiting embodiment. The system or method comprises using an algorithm to collect, process, and analyze the user information and data and generate and produce one or more outputs. The outputs may include but are not limited to one or more scores and / or one or more recommendations. In an embodiment, the algorithm may be a machine learning algorithm or the like.

[0256] The system may comprise one or more computing devices (e.g., computing device 104 of FIG. 1) associated with the user. The one or more computing devices may comprise a user interface component. The user interface component may accept input from the user and based on the input generate an output indicative of the health or wellbeing of the user. Input may be received from the user and output displayed to the user on the user interface component.

[0257] The system may comprise a server (e.g., server 102 of FIG.1). The server may receive the input, process the input, provide the output, or any combination thereof. The server may comprise one or more components or modules. The one or more components or modules may comprise an analysis component (e.g., analysis component 112 of FIG. 1). The analysis component may perform a processing, analysis, or comparison of the input. The one or more components or modules may comprise a scoring component (e.g., scoring component of FIG.1). The scoring component may generate a score indicative of the health or wellbeing of the person based on the input or processed input. The score may be indicative of the person’s holistic health or wellbeing, or the score may be indicated of one aspect or factor of the person’s health or wellbeing. In a non-limiting example, the score may be indicative of specifically a person’s cortisol level. The score may be a numerical representation of the person’s health or wellbeing. The score may be a numerical representation of the person’s holistic health or wellbeing, or the score may be indicative of one aspect or factor of the person’s health or wellbeing. In a non-liming example, the score may be indicative of specifically a person’s cortisol level. The one or more components or modules may comprise a feedback component (e.g., feedback component 116 ofWSGR Docket No.59851-708.601 FIG.1). The feedback component may generate feedback based on the input or processed input. The feedback may comprise a recommendation to the user (e.g., to take a composition as described elsewhere herein, to make a lifestyle change). The feedback may comprise a visual indication to the user. In some cases, the visual feedback may comprise a color change, a particular text output, a numerical output, or any combination thereof. The one or more components or modules may comprise a database (e.g., database 118 of FIG.1). The database may store data about the user or one or more additional persons. In some cases, the analysis unit may process, analyze, or compare the input or processed input based on data contained in the database. In some cases, the scoring component or feedback component may generate the score or feedback, respectively, based on data contained in the database. The score or feedback may be based on a comparison.

[0258] The system may provide an output comprising a score. The output or score may be feedback. The score may summarize the state of the person’s health or wellbeing. Alternatively, or additionally, the score may characterize a specific factor of aspect of the person’s health or wellbeing. In a non-limiting example, the score may characterize specifically a person’s cortisol level. The score may be numerical and may correspond to a discrete scale (e.g., whole numbers from 0 to 10 or from 0 to 100) or a continuous scale (e.g., any number from 0 to 10 or 0 to 100). Alternatively, or additionally, the output may provide feedback. The feedback may be a visual indication to the user. In some cases, the visual feedback may comprise a color change, a particular text output, a numerical output, or any combination thereof. The feedback may comprise one or more text-based indicators corresponding to a category (e.g., low, medium, high; or bad, poor, fair, good, excellent) characterizing the health or wellbeing of the person.

[0259] In some cases, for a 0-100 scale, a score between 0-10, 0-20, 0-30, 0-40, 0-50, 0-60, 0-70, or 0-80 may indicate a high cortisol level; a score between 0-90, 10-90, 20-90, 30-90, 40- 90, 50-90, 60-90, 70-90 or 80-90, may indicate a medium cortisol level; a score between 50-100, 60-100, 70-100, 80-100, 90-100 may indicate a low cortisol level.

[0260] In some cases, for a 0-100 scale, a score between 0-10, 0-20, 0-30, 0-40, 0-50, 0-60, 0-70, or 0-80 may indicate a bad or poor cortisol level; a score between 0-90, 10-90, 20-90, 30- 90, 40-90, 50-90, 60-90, 70-90 or 80-90, may indicate a fair or good cortisol level; a score between 50-100, 60-100, 70-100, 80-100, 90-100 may indicate an excellent cortisol level.

[0261] The feedback may comprise one or more recommendations to the person. The one or more recommendations may comprise a lifestyle, diet, and / or nutrient adjustment. The one or more recommendations may comprise a lifestyle recommendation. The lifestyle recommendations may comprise one or more changes to the person’s exercise or sleep behavior. The one or more recommendations may comprise a diet adjustment, such as recommending a person intake more vegetables, protein, or the like. The one or more recommendations may comprise a nutrientWSGR Docket No.59851-708.601 adjustment. As a non-limiting example, the recommendation is to take a vitamin, mineral, or nutraceutical. The nutraceutical may modulate cortisol levels. The nutraceutical may comprise ashwagandha extract.

[0262] In some cases, (e.g., those in which a sample is input into the system) the feedback may comprise one or more levels of a substance in the sample associated with the person. For example, cortisol, biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, magnesium, water, vitamin B12, calcium, and / or sodium.

[0263] FIG. 1 illustrates an example system 100 for monitoring the health of a user in accordance with the disclosure. The system 100 may comprise a server 102 in communication with a computing device 104. The server 102 may comprise one or more modules or components illustrated in FIG.1 (e.g., analysis component 112, scoring component 114, feedback component 116, and database 118).

[0264] The computing device 104 may comprise a user interface component 122. The user interface component 122 may comprise a graphical user interface (GUI), a web-based user interface, a command line interface, a menu-driven interface, a touchscreen GUI, or any combination thereof. Through the user interface component 122, a user may input information about a person and receive output based on the input.

[0265] In this depicted embodiment, the server 102 comprises an analysis component 112. The analysis component 112 may process or analyze one or more pieces of information. The analysis component may identify and remove outliers in the input information, compare the input or processed input to goal information, analyze the input information compared to goal information, analyze the input information (e.g., a sample) for the level of one or more substances in the sample, or any combination thereof. In cases where a database 118 is present, the analysis component 114 analyze the information based on data in the database 108.

[0266] In some embodiments, the analysis component 112 may exclude one or more outlier aspects. A user may provide one or more datasets from multiple points throughout the day. For example, a user may provide a urine or blood sample, or information regarding a urine or blood sample, at four times throughout the day. The analysis component 112 may determine information directly from the urine or blood samples or may receive the information regarding the urine or blood samples. The analysis component 112 may then further recognize one or more outlier aspects regarding each dataset by determining what aspects are primarily affected by the time that the sample was taken, and thus, are unreliable. For example, the analysis component 112 may receive four datasets, concerning samples taken right when the user wakes up, four hours after the user wakes up, four hours before the user goes to sleep, and right before the user goes to sleep. The information may show that the hydration levels of the user are extremely low after the userWSGR Docket No.59851-708.601 wakes up, but are at normal levels for the rest of the datasets. The analysis component 112 may recognize that the hydration level in the dataset collected right after the user wakes up are extremely low because the user has not been able to drink for the past eight hours (e.g., because the user was asleep), and may label the data point as an outlier. Thus, when the analysis component sends data the scoring component 114 and feedback component 116, it may not send the outlier data points.

[0267] In this depicted embodiment, the server 102 comprises a scoring component 114. The scoring component 114 may process information to generate a score indicative of the health state or wellbeing of the person. In some cases, the scoring component 114 may operate on information that has been processed or analyzed by the analysis component 112. Alternatively, or additionally, the scoring component 114 may operate on the raw input information. In cases where a database 118 is present, the scoring component 114 may produce a score based on the data in the database 118.

[0268] In this depicted embodiment, the server 102 comprises a feedback component 116. The feedback component may generate one or more outputs sent to the user interface component 122 to provide feedback to the user based on the information. The feedback may comprise a recommendation to the user. The feedback may comprise one or more recommendations, such as a lifestyle, diet, and / or nutrient adjustment. The lifestyle recommendations may comprise one or more changes to the person’s exercise or sleep behavior. The one or more recommendations may comprise a diet adjustment, such as recommending a person intake more vegetables, protein, or the like. The one or more recommendations may comprise a nutrient adjustment. As a non- limiting example, the recommendation is to take a vitamin, mineral, or nutraceutical. The nutraceutical may modulate cortisol levels. The nutraceutical may comprise ashwagandha extract.

[0269] In this depicted embodiment, the server 102 comprises a database 118. The database 118 may contain information from one or more users. The database 118 may contain information not associated with a particular person, such as goal values for aspects or factors associated with a user. For example, a goal value for aspects or factors may be a goal time for exercise each day or a goal cortisol level. In some cases, the database 118 may contain data used by the analysis component 112, the scoring component 114, or the feedback component 116. In an example, the analysis component 112 may use information stored in the database to identify one or more outlier values in the input information and remove the outlier(s) from the input. In another example, the scoring component 114 may compare the input information or processed information from the analysis component 112 to other information in the database to determine a score for the user. In some cases, the database 118 may contain goal information, such as the goal values described above. The goal information may be used by the score component to generate a score indicativeWSGR Docket No.59851-708.601 of the health state of the user. The score may be generated by comparing the goal information to the information. The goal information may be used by the feedback component to generate feedback based on the health state of the user. The feedback may be generated by comparing the goal information to the information.

[0270] The score may indicate one or more recommendations. The recommendations may include lifestyle changes, dietary changes, and / or nutrient adjustments, such as exercising more, drinking more water, or eating less unhealthy foods. The recommendations may also include a recommendation to take a product. In some embodiments, the product contains ashwagandha product. In some embodiments, the product also contains a chelating agent (e.g., EDTA or disodium EDTA) and a delivery enhancing agent (AstraGin®). The product may also contain various ingredients, such as maca, a fenugreek seed extract source (e.g., Testosurge®), cordyceps mushroom (e.g., Cordyceps PrimeTM), one or more vitamins (e.g., vitamin B6), a nitric oxide source (e.g., beet root powder), a green tea extract, one or more amino acids (e.g., D-Aspartic Acid, L-theanine, and / or L-tryptophan), a panax ginseng source, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, bacopa, phosphatidylserine, magnesium glycinate, magnolia officinalis, ginger, sage (e.g., sage leaf powder), DIM, one or more minerals (e.g., zinc citrate), an oat straw source, reishi mushroom, and / or melatonin.

[0271] FIG.2 illustrates an example user interface 200. The user interface 200 comprises an input pane 202 with an input row 208, feedback output pane 204, and score output pane 206. The input pane 200 may prompt the user to provide information related to the age of the person, sleep data of the person, diet of the person, libido level of the person, mental clarity of the person, fatigue level of the person, mood of the person, exercise level of the person, level of energy during exercise of the person, daily stress levels of the person, or levels of one or more substances (e.g., cortisol) measured (e.g., at one or more timepoints) in a sample associated with the person.

[0272] The input pane 200 may comprise one or more input rows 208. Input row 208 may receive input regarding the user. In some embodiments, the input regarding the user may be associated with the user’s health. The input row 208 may be directed to particular pieces of information about the person as discussed above. Additionally, in some embodiments, any number of input rows may be used. The input pane 200 may prompt the user to select form a predetermined list for each piece of data requested. Alternatively, or additionally, the input pane 200 may prompt the user to supply the data as a free entry, e.g., a numerical value.

[0273] The user interface 200 may comprise a feedback output pane 204. The feedback output pane may display to the user feedback based on the one or more input values. The feedback may comprise visual feedback. The visual feedback may comprise a color or color change. Alternatively, or additionally, the visual feedback may comprise textual feedback whichWSGR Docket No.59851-708.601 summarizes an assessment of the person’s health or wellbeing. FIG. 9 provide one possible example of the described visual feedback for summarizing an assessments of a person’s health or well being. The feedback may comprise one or more recommendations, such as a lifestyle, diet, and / or nutrient adjustment. The lifestyle recommendations may comprise one or more changes to the person’s exercise or sleep behavior. The one or more recommendations may comprise a diet adjustment, such as recommending a person intake more vegetables, protein, or the like. The one or more recommendations may comprise a nutrient adjustment. As a non-limiting example, the recommendation is to take a vitamin, mineral, or nutraceutical. The nutraceutical may modulate cortisol levels. The nutraceutical may comprise ashwagandha extract. In cases where a sample associated with the user or a portion thereof is provided as input, the feedback output pane may additionally provide output indicative of the level of one or more substances (e.g., metabolite or hormone, such as biotin (vitamin B7), ketones, vitamin C, vitamin B9, creatinine, cortisol, magnesium, water, vitamin B12, calcium, or sodium).

[0274] The user interface 200 may comprise a score output pane 206. The score output pane may display to the user a score based on the one or more input values. The score may comprise a numerical result. The score may summarize the state of the person’s health or wellbeing. The score may be numerical and may correspond to a discrete scale (e.g., whole numbers from 0 to 10 or from 0 to 100) or a continuous scale (e.g., any number from 0 to 10 or 0 to 100). Methods Monitoring and Providing Feedback Based on a Person’s Health

[0275] An aspect of the present disclosure provides for methods of monitoring the health of a user by receiving and processing information associated with the user. The method may comprise receiving information associated with the user. The method may comprise analyzing or processing the information, such as to remove outlier information. The raw or processed information may then be analyzed. The methods may be implemented by systems as described elsewhere herein.

[0276] The method may comprise an operation of accepting input from a user. The user may provide the input through a user interface, such as a user interface associated with a computing device. The information may comprise information related to the age of the person, sleep data of the person, diet of the person, libido level of the person, mental clarity of the person, fatigue level of the person, mood of the person, exercise level of the person, level of energy during exercise of the person, daily stress levels of the person, or levels of one or more substances (e.g., cortisol) measured (e.g., at one or more timepoints) in one or more samples (e.g., a bodily fluid, such as blood, saliva, or urine) associated with the person.

[0277] The method may comprise an operation of preprocessing the input. The preprocessing operation may apply one or more transformations to the input data. The preprocessing operation may discard spurious or outlier information. Outlier information may be determined by comparingWSGR Docket No.59851-708.601 the input information to one or more references. The references may correspond to information associated with the person or one or more other persons. The references may be stored in a database. The references may correspond to information associated with the person from one or more other timepoints. The preprocessing operation may further standardize the encoding of information depending on the user input or source of the data.

[0278] The method may comprise an operation of comparing the input (processed) information to goal information. The goal information may be stored in a database. The goal information may be selected based on the user input such that the goal information is specific to an aspect or factor of the person. For example, the goal information may be selected based on the age, sex, activity level, stress level, diet, level or one or more substances (e.g., cortisol) associated with the person, or any combination thereof.

[0279] The method may comprise an operation of generating a score based on the comparison to the goal information. The score may express how close the input information is to the goal information. In some cases, a relatively higher score may mean that the input information is relatively closer to the goal information. Alternatively, in some cases, a lower score may mean that the input information is relatively closer to the goal information. Closeness may be assessed in any suitable way depending on the type of information. For example, in a case wherein the input and corresponding goal information may be expressed numerically, closeness may be determined by determining a difference between the goal and the input information. In another example, when the input and corresponding goal information are categorical data, the categorical data may be converted to a numerical representation and the determination of closeness made based on the corresponding numerical representation.

[0280] The operation of generating the score may comprise combining one or more different measures of closeness corresponding to different types of information (e.g., diet, exercise level, cortisol level, etc.) of the same or different modalities (e.g., categorical, numerical). The results of the different comparisons may be combined into one score to be output to the user. The different comparisons may be combined by any suitable averaging operation, such as an arithmetic mean, weighted arithmetic mean, geometric mean, weighted geometric mean, harmonic mean, quadratic mean, generalized mean, or any combination thereof. The result of the averaging operation may be scaled or transformed to make the score lie on a certain interval (e.g., 0 to 1, 0 to 100) or otherwise have a certain property (e.g., rounded or truncated to a whole number).

[0281] The method may comprise an operation of generating feedback based on the comparison to the goal information. The feedback may comprise visual feedback summarizing the overall health of the person. Alternatively, the feedback may summarize only one factor (e.g., diet, exercise, cortisol) or subset of factors corresponding to the input information. The feedbackWSGR Docket No.59851-708.601 may indicate that one or more of the user’s behaviors should be maintained. Alternatively, the feedback may indicate the person should adjust one or more changes to their behavior or lifestyle, diet, and / or nutrient intake (e.g., changes in daily habits, change in the person’s diet, change in the person’s sleep habit).

[0282] The feedback may comprise a recommendation to the user. The recommendation may indicate one or more changes that the person should make (e.g., changes in daily habits, change in the person’s diet, change in the person’s sleep habit, or change in the amount of a composition the person should take). The recommendation may be based on one or more levels of the one or more substances in the sample(s) associated with the user. In such cases, the recommendation may indicate that one or more levels of the one or more substances is higher or lower than a recommended level, that the person should adjust one or more aspect of the person’s lifestyle, diet, and / or nutrient intake for various purposes (e.g., to change the one or more levels of the one or more substances into a recommended range), and / or that the person should take or stop taking one or more products (e.g., a composition comprising ashwagandha extract).

[0283] The method may comprise an operation of outputting the score or feedback to the user. The score or feedback may be output to the same user interface device through which the user input the information. Alternatively, the score or feedback may be output to another computing device not associated with (e.g., separate from) the user. For example, the score or feedback may be output to another individual associated with the person, such as a physician.

[0284] FIG.3 illustrates an example method 300 for monitoring the health of a person (e.g., such as a user) and providing a recommendation to the user in accordance with the disclosure. The method 300 may comprise operations of (a) receiving, based on user input to a user interface, information regarding the health of the user 302; (b) removing one or more outlier aspects of a first subset of the information based on a characteristic of the one or more outlier aspects 304; (c) removing a one or more outlier aspects of a second subset of the information based on a characteristic of the one or more outlier aspects 306; (d) comparing the information to goal information 308; (e) generating a score based on the comparison 310; (f) generating feedback based on the comparison 312; and (g) providing the score or feedback to the user 314.

[0285] In some embodiments, a machine learning algorithm may perform one or more of the steps of (a) receiving, information regarding the health of the user 302; (b) removing one or more outlier aspects of a first subset of the information based on a characteristic of the one or more outlier aspects 304; (c) removing a one or more outlier aspects of a second subset of the information based on a characteristic of the one or more outlier aspects 306; (d) comparing the information to goal information 308; (e) generating a score based on the comparison 310; (f) generating feedback based on the comparison 312; and (g) providing the score or feedback to theWSGR Docket No.59851-708.601 user 314. The machine learning algorithm may be stored on a memory. The machine learning algorithm may be a supervised machine learning algorithm.

[0286] In some embodiments, the system may determine that a person should take the composition based on the received information using a server (e.g., a physical processing device or a virtual server) or a computing device (e.g., a laptop, smartphone, or another processing device) of the system. In those embodiments, the received information to the clinical data may be compared and whether the composition should be taken may be determined based on the comparison. The clinical data may be received by the server or computing device or may be stored in a database on the server or computing device. In some cases, the server or computing device may receive the clinical information from a processing device associated with the clinical information.

[0287] In some embodiments, the recommendation is made using the received information and the clinical data. As described above, in some embodiments, recommendations are determined based one or more factors. The one or more factors may include cortisol levels of the person. The cortisol levels of the person may include current cortisol levels of the person as well as desired cortisol levels of the person. The cortisol levels of the person may be determined based on the received information. The information received may be a cortisol level from 1, 2, 3, 4, 5, or 6 levels tested in a day. The cortisol level may be an average.

[0288] In some embodiments, a second recommendation may be provided based on additional information, edit information, or re-input information. In those embodiments, the person may have the option to input additional information, edit information, or re-input information to receive the second recommendation.

[0289] FIG.5 illustrates an example of a computer implemented method for monitoring the health of a person (e.g., such as a user) and providing feedback such as an indication of cortisol and / or a recommendation to the user 600 in accordance with the disclosure. The method may comprise at least one or more steps of: a) prompting a user to access a website landing page 612, wherein the website is integrated into a mobile responsive design 618, such as, a mobile webpage; b) providing a dynamic questionnaire 614 to the user; c) displaying a health assessment quiz on the webpage 618, wherein the quiz provides a user with health related questions and optionally a pre-defined sequence of answer options per question; d) providing a prompt from the webpage, for the user to answer a question 602; e) receiving a user responses to the one or more questions 620, the response comprising, health information and data, wherein the input can either be enter by the user or selected from a pre-determined list of answer options; f) submitting the one or more user responses 622 to be analyzed; g) analyzing the one or more responses 624 h) outputting one or more personalized scores and / or recommendations to the userWSGR Docket No.59851-708.601 in response to the provided health information and data 626; and optionally i) sending an email of the one or more personalized scores and / or recommendations to the user’s email, one example is illustrated in FIG.9. Optionally, steps 618, 602, and 620 are repeated until each question is answered by the user 604.

[0290] In some embodiments, providing the dynamic questionnaire 614 may comprise accessing through web service 642 a questionnaire. As illustrated in FIG.5, providing the dynamic questionnaire 642 may comprise one or more operations of generating the dynamic questionnaire 644, gathering a list of questions and corresponding answer options 646, and getting a randomized answer sequence 648. The web service 642 may then forward the dynamic questionnaire to the user in operation 614.

[0291] In some embodiments, analyzing the one or more responses 624 may comprise accessing through web service 652 a module which implements an operation of processing the user submitted answer data 654 in order to return one or more personalizes scores and / or recommendations to the user.

[0292] In some embodiments, the computer implemented system and / or computer implemented method comprises a) generating a dynamic questionnaire, in response to a user accessing the website; b) gathering a list of questions and corresponding answer options based on randomized answer categories; c) providing a list of questions and corresponding answer options to the user on the website; d) prompting the user to input an answer for each provided question; and / or e) processing the user submitted answer data and calculate a score based on the users answers and / or data.

[0293] As described above, in some cases, the provided questions may ask for a person’s health information and data regarding one or more factors. Non-limiting examples of questions include asking for the person’s age, daily sleep, daily diet, libido level, mental clarity, daily fatigue levels, daily mood, daily exercise, level of energy during exercise, daily stress levels, measured cortisol levels in the morning, measured cortisol levels at midday, measured cortisol levels in the evening, and measured cortisol levels at night. In some embodiments, recommended regimens may change based on new incoming information received by the system.

[0294] FIGS.7A-7O illustrate an example system for monitoring a health score and making recommendations based of a user’s health information in one example of the present disclosure. FIG. 7A illustrates a prompt to a user to the user to be begin a questionnaire by inputting their name. By way of nonlimiting example, the prompt may comprise a clickable web object comprising text or an image, a button or more than one button, or the like. In some cases, the prompt comprises a clickable web object comprising a button. In some cases, the prompt mayWSGR Docket No.59851-708.601 comprise a field for user input. The field may be a text field, checkbox, radio button, drop-down list or other graphical control element to direct user input. As illustrated in FIG.7A, the prompt may comprise a text box for the user to input biographical data (e.g., a name of the user). When the user selects the prompt, the system may direct the user to another prompt to indicate the subject in need of mental crisis assistance. The prompt may be on another page on the GUI or a web page. The prompt may comprise an additional button and / or additional button or text input field.

[0295] FIGS. 7B-7N show examples of health-related question prompts and accompanied pre-selected answer choices for a user to answer. In some cases, the prompt comprises presenting a landing web page to the user. The user may indicate their answer to the displayed question by selecting the appropriate answer choice from the prompt. Once the user has indicated their answer to the displayed question, the user is then directed to another web page which prompts the user to answer another health-related question. These questions and answers prompts can comprise one or more of the illustrated questions in FIGS.8A-8N and or one or more questions described within the present application. The list of possible questions and answer prompts are not limited to those described in the present application and it should be understood that any health-related question and possible answer may be asked as is known in the art.

[0296] As illustrated in FIGS.7B-7N, any graphical control element may be employed with systems of the disclosure to prompt the user for input. In some cases, the graphical control element is a radio button. In some cases, the graphical control element is a text field. In some cases, the graphical control element is a drop-down menu. In some cases, the graphical control element comprises more than one of these graphical control elements. Further, the possible graphical control elements are not limited to those described in the present application.

[0297] FIG.7O show examples of a prompt for a user to enter an email after answering the health related questions to receive the result which may include a health score that is indicative of the users cortisol level or health and feedback such as one or more recommendations.

[0298] The feedback may comprise visual feedback summarizing the overall health of the person. Alternatively, the feedback may summarize only one factor (e.g., diet, exercise, cortisol) or subset of factors corresponding to the input information. The feedback may indicate that one or more of the user’s behaviors should be maintained. Alternatively, the feedback may indicate the person should adjust one or more changes to their behavior or lifestyle, diet, and / or nutrient intake (e.g., changes in daily habits, change in the person’s diet, change in the person’s sleep habit).

[0299] The feedback may comprise a recommendation to the user. The recommendation may indicate one or more changes that the person should make (e.g., changes in daily habits, change in the person’s diet, change in the person’s sleep habit, or change in the amount of a compositionWSGR Docket No.59851-708.601 the person should take). The recommendation may be based on one or more levels of the one or more substances in the sample(s) associated with the user. In such cases, the recommendation may indicate that one or more levels of the one or more substances is higher or lower than a recommended level, that the person should adjust one or more aspect of the person’s lifestyle, diet, and / or nutrient intake for various purposes (e.g., to change the one or more levels of the one or more substances into a recommended range), and / or that the person should take or stop taking one or more products (e.g., a composition comprising ashwagandha extract).

[0300] The method may comprise an operation of outputting the score or feedback to the user through an email message. The score or feedback may be output to the same user interface device through which the user input the information. Alternatively, the score or feedback may be output to another computing device not associated with (e.g., separate from) the user. For example, the score or feedback may be output to another individual associated with the person, such as a physician.

[0301] In any one of the embodiments described above the calculated score may be a representation of a person’s cortisol level. Computer Systems

[0302] FIG.4 shows a computer system 401 suitable for implementing the machine learning model methods described herein. The computer system 401 may process various aspects of information of the present disclosure, such as, for example, information about a person and score and recommendation determination. The computer system 401 may be an electronic device. The electronic device may be a mobile electronic device.

[0303] The computer system 401 may comprise a central processing unit (CPU, also “processor” and “computer processor” herein) 405, which may be a single core or multi core processor, or a plurality of processor for parallel processing. The computer system 401 may further comprise memory or memory locations 404 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 406 (e.g., hard disk), communications interface 408 (e.g., network adapter) for communicating with one or more other devices, and peripheral devices 407, such as cache, other memory, data storage and / or electronic display adapters. The memory 404, storage unit 406, interface 408, and peripheral devices 407 are in communication with the CPU 405 through a communication bus (solid lines), such as a motherboard. The storage unit 406 may be a data storage unit (or a data repository) for storing data. The computer system 401 may be operatively coupled to a computer network (“network”) 400 with the aid of the communication interface 408. The network 400 may be the Internet, an internet and / or extranet, or an intranet and / or extranet that is in communication with the Internet. The network 400 may, in some case, be a telecommunication and / or data network. The network 400 mayWSGR Docket No.59851-708.601 include one or more computer servers, which may enable distributed computing, such as cloud computing. The network 400, in some cases with the aid of the computer system 401, may implement a peer-to-peer network, which may enable devices coupled to the computer system 401 to behave as a client or a server.

[0304] The CPU 405 may execute a sequence of machine-readable instructions, which may be embodied in a program or software. The instructions may be directed to the CPU 405, which may subsequently program or otherwise configured the CPU 405 to implement methods of the present disclosure. Examples of operations performed by the CPU 405 may include fetch, decode, execute, and writeback.

[0305] The CPU 405 may be part of a circuit, such as an integrated circuit. One or more other components of the system 401 may be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).

[0306] The storage unit 406 may store files, such as drivers, libraries and saved programs. The storage unit 406 may store information from one or more persons and programs that act on the information. The computer system 401, in some cases may include one or more additional data storage units that are external to the computer system 401, such as located on a remote server that is in communication with the computer system 401 through an intranet or the internet.

[0307] Methods as described herein may be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer device 401, such as, for example, on the memory 404 or electronic storage unit 406. The machine executable or machine-readable code may be provided in the form of software. During use, the code may be executed by the processor 405. In some instances, the code may be retrieved from the storage unit 406 and stored on the memory 404 for ready access by the processor 405. In some instances, the electronic storage unit 406 may be precluded, and machine-executable instructions are stored on memory 404.

[0308] The code may be pre-compiled and configured for use with a machine having a processor adapted to execute the code or may be compiled during runtime. The code may be supplied in a programming language that may be selected to enable the code to be executed in a pre-complied or as-compiled fashion.

[0309] Aspects of the systems and methods provided herein, such as the computer system 401, may be embodied in programming. Various aspects of the technology may be thought of a “product” or “articles of manufacture” typically in the form of a machine (or processor) executable code and / or associated data that is carried on or embodied in a type of machine readable medium. Machine-executable code may be stored on an electronic storage unit, suchWSGR Docket No.59851-708.601 memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. “Storage” type media may include any or all of the tangible memory of a computer, processor the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible “storage’ media, term such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.

[0310] Hence, a machine readable medium, such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media may include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media includes coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer device. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefor include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with pattern of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one more instruction to a processor for execution.

[0311] The computer system may include or be in communication with an electronic display 402 that comprises a user interface (UI) 403 for inputting donor parameters and viewing theWSGR Docket No.59851-708.601 association of a donor’s parameters with a generated model. Examples of UI’s include, without limitation, a graphical user interface (GUI) and web-based user interface.

[0312] Methods and systems of the present disclosure can be implemented by way of one or more algorithms and with instructions provided with one or more processors as disclosed herein. An algorithm can be implemented by way of software upon execution by the central processing unit 405. The algorithm can be, for example, random forest, graphical models, support vector machine or other.

[0313] FIG.6 shows a web-based computer system 700 configured to implement the methods of the present disclosure. The methods may comprise, by way of non-limiting example, monitoring, tracking and / or making recommendations based on person’s health in accordance with the disclosure. The system 700 may comprise a web service 702 in communication with a database 704. The web service 702 may be configured to permit communication between a user (e.g., providing a request on a website) 703 and server 705 (as well as data in database 704). The server 705 may comprise one or more modules 710, 720, 730, 740, and 750 or components illustrated in FIG.6 (e.g., notification module 710, quiz module 720, stats module 730, contacts module 740, and an account module 750). The notification module 710 may be configured for providing information and recommendation to users. The notifications may be output as an email to one or more users as described above. In some embodiments, the information and recommendations to the user are in response to results generated by the stats module 730.

[0314] In some embodiments, the notification module 710 may be configured to receive the question prompts for the health quiz, generated by the quiz module 720 and display the question prompts to a user and / or prompt the user for an input. In a non-limiting embodiment, the quiz module 720 may be configured to perform operations, retrieve and / or generate elements such as questionnaire categories 721, questionnaires 722, one or more questions 723, and / or one or more answers 724 corresponding to the one or more questions 723. The quiz module 720 may be configured to provide to the user (e.g., health-related) questions prompts and / or pre-selected answer choices, such as those described elsewhere herein. The questions prompts and / or preselected answer choices can be generated and displayed to a user on a webpage as illustrated in FIGS.7A-7O.

[0315] The quiz module 720 may be configured to generate a dynamic questionnaire and health assessment quiz that is presented to a user; wherein the quiz provides a user with health- related question prompts and optionally a pre-defined sequence of answer options per question; and / or receive a user input, i.e. health information and data and / or answers, in response to the one or more question prompts of the quiz. The quiz module 720 may be configured to provide the input data to the stats module 730.WSGR Docket No.59851-708.601

[0316] In a non-limiting embodiment, the stats module 730 may be configured to perform operations such as filtering information 731, wherein the data is filtered by at least one of a date range, a score range, one or more health factors and / or health information or data. The information and data may be filter by any other well known or obvious factor or category. The stat module 730 may also perform operations to receive and / or generate one or more stats report 733. The stat module 730 may also perform operations and / or generate one or more downloads 732. The stat module may be configured to implement one or more operations associated with scoring a user input to (e.g., a health-related) questionnaire as described elsewhere herein.

[0317] The stats module 730 may be configured to receive input information and data from the quiz module 720 and output information such as a stats report 736 to the notification module 710 to present information to the user in response to their answers and / or store the stats report in a database 704.

[0318] In a non-limiting embodiment, the contacts module 740 may be configured to perform operations to receive and / or generate lists of contacts 742. The contacts module 740 may be configured to perform operations such as filtering searches 741, wherein the search is filtered by at least one of a contact name, age range, a score range, one or more health factors and / or health information or data. The contact name, age range, score range, or one or more health factors and / or health information or data may be provided by the user 703, as illustrated in FIGS. 7A-7O, or accessed from database 704. The search may be filtered by any other well-known or obvious factor or category.

[0319] In a non-limiting embodiment, the account module 750 may be configured to perform operations and functions for anything related to one or more user information and access to the system. This information and access includes but is not limited to, users 751, profile 752, options 753, password 754, logout 755 and about 756. The information can be associated with the user accessing server 705 through the web service 702. Alternatively, the information can be associated with another user or users. The account module or any module is not limited in its function and each module may include and perform one or more of the elements and functions from any other module or not listed above. Example system embodiments

[0320] Embodiment 1. A method for recommending whether to make a lifestyle, diet, and / or nutrient adjustment, comprising: receiving information regarding health of a user, wherein a first subset of the information is subjective and a second subset of the information is objective; removing one or more outlier aspects of the second subset of the information based on a characteristic of the one or more outlier aspects to create a third subset of the information; comparing the third subset of information to a goal subset of information; analyzing the first subsetWSGR Docket No.59851-708.601 of information based on the goal subset of information; generat...

Claims

WSGR Docket No.59851-708.601 CLAIMS WHAT IS CLAIMED IS:

1. A composition comprising: about 60 mg to about 420 mg of a maca, about 60 mg to about 300 mg of a fenugreek seed extract, about 1 mg to about 25 mg of a cordyceps species, about 1 mg to about 25 mg of a tea extract, about 1 mg to about 25 mg of a nitric oxide source, about 1 mg to about 25 mg of bacopa monnieri, about 0.5 mg to about 15 mg of an amino acid comprising D-aspartic acid, about 0.5 mg to about 15 mg of panax ginseng, and about 0.1 mg to about 10 mg of a vitamin.

2. The composition of claim 1, comprising: (i) about 120 mg to about 320 mg of maca about 120 mg to about 220 mg of fenugreek seed extract, about 5 mg to about 15 mg of cordyceps species, about 5 mg to about 15 mg of the tea extract, about 5 mg to about 15 mg of the nitric oxide source, about 5 mg to about 15 mg of the bacopa monnieri, about 1 mg to about 10 mg of the amino acid, about 1 mg to about 10 mg of the panax ginseng, and about 0.5 to about 5 mg of the vitamin; or (ii) about 60 mg to about 160 mg of maca about 60 mg to about 110 mg of fenugreek seed extract, about 2.5 mg to about 7.5 mg of cordyceps species, about 2.5 mg to about 7.5 mg of the tea extract, about 2.5 mg to about 7.5 mg of the nitric oxide source, about 2.5 mg to about 7.5 mg of the bacopa monnieri, about 0.5 mg to about 5 mg of the amino acid, about 0.5 mg to about 5 mg of the panax ginseng, and about 0.25 to about 2.5 mg of the vitamin.

3. The composition of claim 1 or claim 2, comprising: (i) about 220 mg of maca, about 170 mg of fenugreek seed extract, about 10 mg of cordyceps species, about 10 mg of the tea extract, about 10 mg of the nitric oxide source, about 10 mg of the bacopa monnieri, about 5 mg of the amino acid, about 5 mg of the panax ginseng, and about 1.7 mg of the vitamin; or (ii) about 110 mg of maca, about 85 mg of fenugreek seed extract, about 5 mg of cordyceps species, about 5 mg of the tea extract, about 5 mg of the nitric oxide source, about 5 mg of the bacopa monnieri, about 2.5 mg of the amino acid, about 2.5 mg of the panax ginseng, and about 0.85 mg of the vitamin.

4. The composition of any one of claims 1-3, wherein the cordyceps species is a cordyceps mushroom.

5. The composition of any one of claims 1-4, wherein the tea extract is a green tea extract.

6. The composition of any one of claims 1-5, wherein the nitric oxide source is a beet root powder.

7. The composition of any one of clams 1-6, wherein the vitamin is vitamin B6.WSGR Docket No.59851-708.601 8. The composition of any one of claims 1-7, further comprising: (i) about 75 mg to about 450 mg of an ashwagandha extract, about 1 mg to about 175 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 175 mg of a second excipient comprising a chelating agent; or (ii) about 37.5 mg to about 225 mg of an ashwagandha extract, about 0.5 mg to about 87.5 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 0.5 mg to about 87.5 mg of a second excipient comprising a chelating agent.

9. The composition of claim 8, comprising: (i) about 150 mg to about 350 mg of the ashwagandha extract, about 5 mg to about 100 mg of the first excipient, and about 5 mg to about 100 mg of the second excipient; or (ii) about 75 mg to about 175 mg of the ashwagandha extract, about 2.5 mg to about 50 mg of the first excipient, and about 2.5 mg to about 50 mg of the second excipient.

10. The composition of claim 8 or claim 9, comprising: about 230 mg of the ashwagandha extract; about 250 mg of the ashwagandha extract; about 241 mg of the ashwagandha extract; about 285 mg of the ashwagandha extract; about 281 mg of the ashwagandha extract; about 115 mg of the ashwagandha extract; about 125 mg of the ashwagandha extract; about 120.5 mg of the ashwagandha extract; about 142.5 mg of the ashwagandha extract; or about 140.5 mg of the ashwagandha extract.

11. The composition of any one of claims 8-10, comprising: about 55 mg of the first excipient; about 65 mg of the first excipient; about 59 mg of the first excipient; about 50 mg of the first excipient; about 79 mg of the first excipient; about 27.5 mg of the first excipient; about 32.5 mg of the first excipient; about 24.5 mg of the first excipient; about 25 mg of the first excipient; orWSGR Docket No.59851-708.601 about 39.5 mg of the first excipient.

12. The composition of any one of claims 8-11, comprising: about 56 mg of the second excipient; about 81 mg of the second excipient; about 59 mg of the second excipient; about 50 mg of the second excipient; about 51 mg of the second excipient; about 28 mg of the second excipient; about 40.5 mg of the second excipient; about 24.5 mg of the second excipient; about 25 mg of the second excipient; or about 25.5 mg of the second excipient.

13. The composition of any one of claims 8-12, wherein the chelating agent is disodium EDTA.

14. A composition comprising: about 50 mg to about 400 mg of a cordyceps mushroom, about 25 mg to about 250 mg of a component of a magnolia tree, about 1 mg to about 75 mg of oat straw, about 1 mg to about 25 mg of ginger, about 1 mg to about 25 mg of sage, about 1 mg to about 25 mg of diindolylmethane (DIM), about 25 mg to about 250 mg of a compound comprising magnesium, and about 1 mg to about 25 mg of zinc citrate.

15. The composition of claim 13, comprising: (i) about 100 mg to about 300 mg of the cordyceps mushroom, about 50 mg to about 150 mg of the component of the magnolia tree, about 5 mg to about 50 mg of the oat straw, about 5 mg to about 15 mg of the ginger, about 5 mg to about 15 mg of the sage, about 5 mg to about 15 mg of the DIM, about 50 mg to about 150 mg of the compound comprising magnesium, and about 5 mg to about 15 mg of the zinc citrate; or (ii) about 50 mg to about 150 mg of the cordyceps mushroom, about 25 mg to about 75 mg of the component of the magnolia tree, about 2.5 mg to about 25 mg of the oat straw, about 2.5 mg to about 7.5 mg of the ginger, about 2.5 mg to about 7.5 mg of the sage, about 2.5 mg to about 7.5 mg of the DIM, about 25 mg to about 75 mg of the compound comprising magnesium, and about 2.5 mg to about 7.5 mg of the zinc citrate.

16. The composition of claim 13 or claim 14, comprising: (i) about 185 mg of the cordyceps mushroom, about 100 mg of the component of the magnolia tree, about 25 mg of the oat straw, about 12.5 mg of the ginger, about 10 mg of the sage, about 10 mg of the DIM, about 100 mg of the compound comprising magnesium, and about 8 mg of the zinc citrate; orWSGR Docket No.59851-708.601 (ii) about 92.5 mg of the cordyceps mushroom, about 50 mg of the component of the magnolia tree, about 12.5 mg of the oat straw, about 6.25 mg of the ginger, about 5 mg of the sage, about 5 mg of the DIM, about 50 mg of the compound comprising magnesium, and about 4 mg of the zinc citrate.

17. The composition of any one of claims 14-16, wherein the component of the magnolia tree is magnolia officinalis.

18. The composition of any one of claims 14-17, wherein the sage comprises a sage leaf powder.

19. The composition of any one of claims 14-18, wherein the compound comprising magnesium is magnesium glycinate.

20. The composition of any one of claims 14-19, further comprising: (i) about 75 mg to about 450 mg of an ashwagandha extract, about 1 mg to about 175 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 175 mg of a second excipient comprising a chelating agent; or (ii) about 37.5 mg to about 225 mg of an ashwagandha extract, about 0.5 mg to about 87.5 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 0.5 mg to about 87.5 mg of a second excipient comprising a chelating agent.

21. The composition of claim 20, comprising: (i) about 150 mg to about 350 mg of the ashwagandha extract, about 5 mg to about 100 mg of the first excipient, and about 5 mg to about 100 mg of the second excipient; or (ii) about 75 mg to about 175 mg of the ashwagandha extract, about 2.5 mg to about 50 mg of the first excipient, and about 2.5 mg to about 50 mg of the second excipient.

22. The composition of claim 20 or claim 21, comprising: about 160 mg of the ashwagandha extract; about 218 mg of the ashwagandha extract; about 250 mg of the ashwagandha extract; about 251 mg of the ashwagandha extract; about 300 mg of the ashwagandha extract; about 80 mg of the ashwagandha extract; about 109 mg of the ashwagandha extract; about 125 mg of the ashwagandha extract; about 125.5 mg of the ashwagandha extract; or about 150 mg of the ashwagandha extract.

23. The composition of any one of claims 20-22, comprising:WSGR Docket No.59851-708.601 about 51 mg of the first excipient; about 50 mg of the first excipient; about 29 mg of the first excipient; about 90 mg of the first excipient; about 71 mg of the first excipient; about 25.5 mg of the first excipient; about 25 mg of the first excipient; about 14.5 mg of the first excipient; about 45 mg of the first excipient; or about 35.5 mg of the first excipient.

24. The composition of any one of claims 20-23, comprising: about 50 mg of the second excipient; about 61 mg of the second excipient; about 58 mg of the second excipient; about 51 mg of the second excipient; about 30 mg of the second excipient; about 25 mg of the second excipient; about 30.5 mg of the second excipient; about 29 mg of the second excipient; about 25.5 mg of the second excipient; or about 15 mg of the second excipient.

25. The composition of any one of claims 20-24, wherein the chelating agent is disodium EDTA.

26. A composition comprising: about 1 mg to about 25 mg of phosphatidylserine, about 1 mg to about 25 mg of a component of a magnolia tree, about 1 mg to about 25 mg of an amino acid comprising L-theanine, about 1 mg to about 25 mg of an amino acid comprising L- tryptophan, about 0.5 mg to about 15 mg of a reishi mushroom, and about 0.05 mg to about 10 mg of melatonin.

27. The composition of claim 26, comprising about 5 mg to about 15 mg of the phosphatidylserine, about 5 mg to about 15 mg of the component of the magnolia tree, about 5 mg to about 15 mg of the amino acid comprising L-theanine, about 3 mg to about 15 mg of the amino acid comprising L-tryptophan, about 1 mg to about 10 mg of the reishi mushroom, and about 0.1 mg to about 5 mg of the melatonin.

28. The composition of claim 26 or claim 27, comprising about 12.5 mg of the phosphatidylserine, about 12.5 mg of the component of the magnolia tree, about 10 mg ofWSGR Docket No.59851-708.601 the amino acid comprising L-theanine, about 7.5 mg of the amino acid comprising L- tryptophan, about 5 mg of the reishi mushroom, and about 2.5 mg of the melatonin.

29. The composition of any one of claims 26-28. wherein the component of the magnolia tree is magnolia officinalis.

30. The composition of any one of claims 26-29, further comprising: about 25 mg to about 250 mg of an ashwagandha extract, about 1 mg to about 75 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 75 mg of a second excipient comprising a chelating agent.

31. The composition of claim 20, comprising about 50 mg to about 150 mg of the ashwagandha extract, about 5 mg to about 50 mg of the first excipient, and about 5 mg to about 50 mg of the second excipient.

32. The composition of claim 30 or claim 31, comprising: about 125 mg of the ashwagandha extract; about 135 mg of the ashwagandha extract; about 100 mg of the ashwagandha extract; about 75 mg of the ashwagandha extract; or about 120 mg of the ashwagandha extract.

33. The composition of any one of claims 30-32, comprising: about 35 mg of the first excipient; about 25 mg of the first excipient; about 29 mg of the first excipient; about 21 mg of the first excipient; or about 40 mg of the first excipient.

34. The composition of any one of claims 30-33, comprising: about 25 mg of the second excipient; about 35 mg of the second excipient; about 28 mg of the second excipient; about 26 mg of the second excipient; or about 45 mg of the second excipient.

35. The composition of any one of claims 30-34, wherein the chelating agent is disodium EDTA.

36. A composition comprising: about 1 mg to about 25 mg of phosphatidylserine, about 1 mg to about 25 mg of a component of a magnolia tree, about 1 mg to about 175 mg of an amino acid comprising L-theanine, about1 mg to about 25 mg of an amino acid comprising L- tryptophan, about 0.5 mg to about 15 mg of a reishi mushroom, about 1 mg to about 75 mgWSGR Docket No.59851-708.601 of GABA, about 1 mg to about 75 mg of a combination of magnesium citrate and magnesium glycinate (magnesium citrate glycinate), and about 1 mg to about 175 mg of magnesium L-threonate.

37. The composition of claim 36, comprising about 5 mg to about 15 mg of the phosphatidylserine, about 5 mg to about 15 mg of the component of the magnolia tree, about 5 mg to about 100 mg of the amino acid comprising L-theanine, about 3 mg to about 15 mg of the amino acid comprising L-tryptophan, about 1 mg to about 10 mg of the reishi mushroom, about 5 mg to about 50 mg of the GABA, about 5 mg to about 50 mg of the magnesium citrate glycinate, and about 5 mg to about 100 mg of the magnesium L- threonate.

38. The composition of claim 36 or claim 37, comprising about 12.5 mg of the phosphatidylserine, about 12.5 mg of the component of the magnolia tree, about 53 mg of the amino acid comprising L-theanine, about 8 mg of the amino acid comprising L- tryptophan, about 5 mg of the reishi mushroom, about 26 mg of the GABA, about 33 mg of the magnesium citrate glycinate, and about 63 mg of the magnesium L-threonate.

39. The composition of any one of claims 36-38, wherein the component of the magnolia tree is magnolia officinalis.

40. The composition of any one of claims 36-39, further comprising: about 25 mg to about 250 mg of an ashwagandha extract, about 1 mg to about 75 mg of a first excipient comprising an extract of astragalus membranaceus and an extract of panax notoginseng, and about 1 mg to about 75 mg of a second excipient comprising a chelating agent.

41. The composition of claim 40, comprising about 50 mg to about 150 mg of the ashwagandha extract, about 5 mg to about 50 mg of the first excipient, and about 5 mg to about 50 mg of the second excipient.

42. The composition of claim 40 or claim 41, comprising: about 134 mg of the ashwagandha extract; about 131 mg of the ashwagandha extract; about 125 mg of the ashwagandha extract; about 120 mg of the ashwagandha extract; or about 140 mg of the ashwagandha extract.

43. The composition of any one of claims 40-42, comprising: about 26 mg of the first excipient; about 25 mg of the first excipient; about 28 mg of the first excipient; about 35 mg of the first excipient; orWSGR Docket No.59851-708.601 about 31 mg of the first excipient.

44. The composition of any one of claims 40-43, comprising: about 25 mg of the second excipient; about 34 mg of the second excipient; about 26 mg of the second excipient; about 45mg of the second excipient; or about 21 mg of the second excipient.

45. The composition of any one of claims 40-44, wherein the chelating agent is disodium EDTA.

46. A method of alleviating a symptom associated with perimenopause or menopause in an individual, the method comprising the individual taking the composition of any one of claims 1-45, thereby alleviating the symptom.

47. The method of claim 46, wherein the symptom comprises a hot flash, change in hormone levels, mood changes, difficulty sleeping, or a combination of two or more thereof.

48. A method of reducing hot flashes in an individual, the method comprising the individual taking the composition of any one of claims 1-45, thereby reducing the hot flashes.

49. A method of reducing symptoms associated with anxiety in an individual, the method comprising the individual taking the composition of any one of claims 1-45, thereby reducing the anxiety.

Images